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CHAPTER I* 
 
INTRODUCTION 
 
Membranes provide a physical boundary to separate a living organism from its 
environment and to divide eukaryotic cells into functionally distinct subcellular 
compartments. The plasma membrane of the cell has a unique protein and lipid 
composition that is optimized for establishing an interface between the intracellular and 
extracellular environments. An important aspect of this interface is the asymmetrical 
distribution of plasma membrane phospholipids between the two leaflets (Bretscher, 
1973; Devaux, 1992) (Figure 1-1). For example, the cytosolic leaflet is enriched in 
phosphatidylserine (PS) and phosphatidylethanolamine (PE), whereas the extracellular 
leaflet contains primarily phosphatidylcholine (PC) and sphingolipids (Devaux, 1992; 
Zwaal and Schroit, 1997). This lipid organization appears to be conserved from yeast to 
man, but how is membrane asymmetry established and maintained? Research over the 
last two decades suggest that a P-type ATPase subfamily, called type-IV P-type 
ATPases or P4-ATPases, contributes significantly to this process by flipping specific 
phospholipid substrates from the extracellular or lumenal leaflet to the cytosolic leaflet of 
the membrane bilayer (so-called “flippases”) (Daleke, 2003; Graham, 2004; Pomorski et 
al., 2004). Particularly, studies on the P4-ATPases from the yeast Saccharomyces 
cerevisiae, especially the founding member of the family, Drs2p, have greatly expanded 
our knowledge in this field. In addition to their potential flippase function and contribution 
to membrane asymmetry, the yeast P4-ATPases also play important roles in protein 
transport and vesicle budding (Graham, 2004; Muthusamy et al., 2009a; Zhou et al., 
2010). These P4-ATPase activities create an intriguing link between phospholipid 
translocation and vesicle formation. 
*This chapter was modified from: Zhou X, Liu K, Natarajan P, Muthusamy BP, and Graham TR (2010). "Coupling Drs2p to 
Phospholipid Translocation, Membrane Asymmetry and Vesicle Budding" In: Membrane Asymmetry and Transmembrane 
Motion of Lipids. (P. F. Devaux, ed.) John Wiley & Sons.
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Figure 1-1. Asymmetrical distribution of phospholipids between the two leaflets of the 
erythrocyte plasma membrane (from: Principles of Biochemistry, 4th edition). 
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Section 1.1: P4-ATPases in Budding Yeast 
 
Section 1.1.1: The yeast P-type ATPases and nomenclature 
Sequencing of the S. cerevisiae genome identified a total of 16 P-type ATPases, 
which were initially categorized phylogenetically into three classes called P1-, P2- and 
P4-ATPases (Catty et al., 1997) (Figure 1-2). 
The original P1 family consisted of two members of heavy metal ion pumps. The 
Drs2p family members, which are potential flippases, were originally placed in the P2 
class together with H+, Na+ and Ca2+ pumps, whereas the term P4 was proposed for two 
new P-type ATPases whose substrates are still unknown. 
In a more recent and detailed phylogenetic classification that included P-type 
ATPases from bacteria, fungi, plants and animals (Axelsen and Palmgren, 1998; 
Kuhlbrandt, 2004), yeast P-type ATPases, especially the original P2 family members, 
were reorganized into new categories and a new naming system was utilized. The heavy 
metal ion transporters remain in the first category, but were renamed type-I P-type 
ATPases (P1). Na+ and Ca2+ pumps were categorized as type-II (P2) and H+ ATPases 
type-III (P3). The Drs2p family was also placed into an independent new branch 
designated type-IV P-type ATPases (P4). The P-type ATPases with unknown substrates, 
i.e. the original P4-ATPases, were designated type-V P-type ATPases (P5). To promote 
a less cumbersome nomenclature, we and other groups have used the term P4-
ATPases for the Drs2p family of potential phospholipid translocases. 
 
Section 1.1.2: P4-ATPases in the yeast S. cerevisiae 
The budding yeast S. cerevisiae contains five P4-ATPases: Drs2p, Neo1p, Dnf1p, 
Dnf2p and Dnf3p (Axelsen and Palmgren, 1998; Catty et al., 1997; Kuhlbrandt, 2004) 
(Figure 1-2). NEO1 is the only essential gene of the P4-ATPase family and yeast 
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Figure 1-2. Phylogenetic tree of the yeast S. cerevisiae P-type ATPases (modified from 
Catty et al., 1997). Totally 16 P-type ATPases are divided into six subgroups. Numbers 
indicate the relative evolution distance between proteins. Boxed names are the terms 
used in the original classification. An updated classification for each subgroup is 
indicated in parentheses. 
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carrying a complete disruption of NEO1 fail to grow at any temperature tested (Hua and 
Graham, 2003; Prezant et al., 1996). However, phenotypes associated with loss of 
NEO1 function have been characterized in strains carrying temperature-conditional 
alleles of NEO1 (neo1-ts) or by placing the NEO1 gene under transcriptional control of a 
galactose-regulated promoter (Hua and Graham, 2003; Wicky et al., 2004). In the latter 
case, expression of NEO1 can be shut off by growth of the strain in glucose. 
The remaining members of the P4-ATPase family constitute an essential group (Hua 
et al., 2002). Disruption of DRS2 yields a viable strain although these cells display an 
unusually strong cold-sensitive growth defect. Yeast normally grow over a range of 
temperatures, from approximately 10 C to 40 C, but drs2∆ cells fail to grow at 
temperatures below 23 C (Ripmaster et al., 1993). Individual knockout of DNF genes, or 
even the triple knockout (dnf1,2,3∆), does not perturb growth of yeast. However, 
disruption of DNF genes in a drs2∆ background exacerbates the growth defect caused 
by drs2∆, in decreasing order of severity: drs2∆dnf1∆, drs2∆dnf2∆ and drs2∆dnf3∆. 
Growth defects become more severe as more DRS2-DNF genes are deleted and the 
quadruple mutant (drs2∆dnf1,2,3∆) is inviable. These observations indicate some 
degree of functional redundancy between the DRS2 and DNF genes, with Drs2p 
primarily providing the essential activity of the group (Hua et al., 2002). 
DRS2 was the first P4-ATPase gene cloned and was originally thought to be a Ca2+-
ATPase based on homology searches with sequences available at the time (Ripmaster 
et al., 1993). Drs2p contains 1355 amino acids and is 14% identical and 41% similar to 
the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1 (SERCA1, Figure 1-3). By 
comparison, Drs2p shares 20-30% identity and 40-50% similarity with other yeast P4-
ATPases (Hua et al., 2002). Sequence analysis of Drs2p identified the key sequence 
“DKTGTLT”, containing the aspartyl phosphorylation site conserved in all P-type 
ATPases, as well as other signature motifs for P-type ATPases (Catty et al., 1997).  
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Figure 1-3. Sequence alignment between Drs2p and SERCA1. 
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Figure 1-3. Sequence alignment between Drs2p and the sarcoplasmic/endoplasmic 
reticulum Ca2+ ATPase 1 (SERCA1). The alignment was performed using ClustalW on 
the PBIL server (Combet et al., 2000). Identical residues are shown in black blocks, and 
similar residues in grey. Numbers indicate residue positions in Drs2p. 
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Drs2p was also predicted to contain ten transmembrane segments as does SERCA1. 
SERCA1 can be considered an archetype of the entire P-type ATPase family because it 
was the first P-type ATPase whose atomic structure was determined by x-ray 
crystallography (Toyoshima et al., 2000). Moreover, the crystal structures of SERCA1 
representing nine different states, which cover almost the entire reaction cycle, have 
been solved, providing the first structure-based mechanistic model for the pumping cycle 
of a P-type ATPase (Toyoshima, 2009). 
An atomic structure of a P4-ATPase would be of great value to gain mechanistic 
insight into the function of these enzymes, but unfortunately this has not yet been 
achieved. However, we have built a homology model of Drs2p by threading its sequence 
on the atomic structure of SERCA1 (Zhou et al., 2010) (Figure 1-4). The premise of this 
method is a high degree of sequence similarity between the target and the template 
protein, which normally requires 60-70% similarity or above. However, using the 
predicted transmembrane segments as anchor points, the intervening loops of Drs2p 
could be successfully threaded onto the SERCA1 structure. In this homology model, 
Drs2p has a ten-transmembrane-segment membrane domain, with three well organized 
cytosolic domains easily recognized as the actuator domain (A), nucleotide binding 
domain (N), and phosphorylation domain (P). In the overlay mode, the majority of Drs2p 
can be superimposed well with the SERCA1 template, despite their relatively low 
homology. This homology model of Drs2p is not sufficient to substitute for an 
experimentally determined atomic model, but rather serves as complementary 
information that may facilitate mutational studies. 
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Figure 1-4. Homology model of Drs2p based on the crystal structure of the sarcoplasmic 
reticulum Ca2+ ATPase 1 (SERCA1) in the E2·P conformation (Toyoshima et al., 2004) 
(PDB ID: 1WPG). Green: SERCA1 template; red: Drs2p. A, actuator domain; N, 
nucleotide binding domain; P, phosphorylation domain; TM, transmembrane domain. 
The two panels display two different viewing angles. Homology modeling was performed 
using the SWISS-MODEL server (Guex and Peitsch, 1997; Kopp and Schwede, 2004; 
Schwede et al., 2003). 
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Section 1.1.3: P4-ATPase chaperones 
Recent studies showed that most yeast P4-ATPases require Cdc50p family members 
(Cdc50p, Lem3p and Crf1p) for exit from the endoplasmic reticulum (ER) (Chen et al., 
2006; Furuta et al., 2007; Saito et al., 2004) (Figure 1-5). In the absence of Lem3p, 
Dnf1p and Dnf2p show a characteristic ER pattern that is distinct from their normal 
localization. Similarly, the absence of Cdc50p causes ER localization of Drs2p, and 
absence of Crf1p causes ER retention of Dnf3p. A similar phenomenon was also 
observed with P4-ATPases in other organisms (Paulusma et al., 2008; Perez-Victoria et 
al., 2006; Poulsen et al., 2008). The chaperone function between the P4-ATPases and 
the Cdc50p family appears to be reciprocal. Cdc50p and Lem3p are also retained in the 
ER when their corresponding P4-ATPase partners are missing. In wild-type cells, 
Cdc50p co-localizes with Drs2p, and Lem3p with Dnf1p/Dnf2p. Co-immunoprecipitation 
between P4-ATPases and Cdc50p family members also supports the formation of 
physical complexes between Drs2p and Cdc50p, and Dnf1p (or Dnf2p) and Lem3p 
(Chen et al., 2006; Furuta et al., 2007; Saito et al., 2004). 
The relationship between P4-ATPases and Cdc50p family members is reminiscent of 
Na+/K+ and H+/K+ ATPases, members of the type-IIC P-type ATPases (P2C-ATPases), 
which are among a few oligomeric P-type ATPases possessing a β and even a γ subunit 
in addition to the catalytic α subunit (Geering, 2001; Kuhlbrandt, 2004). Cdc50p family 
members may be considered the β subunit for P4-ATPases (α subunit). An important 
unanswered question is whether the β subunits function solely as a chaperone or if they 
also contribute in a more direct manner to phospholipid translocation and in vivo function 
of the α subunits. Co-localization and co-immunoprecipitation data suggest that the α/β 
subunits remain associated after ER exit (Saito et al., 2004), but this does not 
necessarily reflect a requirement of β subunits for the α subunits beyond the ER Æ Golgi 
transport step. Since it is not possible to directly evaluate the function of Drs2p in its  
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Figure 1-5. Yeast P4-ATPases and their noncatalytic subunits (modified from Zhou et al., 
2010). The P4-ATPase (α subunit) is modeled on the crystal structure of SERCA1 in the 
E1·2Ca2+ conformation (Toyoshima et al., 2000). The connecting lines indicate the 
noncatalytic β subunit required to chaperone each P4-ATPase out of the ER. No β 
subunit for Neo1p has been identified. 
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native Golgi membrane environment in the absence of Cdc50p, alternative strategies are 
required. For example, a conditional allele of CDC50 that disrupts its association with 
Drs2p could potentially be used to assess the requirement of the Drs2p-Cdc50p 
interaction for the flippase activity. 
 
Section 1.2: Drs2p as a Potential Flippase 
 
Section 1.2.1: Flip-flop of phospholipids 
Phospholipids are amphiphilic molecules that can freely diffuse laterally in their own 
leaflet, but face a substantial barrier to transverse movement across the bilayer, known 
as flip-flop, due to their hydrophilic head groups. This barrier can be circumvented by 
involvement of lipid transporters, and several different types of lipid transporters are 
proposed to exist in eukaryotic cells (Daleke, 2003; Devaux, 1992; Graham, 2004; 
Menon, 1995; Pomorski et al., 2004) (Figure 1-6). The ER contains an ATP-independent 
flippase activity that moves phospholipids bidirectionally and without apparent 
headgroup specificity (Bishop and Bell, 1985; Menon et al., 2000). This ER flippase 
activity is presumably responsible for balanced growth of both leaflets of the ER during 
phospholipid synthesis, which appears to be catalyzed primarily on the cytosolic leaflet. 
Therefore, the ER membrane should be symmetric in lipid distribution. Membrane 
asymmetry appears to be generated in the post-ER compartments by ATP-consuming 
flippases and floppases that translocate specific lipid substrates unidirectionally across 
the membrane bilayer. Flippases mediate the inward movement of phospholipid from the 
extracellular or lumenal leaflet to the cytosolic leaflet of the membrane, whereas 
floppases act in the reverse, outward direction. The scramblase, upon activation, 
collapses the lipid asymmetry of the plasma membrane and results in PS and PE 
exposure on the outer leaflet. 
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Figure 1-6. Proteins proposed to mediate the transbilayer movement of phospholipids 
and regulate membrane asymmetry (modified from Graham, 2004). ATP-dependent 
flippases mediate the inward movement of phospholipids from the extracellular or 
lumenal leaflet to the cytosolic leaflet of membranes, whereas floppases catalyze the 
opposing outward movement of phospholipids. Scramblase at the plasma membrane is 
activated by Ca2+ influx and causes exposure of phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) on the surface of the cell. The ER flippase allows 
phospholipids to diffuse across the ER membrane in an energy-independent manner 
without headgroup specificity. PI, phosphatidylinositol; PC, phosphatidylcholine; SM, 
sphingomyelin. 
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Despite decades of effort to uncover the identities of these lipid transporters, much 
uncertainty remains. The ER flippase has not been unambiguously identified (Sanyal et 
al., 2008), nor is the identity of the scramblase known even though several candidates 
have been suggested, including the ABC1/CED-7 ATP-binding cassette (ABC) 
transporters (Hamon et al., 2000; Venegas and Zhou, 2007; Wu and Horvitz, 1998), 
phospholipid scramblase (PLSCR) (Venegas and Zhou, 2007; Wang et al., 2007) and 
the TAT-1 P4-ATPase (Zullig et al., 2007). A class of ABC transporters involved in 
multidrug resistance (MDR) and bile secretion appears to be responsible for the floppase 
activity. For example, the human MDR3 and the mouse mdr2 P-glycoproteins 
specifically flop a PC analogue, NBD-PC (Ruetz and Gros, 1994), whereas the human 
MDR1 and the mouse mdr1a flop lipids with a broader substrate specificity including 
NBD-PC, NBD-PE and NBD-sphingomyelin (NBD-SM) (Raggers et al., 1999; Romsicki 
and Sharom, 2001; van Helvoort et al., 1996). The floppase function of ABC transporters 
appears to be conserved even in prokaryotic cells. For instance, MsbA is a bacterial 
ABC transporter that is closely related to mammalian MDR proteins and is responsible 
for translocation of the lipid A moiety of lipopolysaccharide and probably PE from the 
cytoplasmic leaflet to the periplasmic leaflet of the inner membrane of Gram-negative 
bacteria (Doerrler et al., 2004; Dong et al., 2005). Specific phospholipids (such as PS 
and PE) are rapidly transported inwardly by flippases, whereas floppases move a much 
broader spectrum of lipids outwardly. These activities may establish the observed 
phospholipid asymmetry of the plasma membrane. The primary candidates for the 
inward-directed flippase activity are members of the ATPase II/Drs2p P4-ATPase family 
(Alder-Baerens et al., 2006; Gomes et al., 2000; Natarajan et al., 2004; Pomorski et al., 
2003; Tang et al., 1996). 
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Section 1.2.2: Implication of Drs2p as a flippase 
The first flippase activity observed was the aminophospholipid translocase activity in 
the plasma membrane of human red blood cells and was subsequently found to exist in 
the plasma membrane of many other cell types (Devaux et al., 2006; Seigneuret and 
Devaux, 1984). Spin-labeled PS and to a lesser extent PE, but not PC, were found to 
undergo rapid transverse movement across the bilayer resulting in their enrichment in 
the inner, cytosolic leaflet. Furthermore, shape changes of red blood cells induced by 
externally added phospholipids are indicative of and correlative of incorporation of these 
phospholipids in the outer leaflet and subsequent translocation of some lipid species to 
the inner leaflet. For example, incorporation of PS, PE and PC in the outer leaflet 
induced crenation of red blood cells (Daleke and Huestis, 1985; Daleke and Huestis, 
1989; Seigneuret and Devaux, 1984) (Figure 1-7). PS-treated cells and to a lesser 
extent PE-treated cells reverted quickly from echinocytes back to discocytes and 
proceeded to stomatocytes, indicating movement of phospholipids to the cytosolic leaflet, 
whereas PC-treated cells remained echinocytes. 
The aminophospholipid translocase activity is Mg2+-ATP-dependent and sensitive to 
the ATPase inhibitors orthovanadate and N-ethylmaleimide, which are in good 
accordance with the properties of a novel ATPase, called ATPase II (now designated 
Atp8a1), purified from bovine chromaffin granules (Moriyama and Nelson, 1988). The 
connection between the aminophospholipid translocase activity and ATPase II/Atp8a1 
was further enhanced by the observation of PS flippase activity in bovine chromaffin 
granules with a similar inhibitor spectrum as ATPase II/Atp8a1 (Zachowski et al., 1989). 
Tang et al. cloned a cDNA encoding bovine ATPase II/Atp8a1, and found that it shares 
47% amino acid sequence identity and 67% similarity to the yeast protein Drs2p (Tang 
et al., 1996). There have been several reports describing purification of ATPase 
II/Atp8a1 (Ding et al., 2000; Paterson et al., 2006). Although this enzyme has not been  
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Figure 1-7. Shape changes of human red blood cells by scanning electron microscopy 
(modified from Daleke and Huestis, 1989). Echinocytes are assigned scores of +1 to +5 
with increasing value denoting more severe crenation. Discocytes are scored 0, and 
stomatocytes are assigned scores of -1 to -4 with decreasing value denoting more 
severe invagination. Therefore, from the most crenate state to the most invaginated 
state, the cell morphology changes from +5 to -4. Human red blood cells treated with a 
relatively high concentration of dilauroylphosphatidylserine (DLPS) undergo shape 
changes from +5 to -4 within 1 h. Treatment of dilauroylphosphatidylethanolamine 
(DLPE) also causes shape changes of red blood cells from +3 to -1, although at a slower 
rate (2-3 h). In contrast, dilauroylphosphatidylcholine (DLPC) treatment only induces 
echinocytes (~+4), which revert to discocytes very slowly (t1/2 ~ 8 h). Scale bar, 1 μm. 
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reconstituted into liposomes to demonstrate that it can directly catalyze phospholipid 
flippase activity, its ATPase activity was showed to be maximally stimulated by PS and 
not stimulated by PC, suggesting that PS is a preferred substrate for ATPase II/Atp8a1. 
 
Section 1.2.3: Yeast plasma membrane flippase activities 
While we still do not know if a P4-ATPase in a purified form is sufficient to catalyze 
phospholipid flippase activity, a number of studies have tested whether P4-ATPases are 
necessary for flippase activity using genetic approaches in yeast. As with mammalian 
cells, yeast also sequester most PS and PE to the inner leaflet of the plasma membrane, 
and possess flippase activity there that mediates translocation of PS and PE fluorescent 
analogues (NBD-PS and NBD-PE) (Chen et al., 2006; Grant et al., 2001; Kato et al., 
2002; Kean et al., 1997; Pomorski et al., 2003; Stevens et al., 2008; Tang et al., 1996). 
Distinct from the aminophospholipid translocase activity in the plasma membrane of 
human red blood cells, NBD-PC is also actively internalized by translocation (Grant et al., 
2001; Kean et al., 1997; Pomorski et al., 2003), indicating that the yeast plasma 
membrane flippase(s) has a broader substrate spectrum than the mammalian red blood 
cell counterpart. 
From the early studies after cloning of bovine ATPase II/Atp8a1, a major debate, that 
is still unresolved, has centered around the contribution of Drs2p to the yeast plasma 
membrane flippase activity that mediates NBD-PS uptake. Tang et al. exploited a back-
exchange approach to monitor the translocation of NBD-PS across the yeast plasma 
membrane under conditions of partial energy depletion and low temperature (4 C) to 
block endocytic uptake of the probe (Tang et al., 1996). Wild-type yeast cells showed 
substantial uptake of PS analogue whereas drs2∆ cells were defective in doing so, 
suggesting a critical role for Drs2p in NBD-PS flip. However, Siegmund et al. found no 
significant difference between a drs2∆ strain and its isogenic wild-type parent for NBD-
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PS uptake or distribution at low temperature using fluorescence microscopy or flow 
cytometry (Siegmund et al., 1998). The controversy continued as Marx et al. used an 
endocytosis mutant (end4∆) to prevent endocytic uptake of the probe, rather than using 
low temperature and partial energy depletion, and found only a mild reduction of NBD-
PS internalization in drs2∆end4∆ cells compared to the parental end4∆ strain (Marx et 
al., 1999). However, in another study on the ALA1 gene product, a Drs2p homolog in the 
plant Arabidopsis thaliana, Gomes et al. repeated the original observation made by Tang 
et al., and showed that heterologous expression of ALA1 in drs2∆ cells complemented 
the NBD-PS internalization defect (Gomes et al., 2000). 
The reasons for these experimental discrepancies are still unclear. However, factors 
that could have contributed to these contradictory results were the presence of other 
lipid transporters that may also contribute to NBD-PS uptake, the pleiotropic phenotypes 
caused by deletion of the DRS2 gene and lack of information on the subcellular 
localization of Drs2p. We know now that Drs2p is localized primarily to the trans Golgi 
network (TGN) rather than the plasma membrane (Chen et al., 1999; Hua et al., 2002). 
A relatively small percentage of Drs2p traffics to the plasma membrane, but the 
presence of multiple endocytosis signals in Drs2p ensures its rapid retrieval back to the 
TGN (Liu et al., 2007; Liu et al., 2008). The slow egress to the plasma membrane 
coupled with rapid removal leads to undetectable levels of Drs2p at the plasma 
membrane of wild-type cells grown under standard conditions. The influence of partial 
energy depletion and low temperature on Drs2p localization has not been tested. 
However, blocking endocytosis with an end4∆ mutant does cause a near complete 
redistribution of Drs2p to the plasma membrane (Liu et al., 2007). Therefore, the Marx et 
al. work suggests that Drs2p makes a relatively minor contribution to NBD-PS uptake 
across the plasma membrane under conditions where Drs2p is primarily localized to the 
plasma membrane. Overexpression of Drs2p and Cdc50p in an endocytosis mutant, 
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conditions that should dramatically increase the amount of Drs2p on the plasma 
membrane, only increased NBD-PS uptake across the plasma membrane by 2-3 fold 
relative to the control strains (Saito et al., 2004). As described below, Drs2p is required 
for robust NBD-PS flippase activity in Golgi membranes (Natarajan et al., 2004) and so it 
is surprising that redeployment of Drs2p to the plasma membrane leads to a relatively 
minor enhancement of NBD-PS flip in this location. We suggest that Drs2p is not fully 
active when it is at the plasma membrane. 
Two other members of the P4-ATPase family, Dnf1p and Dnf2p, are easily detected 
on the plasma membrane and are therefore more likely candidates for the plasma 
membrane flippase activities (Hua et al., 2002). Consistently, the energy-dependent 
uptake of NBD-PC and NBD-PE across the yeast plasma membrane is virtually 
abolished in the dnf1,2∆ double deletion mutant (Pomorski et al., 2003). In addition, the 
lem3∆ mutant, which accumulates Dnf1p and Dnf2p in the ER, also exhibits a near 
complete defect in NBD-PC and NBD-PE uptake (Hanson et al., 2003; Kato et al., 2002; 
Saito et al., 2004). Importantly, the internalization of Lyso-PE across the yeast plasma 
membrane is also impaired in dnf1,2∆ or lem3∆ cells, suggesting that Dnf1p-
Dnf2p/Lem3p can also pump a naturally occurring phospholipid across the plasma 
membrane (Riekhof and Voelker, 2006). Lyso-phospholipids are not transported at an 
appreciable rate by the aminophospholipid translocase in human red blood cells, again 
suggesting a unique mode of substrate recognition for the yeast plasma membrane 
flippases (Daleke and Huestis, 1985; Morrot et al., 1989). Other important potential 
substrates of Dnf1p-Dnf2p/Lem3p transport activity are edelfosine and miltefosine 
(Hanson et al., 2003). These drugs are phosphatidylcholine analogues that are toxic to 
leishmania and trypanosomes. The lem3∆ and dnf1,2∆ yeast strains are resistant to 
these drugs, as are leishmania harboring mutations in the analogous genes (Hanson et 
al., 2003; Perez-Victoria et al., 2006). 
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There remains some controversy on the influence of Dnf1p and Dnf2p on NBD-PS 
translocation across the yeast plasma membrane. The dnf1,2∆ cells were originally 
reported to be deficient in internalization of NBD-PS in addition to NBD-PC and NBD-PE 
(Pomorski et al., 2003). However, several groups found that in the lem3∆ strain, which 
should show the same phenotypes as dnf1,2∆ strains, only the NBD-PC and NBD-PE 
translocation uptake was impaired, leaving NBD-PS internalization unaffected or even 
increased (Hanson et al., 2003; Kato et al., 2002; Saito et al., 2004). A recent study also 
failed to detect any defect in NBD-PS uptake in dnf1,2∆ cells (Stevens et al., 2008). 
Moreover, this group tested a variety of strains carrying mutations in multiple P4-
ATPases and found no deficit in NBD-PS uptake. These data suggest that NBD-PS 
uptake across the plasma membrane is likely not catalyzed by a P4-ATPase, with the 
caveat that neo1 mutants were not tested. It seems that the protein(s) responsible for 
NBD-PS uptake across the yeast plasma membrane is still mysterious. Because the P4-
ATPase mutants also perturb protein trafficking (Chen et al., 1999; Hua et al., 2002; Hua 
and Graham, 2003; Liu et al., 2008; Pomorski et al., 2003), these mutants have great 
potential for displaying pleiotropic phenotypes, for example by mislocalization of 
enzymes more directly involved in a transport process, perhaps contributing to the 
disparate data on the influence of drs2 and dnf mutations on NBD-PS uptake across the 
yeast plasma membrane. 
 
Section 1.2.4: Drs2p-dependent flippase activity in Golgi membranes 
The most direct evidence supporting the potential flippase activity of Drs2p came from 
experiments designed to test if Drs2p is required for an NBD-PS flippase activity in yeast 
TGN membranes (Natarajan et al., 2004), where Drs2p is primarily localized. TGN 
membranes isolated from wild-type yeast cells contained an ATP-dependent activity that 
translocates NBD-PS, and to a lesser extent NBD-PE, from the inner (lumenal) leaflet to 
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the outer (cytosolic) leaflet of the membrane. No NBD-PC flippase activity was observed 
with TGN membranes. This assay required the presence of NBD-phospholipid probes in 
the inner leaflet of the isolated TGN membranes, which was achieved by initial 
incorporation of probes in the outer leaflet and incubation of the membrane in the 
absence of ATP to allow passive diffusion of the probes to the inner leaflet. Flipping of 
NBD-phospholipid probes back to the outer leaflet, induced by ATP addition, was 
monitored by accessibility of the probe to BSA back-extraction (Natarajan and Graham, 
2006; Natarajan et al., 2004). 
Because of the controversies surrounding the influence of deleting DRS2 on NBD-PS 
translocation across the plasma membrane, we sought a method to assess the 
contribution of Drs2p to the TGN flippase activity that could avoid the pleiotropic 
consequences of deleting DRS2. Ideally, one would like to compare the flippase activity 
in two TGN membrane preparations that are identical except for the presence or 
absence of one protein, in this case Drs2p. However, deletion of DRS2 causes 
mislocalization of TGN resident proteins, and TGN membranes from drs2∆ cells were 
deficient in multiple proteins relative to the wild-type control membranes (Chen et al., 
1999; Hua et al., 2002). To circumvent this problem, a temperature-conditional allele of 
drs2 was isolated that could be used to assess the immediate consequences of 
inactivating Drs2p function (Gall et al., 2002). Strains carrying Drs2p-ts as the sole 
source of Drs2p were grown at permissive temperature, where Drs2p-ts is active, so a 
“normal” TGN membrane preparation could be harvested. This membrane preparation 
was split in half and assayed for flippase activity at permissive and nonpermissive 
temperatures (Natarajan et al., 2004). Thus, two membrane samples that are identical 
except for the presence or absence of the activity of a single enzyme could be compared. 
Robust ATP-dependent translocation activity for NBD-PS was detected at permissive 
temperature (27 C), but was lost when the membranes were assayed at nonpermissive 
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temperature (37 C). As a control, the TGN membrane isolated from an isogenic strain 
containing wild-type DRS2 showed a similar NBD-PS flippase activity at both 27 C and 
37 C. These results indicate that Drs2p activity is necessary for the NBD-PS flippase 
activity in the TGN membrane, and Drs2p most likely catalyzes this activity directly. No 
NBD-PE flippase activity was detected with the temperature-conditional mutant form of 
Drs2p, possibly due to insufficient sensitivity of this assay for detecting NBD-PE 
translocation. 
Surprisingly, PS is not an obligatory substrate for Drs2p function in vivo even it 
appears to be the preferred substrate in vitro. Loss of Drs2p function (drs2∆) perturbs 
various protein trafficking pathways (Chen et al., 1999; Hua et al., 2002; Liu et al., 2008). 
If translocation of PS by Drs2p is required to support the role of Drs2p in protein 
trafficking, we would expect cells deficient for PS to display a similar defect. However, 
cho1∆ yeast cells that lack the de novo PS synthesis and are devoid of PS do not 
phenocopy the trafficking defects of drs2∆ (Natarajan et al., 2004). The cho1∆ cells 
transport proteins normally via the secretory pathway, and still require Drs2p for protein 
transport as trafficking defects were observed in drs2∆cho1∆ cells. Therefore, Drs2p 
must have at least one additional substrate other than PS. 
PE may be such a candidate substrate for Drs2p. Saito et al. showed that in addition 
to increased NBD-PS uptake, the accumulation of Drs2p-Cdc50p on the plasma 
membrane of endocytosis mutants also increased NBD-PE internalization (Saito et al., 
2004). Consistently, Alder-Baerens et al. reported a Drs2p-dependent activity that was 
responsible for NBD-PS and NBD-PE translocation across yeast secretory vesicle 
membranes when Drs2p was overexpressed (Alder-Baerens et al., 2006). Importantly, 
this group also showed an ATP-dependent translocation of endogenous PE to the 
cytosolic leaflet of the vesicle membrane, and this activity was abolished in a 
drs2∆dnf3∆ strain. Thus, Drs2p may flip both PE and PS across the TGN membrane, 
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and it is possible that translocation of either substrate is sufficient to support Drs2p-
dependent protein trafficking pathways. However, it is also possible that Drs2p has 
additional lipid or nonlipid substrates that contribute to vesicle budding. 
Although a substantial amount of evidence supports the hypothesis that Drs2p and 
P4-ATPases in general are flippases, the possibility that they may not be direct 
phospholipid transporters cannot be ruled out. For example, in an alternative model, 
Drs2p family members may pump an undetermined ion to establish an ion gradient 
across the membrane, which can be used as an energy source by a second transporter 
(symporter) that is coupled to phospholipid translocation. This hypothesis has been 
partially tested in the isolated TGN membranes with a Drs2p-dependent NBD-PS 
flippase activity (Natarajan et al., 2004). Substitution of other ions for Na+ and Cl-, which 
were the major ions in the assay, did not affect NBD-PS translocation. Thus, if Drs2p 
pumps an ion (or heavy metal) across the membrane, it would have to do so with either 
a lack of ion specificity, or be able to drive the lipid translocation process using a very 
dilute external ion concentration (i.e. contaminating ions in the sample). Potentially 
supporting a secondary transport model, a proton gradient seems to be necessary for 
the translocation of NBD-PC, NBD-PE and NBD-PS across the yeast plasma membrane 
(Hanson and Nichols, 2001; Stevens et al., 2008; Stevens and Nichols, 2007). This 
gradient is generated by the plasma membrane H+ ATPase (Pma1p) rather than the P4-
ATPases Dnf1p/Dnf2p, so how a proton gradient contributes to the Dnf-dependent 
flippase activity is still unclear. The most definitive approach to determine if the P4-
ATPase family members are flippases is to biochemically reconstitute a purified P4-
ATPase into chemically defined proteoliposomes and assay for flippase activity. This has 
been a major goal in the flippase field for 25 years and has not yet been achieved. 
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Section 1.2.5: P4-ATPases in yeast membrane asymmetry 
One major function proposed for Drs2p and other P4-ATPases is to generate and 
maintain membrane phospholipid asymmetry (Daleke, 2003; Devaux, 1992; Graham, 
2004; Pomorski et al., 2004). The fact that the yeast plasma membrane is asymmetrical 
with PS and PE restricted to the cytosolic leaflet suggests that the membrane 
asymmetry must be established as membranes flow through the Golgi and/or upon 
arrival at the plasma membrane. The detection of energy- and P4-ATPase-dependent 
translocation activities for NBD-derivatives of PS, PE and/or PC analogues in the TGN 
(Natarajan et al., 2004), post-Golgi secretory vesicles (Alder-Baerens et al., 2006) and 
the plasma membrane (Pomorski et al., 2003; Riekhof and Voelker, 2006; Stevens et al., 
2008) suggests that P4-ATPases may act at multiple sites to establish and maintain 
phospholipid asymmetry in yeast. While PS and PE are restricted to the cytosolic leaflet, 
the distribution of PC between the inner and outer leaflets of the yeast plasma 
membrane has not been characterized. The presence of an NBD-PC translocase activity 
suggests that PC might also be restricted to the inner leaflet. Intriguingly, the plasma 
membrane of yeast has nearly equal parts of glycosphingolipid and glycerophospholipid 
by mass (Hechtberger et al., 1994; Zinser et al., 1991), perhaps suggesting a partitioning 
of these two lipid classes on either side of the plasma membrane. 
When the function of one or more P4-ATPases is disrupted, the asymmetrical 
distribution of PS and PE on the plasma membrane is perturbed. The detection of cells 
exposing PS and PE on the outer leaflet is greatly facilitated by reagents that specifically 
target, bind, or react with these lipid species, including the use of Ro09-0198 (Ro) 
peptide for PE detection (Chen et al., 2006; Kato et al., 2002; Pomorski et al., 2003), 
papuamide B (PapB) (Chen et al., 2006; Parsons et al., 2006) and annexin V for PS 
detection (Chen et al., 2006; Hamon et al., 2000; Zullig et al., 2007), and 
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trinitrobenzenesulfonic acid (TNBS) (Alder-Baerens et al., 2006; Pomorski et al., 2003) 
for aminophospholipid detection (PE and PS). 
Ro is a tetracyclic peptide antibiotic that specifically binds PE exposed on the cell 
surface and causes cytolysis (Aoki et al., 1994). In a genetic approach to identify 
flippases in yeast that control phospholipid asymmetry of the plasma membrane, yeast 
cells were screened for mutants that exhibit hypersensitivity to Ro peptide (Kato et al., 
2002). One of the most sensitive mutants isolated was ros3 (for Ro-sensitivity), 
indicating more PE was exposed on the cell surface in this mutant. ROS3 (also known 
as LEM3) encodes the chaperone and potential β subunit for Dnf1p and Dnf2p (Saito et 
al., 2004). Moreover, cells losing both Dnf1p and Dnf2p function (dnf1,2∆) exposed more 
endogenous PE to the outer leaflet of the plasma membrane compared to wild-type cells, 
as judged by increased availability to TNBS labeling and increased Ro sensitivity 
(Pomorski et al., 2003). Disruption of DRS2 in dnf1,2∆ cells caused even more PE 
exposure, supporting the role suggested for Drs2p in regulating the plasma membrane 
asymmetry by pumping PE to the cytosolic leaflet of the Golgi prior to export of 
membrane in vesicles targeted to the plasma membrane. Consistently, isolated post-
Golgi secretory vesicles also exhibited less PE to the cytosolic leaflet when the function 
of Drs2p and/or Dnf3p was disrupted (Alder-Baerens et al., 2006). 
In a recent study, PapB, a cyclic lipopeptide, was shown to specifically target PS 
exposed on the cell surface to induce cytolysis (Chen et al., 2006; Parsons et al., 2006). 
Hypersensitivity to PapB and the PS-binding protein annexin V were used to monitor the 
exposure of PS in the P4-ATPase and Cdc50p family mutants. drs2∆, cdc50∆ and 
several P4-ATPase mutant combinations, such as dnf1,2∆, exposed significantly more 
endogenous PS on the cell surface than did wild-type cells. Particularly, the triple mutant 
drs2∆dnf1,2∆ exposed much more PS than either drs2∆ or dnf1,2∆ mutants, supporting 
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the hypothesis that Drs2p at the TGN and Dnf1p/Dnf2p on the plasma membrane are 
working together to maintain PS asymmetry of the plasma membrane. 
An important caveat of this interpretation is that drs2∆, cdc50∆ and other mutants 
such as dnf1,2∆ also perturb the exocytic and endocytic protein transport pathways 
(Chen et al., 1999; Chen et al., 2006; Hua et al., 2002). Thus, it is possible that loss of 
PS asymmetry of the plasma membrane is an indirect consequence of protein and 
membrane trafficking perturbation in these mutants. In fact, clathrin and ARF mutants 
(chc1∆, clc1∆ and arf1∆), as well as endocytosis mutants (end3∆ and end4∆), also 
exposed PS on the cell surface to a level that is comparable to drs2∆ (Chen et al., 2006). 
Surprisingly, a screen of the entire yeast knockout collection for PapB sensitivity 
identified several hundred mutants that displayed an increased sensitivity to PapB 
relative to wild-type cells (Parsons et al., 2006). Moreover, acute inactivation of Drs2p or 
clathrin function by shifting cells bearing drs2-ts or chc1-ts alleles to nonpermissive 
temperature failed to cause exposure of PS on the cell surface (Chen et al., 2006), 
suggesting that loss of PS asymmetry of the plasma membrane may be a secondary 
consequence of a chronic defect in protein transport. Because of a lack of specificity for 
this mutant phenotype, loss of plasma membrane phospholipid asymmetry in P4-
ATPase mutants does not prove that these enzymes directly pump endogenous 
phospholipid across the membrane, nor can these phenotypes be used to infer substrate 
specificity for the P4-ATPases. Again, reconstitution of a P4-ATPase may provide a 
solution to this problem if sufficiently sensitive assays to measure natural phospholipid 
asymmetry in proteoliposomes can be established. 
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Section 1.3: Drs2p in Protein Transport and Vesicle Budding 
 
Section 1.3.1: Vesicle-mediated protein transport 
Protein transport in the exocytic and endocytic pathways is primarily mediated by 
small transport vesicles (Kirchhausen, 2000b) (Figure 1-8). For example, vesicles 
coated with coat protein complex II (COPII) bud from the ER and transport protein 
cargos to the Golgi, whereas COPI-coated vesicles mediate the retrograde transport 
from the Golgi back to the ER. Clathrin associates with pathway-specific adapter 
proteins (APs) and generates clathrin-coated vesicles from the TGN, endosomes and 
the plasma membrane. Vesicle budding involves a sequence of critical steps, including 
recruitment of coat components and accessory proteins to the proper membrane site, 
coat assembly, membrane deformation, incorporation of cargo, and finally scission to 
release the vesicle. 
ADP-ribosylation factor (ARF) is a small GTP-binding protein that plays a key role in 
vesicle biogenesis by directly binding and recruiting coat proteins onto membranes 
(D'Souza-Schorey and Chavrier, 2006). ARF-dependent coats include the COPI 
coatomer complex, clathrin/AP-1, clathrin/GGA (Golgi-localized, γ-ear-containing, ARF-
binding protein), AP-3 and AP-4 coat complexes. ARF acts as a molecular switch by 
cycling between active GTP-bound and inactive GDP-bound forms. The GDP-bound 
form is largely soluble, whereas the GTP-bound form exposes its myristoylated N-
terminus and associates with membranes. The cycling of ARF between its two 
nucleotide bound states requires catalytic assistance from two classes of proteins. The 
guanine nucleotide exchange factors (GEFs) promote exchange of GDP for GTP, 
whereas the GTPase-activating proteins (GAPs) stimulate the hydrolysis of GTP by ARF 
to convert the GTP-bound to the GDP-bound form (Donaldson and Jackson, 2000). 
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Figure 1-8. Vesicle-mediated protein transport and P4-ATPase requirements in various 
trafficking pathways in budding yeast (modified from Muthusamy et al., 2009a). 
Trafficking pathways are defined by cargo proteins (blue text) traveling the route and the 
vesicle coat proteins (labeled in the upper right quadrant) required for sorting and 
transport of the cargo. The three major transporting vesicles are coated by COPI (purple 
coat), COPII (orange coat), and clathrin (yellow, red and blue coats). The coat 
requirement for the early endosome to TGN recycling pathway traveled by Snc1p is 
indicated by Rcy1p, although it is not known if Rcy1p is a vesicle coat constituent. 
Pathways with known P4-ATPase requirements are indicated with colored arrows (see 
text for details). 
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In S. cerevisiae, ARF is encoded by an essential pair of genes, ARF1 and ARF2, 
which are 96% identical in protein sequence and redundant in function (Stearns et al., 
1990a; Stearns et al., 1990b). In wild-type cells, Arf2p is only expressed at 10% of the 
level of Arf1p and strains carrying arf2∆ show a wild-type phenotype (Stearns et al., 
1990a). In contrast, arf1∆ cells exhibit partial defects in protein secretion and Golgi-
specific glycosylation (Stearns et al., 1990b), as well as altered morphology of the Golgi 
and endosomes (Gaynor et al., 1998). To identify other factors involved in vesicle 
biogenesis with ARF, a genetic screen for mutants that are synthetically lethal with arf1∆ 
(the swa mutants) was performed (Chen and Graham, 1998). Seven complementation 
groups were isolated and among them were DRS2 (SWA3) and CDC50 (SWA4) (Chen 
et al., 1999; Chen et al., 2006). This screen also isolated mutant alleles of the clathrin 
heavy chain gene (CHC1/SWA5) and yeast auxilin (SWA2), a protein required for 
uncoating clathrin-coated vesicles (Chen and Graham, 1998; Gall et al., 2000). 
 
Section 1.3.2: Roles of Drs2p-Cdc50p in protein transport 
The genetic interaction between DRS2 and ARF1 first implied a role for Drs2p in 
vesicle-mediated protein transport (Chen and Graham, 1998) (Figure 1-8). Drs2p is 
localized primarily to the TGN, where clathrin-coated vesicles are actively formed. 
Consistently, drs2∆ is also synthetically lethal with a temperature-sensitive allele of 
clathrin, and exhibits several phenotypes in common with clathrin mutants, such as 
accumulation of swollen Golgi cisternae (Chen et al., 1999). This phenotype normally 
indicates a defect in vesicle biogenesis from the Golgi. Consistent with this possibility, 
disruption of DRS2 resulted in a marked reduction of clathrin-coated vesicles that can be 
isolated from these cells (Chen et al., 1999). Another indication that Drs2p facilitates 
vesicle budding came from epistasis analyses in which drs2 alleles were combined with 
mutations that cause an accumulation of transport vesicles (Gall et al., 2002). For 
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example, disrupting the actin cytoskeleton (with the sla2∆ mutation or the drug 
latrunculin A, LatA) causes accumulation of the dense, post-Golgi vesicles carrying the 
exocytic protein invertase. Both clathrin and Drs2p are required for the formation of 
these vesicles as sla2∆ cells harboring temperature-sensitive alleles of DRS2 or clathrin 
rapidly lose these vesicles upon shift to nonpermissive temperature. 
Another similarity to clathrin mutants is that drs2∆ mislocalizes the TGN resident 
protein Kex2p (Chen et al., 1999; Natarajan et al., 2004), which normally cycles between 
the TGN and endosomal compartments to maintain its steady-state TGN localization 
(Bryant and Stevens, 1997). Therefore, Drs2p seems to be involved in the clathrin-
dependent protein trafficking between the TGN and early endosomes, a pathway 
associated with AP-1 and clathrin. Indeed, Drs2p was co-immunoprecipitated with AP-1 
and genetic data argued that Drs2p is essential for AP-1 function in yeast (Liu et al., 
2008). Drs2p itself appears to be a cargo of AP-1/clathrin-coated vesicles that bud from 
the TGN and are presumably targeted to the early endosome. This view is suggested by 
the observation that deletion of AP-1 subunits causes rerouting of Drs2p to the plasma 
membrane, where it can be trapped behind an endocytosis block (Liu et al., 2008). 
When the endocytosis block is lifted, Drs2p returns back to the TGN in the absence of 
AP-1. Thus, Drs2p likely uses an AP-1/clathrin pathway to move from the TGN to the 
early endosome, but does not use AP-1 for retrieval from the early endosome back to 
the TGN. 
Strikingly, inactivation of Drs2p activity (using the temperature-sensitive form of Drs2p) 
also causes rerouting of Drs2p to the plasma membrane (Liu et al., 2008). These data 
strongly suggest that the Drs2p activity drives the formation of AP-1/clathrin-coated 
vesicles from the TGN, and that Drs2p is a cargo of these vesicles. As mentioned above, 
the most likely destination for these AP-1 vesicles is the early endosome; however, it is 
also possible that these vesicles carry Drs2p back to earlier Golgi cisternae. Drs2p is 
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also required for the AP-1-dependent retrograde transport of a cargo protein, Chs3p, 
from the early endosome to the TGN (Liu et al., 2008). In the absence of AP-1 or Drs2p, 
Chs3p is rerouted into the late endosome. Thus, Drs2p is needed at both the TGN and 
early endosome to support AP-1/clathrin function. 
Drs2p and Cdc50p are also required for another early endosome to TGN pathway 
traveled by Snc1p, an exocytic v-SNARE (Hua et al., 2002; Sakane et al., 2006). Snc1p 
cycles in a TGN Æ plasma membrane Æ early endosome Æ TGN loop, but maintains 
steady-state localization at the plasma membrane of wild-type cells (Lewis et al., 2000). 
In contrast, drs2∆ or cdc50∆ cells accumulate Snc1p in punctate, cytosolic organelles, 
shown to be early endosomes in cdc50∆ (Furuta et al., 2007; Hua et al., 2002). The 
recycling of Snc1p also requires Rcy1p, an F-box protein involved in the early endosome 
to TGN transport (Wiederkehr et al., 2000). Cdc50p accumulates in the early endosome 
of rcy1∆ cells, suggesting that Drs2p also requires Rcy1p for retrieval back to the TGN. 
Furthermore, Drs2p-Cdc50p physically associates with Rcy1p, suggesting a direct role 
for Drs2p in budding the “Rcy1p” vesicles (Furuta et al., 2007). A subset of COPI 
mutations also perturb Snc1p recycling (Robinson et al., 2006) and so it is possible that 
Drs2p and Rcy1p facilitate budding of COPI vesicles. How Rcy1p contributes to protein 
transport is unknown. The Rab11 homologs Ypt31p and Ypt32p and the ARF-GAP 
Gcs1p are also implicated in the Snc1p recycling pathway and displayed genetic 
interactions with Drs2p and Cdc50p (Furuta et al., 2007; Sakane et al., 2006). 
 
Section 1.3.3: Influence of other P4-ATPases on protein transport 
Importantly, other members of P4-ATPase family are also involved in various protein 
trafficking pathways (Figure 1-8). Drs2p and Dnf ATPases constitute an essential group 
in yeast with functional redundancy, which also occurs at the level of protein transport 
(Hua et al., 2002). For example, Drs2p and Dnf1p show redundant functions for alkaline 
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phosphatase transport from the TGN to the vacuole in a pathway requiring AP-3, but not 
clathrin. Carboxypeptidase Y (CPY) transport from the TGN to the late endosome, a 
pathway that appears to use GGA adaptors and clathrin, is kinetically delayed in 
drs2∆dnf1∆ cells (Hua et al., 2002). A similar kinetic delay in CPY transport was 
observed when drs2∆ single mutant was shifted to a low, nonpermissive growth 
temperature (Chen et al., 1999). Disruption of DNF1 and DNF2 caused a cold-sensitive 
defect in the internalization step of endocytosis, which was exacerbated by additional 
disruption of DRS2, indicating these three proteins may contribute to endocytosis 
(Pomorski et al., 2003). Moreover, the dnf1,2∆ mutant accumulates Snc1p in internal 
membranes but has no affect on the trafficking of Ste2p, the α-factor receptor that 
travels the endocytic pathway to the vacuole for degradation, suggesting that Dnf1p and 
Dnf2p play overlapping roles with Drs2p in the early endosome to TGN pathway as well 
(Hua et al., 2002). 
The essential Neo1p has also been implicated in vesicle-mediated protein transport 
(Hua and Graham, 2003; Singer-Kruger et al., 2008; Wicky et al., 2004). The neo1-ts 
mutants show several defects at nonpermissive temperature in common with COPI 
mutants (Hua and Graham, 2003), including the cargo-specific defects in secretion, 
aberrant glycosylation of cargos in the Golgi and the mislocalization of Rer1p, a protein 
that normally cycles between the ER and the Golgi, to vacuole. These observations 
suggest that Neo1p is required for a COPI-dependent retrograde transport pathway from 
the Golgi to the ER, a pathway essential for yeast viability. On the other hand, neo1-ts 
mutants were also reported to exhibit fragmented vacuoles and defects in endocytosis 
(Wicky et al., 2004), accumulation of adapter protein Gga2p on aberrant membranes 
(Singer-Kruger et al., 2008) and delayed CPY transport (Wicky et al., 2004). Deletion of 
GGA2 or ARL1, which encodes an ARF-like protein that functions within the 
endosomal/Golgi system, suppressed the temperature-sensitive phenotype of neo1-ts 
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mutants (Singer-Kruger et al., 2008; Wicky et al., 2004). In addition, Neo1p showed both 
genetic and physical interactions with Ysl2p (Singer-Kruger et al., 2008; Wicky et al., 
2004), a potential GEF for Arl1p. Thus, Neo1p seems also to play a role in protein 
trafficking within the endosomal/Golgi system. 
 
Section 1.3.4: Endocytosis of Drs2p 
Drs2p maintains steady-state localization to the TGN, and cannot be detected on the 
plasma membrane of wild-type cells (Chen et al., 1999; Hua et al., 2002; Liu et al., 2007; 
Liu et al., 2008; Saito et al., 2004). However, in several endocytosis-defective mutants 
such as vrp1, end3 and end4, a substantial amount of Drs2p accumulates on the plasma 
membrane concomitant with a depletion of the TGN pool of Drs2p (Liu et al., 2007; Saito 
et al., 2004). This observation suggests that Drs2p transits the plasma membrane as 
part of its normal trafficking itinerary. Consistently, Drs2p is also found in post-Golgi 
secretory vesicles that are targeted to the plasma membrane (Alder-Baerens et al., 
2006). To determine the kinetics of Drs2p transport to the plasma membrane, cells 
expressing GFP-Drs2p were monitored over time after acutely blocking endocytosis by 
treatment with LatA (Liu et al., 2007), an inhibitor of actin assembly. GFP-Drs2p was 
found to accumulate very slowly on the plasma membrane over the course of ~3 h. 
Based on quantitative western blots, we estimate that wild-type yeast cells have ~4,000 
Drs2p molecules per cell distributed among 5-6 TGN cisternae. If the redistribution of 
Drs2p to the plasma membrane occurs linearly over the 3-h incubation with LatA, then 
only 20 Drs2p molecules per min (0.5% of the total) are transported from the TGN to the 
plasma membrane. Upon washout of LatA, Drs2p rapidly returns to the TGN, indicating 
that Drs2p must contain functional endocytosis signals (Liu et al., 2008). 
In yeast, two types of endocytosis signals have been characterized that sort 
membrane proteins into a clathrin/actin-based endocytic pathway for internalization from 
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the plasma membrane: sequences that mediate phosphorylation and ubiquitination of 
the cargo (Hicke and Dunn, 2003), such as PEST-like sequences (Roth et al., 1998), 
and the NPFXD motif (Howard et al., 2002). The NPFXD signal is recognized by the 
Sla1p subunit of an endocytic coat complex consisting of clathrin, Pan1p, End3p, 
Sla2p/End4p and Sla1p (Howard et al., 2002; Kaksonen et al., 2006; Newpher et al., 
2005). Pan1p is a member of the Eps15 family of modular scaffolding proteins and 
interacts with the clathrin binding proteins AP180 and epsin, as well as the Arp2/3 
complex (Aguilar et al., 2003; Duncan et al., 2001; Wendland and Emr, 1998). Therefore, 
Pan1p may be capable of linking adaptor-bound cargo proteins to clathrin and actin 
assembly. Pan1p, End3p and actin assembly are required for both ubiquitin-dependent 
and NPFXD-dependent endocytosis, while Sla1p is only required for endocytosis of 
cargos bearing the NPFXD signal (Howard et al., 2002; Miliaras et al., 2004). 
Drs2p contains two NPFXD motifs in its C-terminal cytosolic tail (Liu et al., 2007) 
(Figure 1-9A). These two NPFXD motifs interact with the Sla1p homology domain 1 in 
Sla1p. Surprisingly, disruption of Sla1p or the NPFXD motifs did not cause accumulation 
of Drs2p on the plasma membrane, suggesting the presence of other endocytic signal(s) 
in Drs2p. Sequence analysis of Drs2p revealed three PEST-like sequences on its N-
terminus, as well as several other weak PEST-like sequences throughout Drs2p. 
Deletion of all three N-terminal PEST-like sequences from Drs2p did not perturb its 
function, but caused accumulation of Drs2p on the plasma membrane in sla1∆ cells. 
These data indicate that Drs2p has multiple endocytosis signals that are functionally 
redundant. 
Interestingly, Dnf1p possesses an NPFXD motif near its N-terminus, which contributes 
significantly to its Sla1p-dependent endocytosis (Liu et al., 2007). However, the closely 
related Dnf2p does not contain such a motif. In addition, Dnf1p, but not Dnf2p, shows  
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Figure 1-9. Proposed model for Drs2p regulation by its C-terminal tail (modified from 
Natarajan et al., 2009). (A) The Drs2p C-terminal tail is predicted to be 137-aa long 
(R1219-I1355) (Chantalat et al., 2004). Various motifs are indicated below the 
corresponding sequences and are color coded throughout Figure 1-9. The 
phosphatidylinositol 4-phosphate (PI4P) binding region is slightly overlapped with the 
Gea2p (ARF-GEF) interacting region. Residues Q1254 and G1299 are also indicated, 
which are discussed in chapter III (see text for details). (B)-(D) A model is proposed for 
Drs2p regulation. In vivo, Drs2p is localized primarily to the trans Golgi network (TGN) 
and is auto-inhibited by its C-terminal tail in the absence of regulators (B). Upon binding 
of regulators, such as Gea2p and PI4P, to its C-terminal tail, Drs2p is activated and 
catalyzes ATP-dependent flippase activity (C). During Drs2p purification, a C-terminally 
cleaved form of Drs2p, designated “NoC” form, is generated by unknown proteolytic 
events (see chapter III for details). When reconstituted into artificial membranes, the 
Drs2p “NoC” form is active even in the absence of regulators such as Gea2p and PI4P, 
and is capable of catalyzing phosphatidylserine (PS) flippase activity (D). 
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redundant protein transport function with Drs2p at the TGN (e.g. in the AP-3 pathway) 
(Hua et al., 2002), suggesting that the NPFXD/Sla1p-dependent endocytosis of Dnf1p 
may be important for its function at the Golgi. Supportively, when the NPFXD motif of 
Dnf1p was mutated to the sequence found in Dnf2p, the mutant Dnf1p was unable to 
support protein transport in the AP-3 pathway (Liu et al., 2007). Similarly, mutation of 
Drs2p NPFXD motifs is lethal in pan1-20 cells (Liu et al., 2007). These data strongly 
imply that P4-ATPases cannot exert their essential function from the plasma membrane. 
 
Section 1.3.5: The C-terminal tail of Drs2p 
The C-terminal tail of Drs2p is essential to Drs2p function as a C-tail truncation allele 
of DRS2 cannot complement the cold-sensitive growth and protein transport defects of 
drs2∆ (Liu et al., 2007). The precise function of the C-terminal tail is not known, although 
it may serve a regulatory function analogous to the C-terminal tail of the plasma 
membrane Ca2+ ATPase in animals (Carafoli, 1994; Enyedi et al., 1989), or the plant or 
yeast plasma membrane H+ ATPase (Palmgren, 2001; Portillo, 2000). Three functionally 
important motifs have been mapped within the Drs2p C-terminal tail so far (from the N- 
to C-terminus): a Gea2p interacting region, a highly conserved region that follows right 
after the Gea2p interacting site, and the NPFXDs (Chantalat et al., 2004) (Figure 1-9A). 
The Gea2p interacting region binds directly to the SEC7 (GEF) domain of the ARF-GEF 
Gea2p, and mutations in the Gea2p interacting region only partially perturb Drs2p 
function in vivo. In addition, the Golgi localization of Gea2p was not perturbed in drs2∆ 
cells, so Drs2p is not required to recruit Gea2p to the Golgi. Adjacent to the Gea2p 
interacting region is a highly conserved region that is found in most close homologs of 
Drs2p, including mammalian ATPase II/Atp8a1. Deletion of this conserved region also 
partially disrupts Drs2p function in vivo. However, a deletion that impinges on both the 
Gea2p interacting region and the conserved region eliminates Drs2p function in vivo. 
  
37 
Recent work from our laboratory showed that the conserved region is part of a 
phosphatidylinositol 4-phosphate (PI4P) binding region that is homologous to a split PH 
domain (Natarajan et al., 2009). Furthermore, binding of Gea2p and PI4P to the C-
terminal tail of Drs2p was found to be necessary to activate the Drs2p flippase activity in 
isolated TGN membranes. These data further support a regulatory function of the C-
terminal tail to the Drs2p activity (Figure 1-9B and C). 
 
Section 1.3.6: Flippases and vesicle formation 
It has been proposed for many years that flippases may play a critical role in vesicle 
biogenesis and protein transport (Devaux, 1991; Graham, 2004; Pomorski et al., 2004). 
Translocation of phospholipids by flippases from the extracellular or lumenal leaflet to 
the cytosolic leaflet of the membrane increases the surface area of the cytosolic leaflet 
at the expense of the extracellular leaflet. As suggested by the bilayer couple hypothesis 
(Sheetz and Singer, 1974), the imbalance of phospholipid number and surface area of 
the membrane bilayer would result in membrane deformation and induction of 
membrane bending toward the side with more phospholipids and a larger surface area. 
For instance, incorporation of exogenous aminophospholipids (PS and PE) to the outer 
leaflet of human red blood cells caused an initial echinocytic morphological change to 
the cells (Daleke and Huestis, 1985; Daleke and Huestis, 1989; Seigneuret and Devaux, 
1984). Subsequent translocation of the added PS or PE to the inner leaflet, catalyzed by 
the aminophospholipid translocase, drove the cells back to discocytes or even 
stomatocytes. Therefore, changes in the shape of red blood cells (membrane curvature) 
correlate well with the imbalance of phospholipid number across the membrane bilayer 
(Figure 1-7). 
Many observations support the concept that unbalanced changes in monolayer 
surface area can impinge on vesicular transport. For example, sphingomyelinase 
  
38 
treatment of cells, which cleaves the head group from SM thereby reducing the surface 
area of the outer leaflet of the plasma membrane, drives ATP-independent formation of 
functional endocytic vesicles (Zha et al., 1998). Similarly, incorporation of exogenous PS 
or PE in the outer leaflet of the plasma membrane and subsequent translocation to the 
inner leaflet significantly enhances endocytosis. In contrast, addition of Lyso-PS, which 
cannot be translocated across the plasma membrane and remains in the outer leaflet, 
inhibits endocytosis (Farge et al., 1999). These observations are in agreement with the 
role proposed for flippases in vesicle budding. However, the limitation of these 
approaches is that they make use of unusual perturbations to the cells. The studies on 
yeast P4-ATPases demonstrate that these enzymes are part of the normal machinery 
required for vesicle-mediated protein transport, providing the first line of evidence that 
cells use a bilayer-couple mechanism under normal physiological conditions to support 
vesicle biogenesis. 
Generation of positive membrane curvature required for vesicle formation is a role that 
has traditionally been assigned to coat proteins such as clathrin (Kirchhausen, 2000a; 
Schmid, 1997). Structural studies have revealed an intrinsic curvature in the clathrin 
triskelion (Musacchio et al., 1999; Smith et al., 1998) and clathrin is capable of self-
assembly into polyhedral baskets in the absence of lipids (Woodward and Roth, 1978). 
In an in vitro system, clathrin-coated buds can form from protein-free liposomes with a 
minimal requirement of clathrin and adaptor proteins (Takei et al., 1998). However, 
recent theoretical studies estimated that the rigidity of clathrin-AP complex is of the 
same order of magnitude as the resistance of lipid membranes to bending (Nossal, 
2001), suggesting that the clathrin coat assembly is unlikely to provide sufficient energy 
to drive membrane deformation in vivo. Instead, it may serve to stabilize an already 
curved membrane and prevent the membrane from collapsing back into a planar form. In 
the “Brownian ratchet” model (Hinrichsen et al., 2006), membranes fluctuate 
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spontaneously, resulting in transient membrane invaginations, which could be captured 
by the clathrin lattice to form vesicles. Formation of the positive curvature may also be 
driven directly by accessory proteins such as the BAR-domain-containing proteins (Itoh 
and De Camilli, 2006; Ren et al., 2006) and epsins (Ford et al., 2002) with the capability 
of deforming membranes. 
Flippases may facilitate vesicle formation by several means (Figure 1-10). First, 
flippases may help generate the positive curvature and prime the membrane 
deformation by pumping phospholipids across the membrane bilayer using the energy 
from ATP hydrolysis (Graham, 2004). Secondly, flippases (e.g. Drs2p) may interact 
directly with coat/accessory proteins (e.g. the AP-1 complex, the ARF-GEF Gea2p and 
Rcy1p) (Chantalat et al., 2004; Furuta et al., 2007; Liu et al., 2008), recruit and 
concentrate these proteins to vesicle budding sites. Interestingly, loss of Drs2p perturbs 
clathrin/AP-1 function and formation of clathrin-coated vesicles but not the association of 
clathrin/AP-1 to the membrane (Chen et al., 1999; Gall et al., 2002; Liu et al., 2008l), 
suggesting that the recruitment role of Drs2p is less important. Rather, the ability of 
Drs2p to generate and/or stabilize positive curvature appears to be more critical to the 
process of vesicle formation. Another influence that flippases may have on vesicle 
biogenesis is that, in the process of translocation of specific phospholipids, flippases 
could concentrate certain lipid species and generate a unique local membrane 
environment (e.g. PE-rich) that is necessary and favorable for vesicle budding. A 
reconstitution system with purified flippases and chemically defined liposomes should be 
useful to assess these hypotheses. 
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Figure 1-10. Proposed model for how Drs2p flippase activity could drive budding of AP-
1/clathrin-coated vesicles (modified from Zhou et al., 2010). Interaction of Drs2p (green) 
with ARF-GEF (Gea2p) helps concentrate ARF (Arf1p), AP-1 (blue) and clathrin triskelia 
(black) at sites of phospholipid translocation. Flippase activity induces membrane 
curvature that is stabilized and localized by assembly of the clathrin lattice. Drs2p is not 
required for recruitment of ARF-GEF, AP-1 or clathrin to the TGN, but these coat 
components appear to be incapable of forming vesicles without Drs2p. 
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Section 1.4: Objectives of the current project 
Research on Drs2p and other yeast P4-ATPases has supported their proposed 
flippase function, and greatly expanded our understanding of how membrane asymmetry 
is generated. From its position in the TGN and the early endosome, Drs2p controls the 
trafficking of proteins between the Golgi, plasma membrane and endocytic pathway, 
thereby influencing the protein composition of the plasma membrane as well as the lipid 
organization in this membrane. Furthermore, the requirement of Drs2p in protein 
trafficking pathways is tightly correlated with the proposed phospholipid flippase activity. 
Conditional mutations in Drs2p inactivate both flippase activity in vitro and vesicle 
budding in vivo. Thus, Drs2p appears to prime the membrane in the TGN-endosomal 
system for delivery to the cell surface by imparting curvature to the membrane to 
facilitate protein sorting into different vesicle-mediated transport pathways, and by 
establishing an asymmetric concentration of PS and PE in the cytosolic leaflet. 
However, many uncertainties remain. For example, although Drs2p is necessary for 
NBD-PS flippase activity in the TGN membrane, is it sufficient to directly catalyze this 
activity when purified and reconstituted in proteoliposomes? What role does Cdc50p 
play in phospholipid translocation? Are there additional, unknown components of the 
phospholipid transport system, such as an ion-coupled phospholipid symporter? How is 
the activity of Drs2p regulated? Does Drs2p induce curvature in the membrane to 
facilitate vesicle formation or is it coupled to vesicle biogenesis by another mechanism? 
The current project was carried out to seek answers to these questions. 
In chapter II, I describe the purification of Drs2p, its reconstitution into chemically 
defined artificial membranes, and the development of an assay for testing if the purified 
Drs2p catalyzes flippase activity directly. The biochemical reconstitution of flippase 
activity has been deemed as a most direct test on the hypothesis that Drs2p and P4-
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ATPases are flippases and has been pursued for years. In a reconstitution system, the 
requirement of Cdc50p and other components for flippase activity can also be assessed. 
In chapter III, I describe a potential regulation of Drs2p activity by its C-terminal tail. 
This study was inspired by an interesting observation that Drs2p purified using a C-
terminal tag seems to be always inactive. The C-terminal tail of Drs2p has been 
suggested to be auto-inhibitory in vivo. Therefore, a mechanistic dissection of the 
inactive, C-terminally purified Drs2p will help to understand the regulation of Drs2p 
activity in vivo. 
In chapter IV, I describe several techniques to generate giant unilamellar vesicles 
(GUVs). The ultimate goal of this study is to reconstitute Drs2p into GUVs and test if 
Drs2p can induce membrane curvature and potentially vesicle budding by phospholipid 
translocation. The preliminary study in this chapter should provide useful information for 
future biochemical reconstitution and morphological studies of Drs2p-containing GUVs. 
Completion of the current project will provide answers to some key questions in the 
flippase field, as well as establishing new techniques and tools to address remaining 
questions in the future. 
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CHAPTER II* 
 
RECONSTITUTION OF PHOSPHOLIPID TRANSLOCASE ACTIVITY WITH PURIFIED 
DRS2 PROTEIN, A TYPE-IV P-TYPE ATPASE FROM BUDDING YEAST 
 
Section 2.1: Abstract 
Type-IV P-type ATPases (P4-ATPases) are putative phospholipid translocases, or 
flippases, that translocate specific phospholipid substrates from the exofacial to the 
cytosolic leaflet of membranes to generate phospholipid asymmetry. In addition, the 
activity of Drs2p, a P4-ATPase from Saccharomyces cerevisiae, is required for vesicle-
mediated protein transport from the Golgi and endosomes, suggesting a role for 
phospholipid translocation in vesicle budding. Drs2p is necessary for translocation of a 
fluorescent phosphatidylserine (PS) analogue across purified Golgi membranes. 
However, flippase activity has not been reconstituted with purified Drs2p, or any other 
P4-ATPase, and so whether these ATPases directly pump phospholipid across the 
membrane bilayer is unknown. Here, we show that Drs2p can directly catalyze 
phospholipid translocation through purification and reconstitution of this P4-ATPase into 
proteoliposomes. The noncatalytic subunit, Cdc50p, was also reconstituted in the 
proteoliposome although at a substoichiometric concentration relative to Drs2p. In 
proteoliposomes containing Drs2p, a PS analogue is actively flipped across the liposome 
bilayer to the outer leaflet in the presence of Mg2+-ATP, while no activity toward the 
phosphatidylcholine (PC) or sphingomyelin (SM) analogues was observed. This flippase 
activity is mediated by Drs2p, since protein-free liposomes or proteoliposomes 
reconstituted with a catalytically inactive form of Drs2p show no translocation activity. 
These data demonstrate for the first time the reconstitution of flippase activity with a 
purified P4-ATPase. 
*This chapter was modified from: Zhou X and Graham TR (2009) Reconstitution of phospholipid translocase activity with 
purified Drs2p, a type-IV P-type ATPase from budding yeast. Proc Natl Acad Sci U S A 106:16586-16591. 
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Section 2.2: Introduction 
Phospholipids are asymmetrically distributed across the plasma membrane of 
eukaryotic cells and the control of this membrane asymmetry plays important roles in 
many cellular processes (Bretscher, 1973; Devaux, 1992). For example, in resting 
human red blood cells, phosphatidylserine (PS) and phosphatidylethanolamine (PE) are 
primarily restricted to the inner leaflet of the plasma membrane, while 
phosphatidylcholine (PC) and sphingomyelin (SM) are exposed on the cell surface 
(Devaux, 1992; Zwaal and Schroit, 1997). Regulated exposure of PS in the outer leaflet 
of red blood cells and platelets provides an interface for stimulating coagulation 
reactions (Zwaal and Schroit, 1997). Apoptotic cells also expose PS as a signal for 
removal by macrophages or other cells (Williamson and Schlegel, 2002). In addition, 
phospholipid asymmetry of the bile canalicular membrane is critical to the integrity of 
membrane and normal bile secretion by hepatocytes (Cai et al., 2009; Paulusma et al., 
2006). Loss of phospholipid asymmetry caused by mutations in the human 
FIC1/ATP8B1 gene may be the fundamental cause of the liver disease progressive 
familial intrahepatic cholestasis (PFIC), and its milder form, benign recurrent intrahepatic 
cholestasis (BRIC) (Bull et al., 1998; Folmer et al., 2009). The altered membrane 
structure appears to make the bile canalicular membrane susceptible to damage by 
secreted bile (Cai et al., 2009; Paulusma et al., 2006). 
Membrane asymmetry is thought to be generated by proteins that transport 
phospholipids unidirectionally across a membrane bilayer (Daleke, 2003; Devaux, 1992; 
Graham, 2004; Pomorski et al., 2004). ATP-dependent flippases are proposed to 
mediate the inward movement of phospholipid from the extracellular leaflet to the 
cytosolic leaflet, whereas the opposing outward transport is carried out by floppases. It 
has been suggested that a subset of ATP-binding cassette (ABC) transporters involved 
in multidrug resistance (MDR) and bile secretion, including human MDR1 P-
  
45 
glycoprotein/ABCB1, MDR3/ABCB4, MRP1/ABCC1, and their homologs in other 
organisms, catalyzes floppase activity (Daleke, 2003; Pomorski et al., 2004). Several of 
these ABC transporters have been purified and reconstituted into liposomes. For 
example, proteoliposomes formed with MDR1 P-glycoprotein purified from Chinese 
hamster ovary cells were shown to transport a variety of lipid analogues, including PS, 
PE, PC, SM and glucosylceramide analogues bearing a fluorescent 7-nitro-2-1,3-
benzoxadiazol-4-yl (NBD) group, across the liposome bilayer (Eckford and Sharom, 
2005; Romsicki and Sharom, 2001). Another class of active transporters, the P4-
ATPases, is proposed to catalyze the flippase activity that restricts PS and PE to the 
cytosolic leaflet of the plasma membrane (Daleke, 2003; Graham, 2004; Pomorski et al., 
2004). Slow flop of phospholipids without headgroup specificity, combined with rapid flip 
of PS and PE, is thought to establish the observed membrane asymmetry. 
The first ATP-dependent flippase activity described was the aminophospholipid 
translocase in human red blood cells, which rapidly translocates spin-labeled or 
unmodified PS and PE in the outer leaflet of the plasma membrane to the inner leaflet 
(Daleke and Huestis, 1985; Seigneuret and Devaux, 1984). Since the discovery of the 
aminophospholipid translocase, a major goal has been to define the enzyme responsible 
for this activity through purification and reconstitution. Flippase activity toward spin-
labeled PS and PE analogues has been reconstituted with a partially purified, but 
unidentified, Mg2+-ATPase from human red blood cells (Auland et al., 1994). ATPase 
II/Atp8a1, a Mg2+-ATPase that potentially catalyzes aminophospholipid translocase 
activity in bovine chromaffin granules (Zachowski et al., 1989), has been purified to 
homogeneity (Ding et al., 2000; Paterson et al., 2006). Phylogenetic analysis of the 
ATPase II/Atp8a1 sequence indicates that it is a member of the P4-ATPase family (Tang 
et al., 1996), which includes Fic1/Atp8b1 and Drs2p from yeast (Axelsen and Palmgren, 
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1998; Kuhlbrandt, 2004). However, flippase activity has not been reconstituted with any 
purified P4-ATPase, including mammalian ATPase II/Atp8a1. 
Although it is not known if a P4-ATPase in a purified form is sufficient to catalyze 
flippase activity, yeast P4-ATPases are necessary for flippase activities detected in the 
plasma membrane (Pomorski et al., 2003; Riekhof and Voelker, 2006; Stevens et al., 
2008), secretory vesicles (Alder-Baerens et al., 2006) and the trans-Golgi network (TGN) 
(Natarajan et al., 2004). Drs2p is localized primarily to the TGN (Chen et al., 1999; Hua 
et al., 2002), and requires a chaperone protein Cdc50p for its proper localization (Chen 
et al., 2006; Saito et al., 2004). Isolated TGN membranes containing a temperature-
sensitive mutant form of Drs2p translocate NBD-PS, but not NBD-PC, to the cytosolic 
leaflet at permissive temperature (Natarajan et al., 2004). However, inactivation of this 
mutant Drs2p at higher temperature ablates the NBD-PS flippase activity (Natarajan et 
al., 2004). One possible interpretation of these data is that Drs2p directly pumps 
phospholipid substrates across membrane bilayer. Alternatively, Drs2p may pump an 
unidentified ion into the TGN to generate an ion gradient, which is then coupled by 
another transporter (an unidentified symporter) to phospholipid translocation. To gain 
further insight into the mechanism of phospholipid translocation, we sought to purify and 
reconstitute Drs2p to determine if it can directly pump phospholipid substrates across a 
lipid bilayer. 
Towards the goal of reconstituting Drs2p, we have overexpressed Drs2p in yeast and 
purified it using affinity purification techniques. The ATPase activity of purified Drs2p is 
Mg2+-ATP dependent and sensitive to orthovanadate. After reconstitution, the Drs2p-
containing proteoliposomes actively translocate NBD-PS to the outer leaflet upon 
addition of Mg2+-ATP, demonstrating that a purified P4-ATPase is sufficient to catalyze 
flippase activity. 
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Section 2.3: Materials and Methods 
 
Section 2.3.1: Reagents 
IgG Sepharose 6 Fast Flow, calmodulin Sepharose 4B and ATP (>99% purity) were 
from GE Healthcare (Uppsala, Sweden). Ni-NTA agarose was from Qiagen (Hilden, 
Germany). AcTEV protease and SimplyBlue SafeStain (Coomassie G-250) were from 
Invitrogen (Carlsbad, CA), and Bio-Beads SM-2 was from Bio-Rad (Hercules, CA). 
Phospholipids and fluorescent derivatives were from Avanti Polar Lipids (Alabaster, AL) 
and were egg PC (L-α-phosphatidylcholine from chicken egg), POPS (1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine), POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine), NBD-PS (1-palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]-
hexanoyl]-sn-glycero-3-phospho-L-serine), NBD-PC (1-palmitoyl-2-[6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]-hexanoyl]-sn-glycero-3-phosphocholine) and NBD-SM (N-[6-
[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]-hexanoyl]-sphingosine-1-phosphocholine). 
Lipids were dissolved in chloroform and stored at -20 C. 
 
Section 2.3.2: Yeast strains and protein purification 
Yeast strains used for protein purification were XZY10b (MATa his3 leu2 ura3 met15 
PGPD::DRS2::TAPC PGPD::CDC50), XZY38b (MATa his3 leu2 ura3 met15 
PGPD::DRS2::TAPC PGPD::CDC50 atp2∆::URA3), and XZY60m (MATα his3 leu2 ura3 lys2 
PGPD::TAPN::DRS2 PGPD::CDC50 atp2∆::URA3), where TAPC encodes the calmodulin 
binding peptide-TEV protease cleavage site-protein A tag, and TAPN encodes the 
protein A-TEV protease cleavage site-decahistidine tag. 
Yeast strains were grown in 1 liter of 2x YPD (2% yeast extract/4% peptone/4% 
dextrose) medium to saturation (usually 10-15 OD600/mL) at 30 C before harvesting by 
centrifugation at 5,000 x g for 5 min. All steps following harvest were performed at 4 C 
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unless otherwise stated. Cells were washed with 10 mM NaN3, resuspended in 20 mL of 
lysis buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl/10% glycerol), and lysed using an 
EmulsiFlex-C3 High Pressure Homogenizer (Avestin, Inc., Ottawa, Canada) at 25,000 
psi for 6 complete passes in the presence of protease inhibitors (500 μM benzamidine 
hydrochloride, 10 μM phenanthroline, 250 nM aprotinin, 3 μM pepstatin A, 4 μM 
leupeptin, 2 mM EDTA, 1 mM PMSF). The cell lysate was centrifuged at 15,000 x g for 
12 min and 10% polyoxyethylene 9-lauryl ether (C12E9) was added to the supernatant to 
a final concentration of 1%. Samples were mixed on an end-over-end rotator for 2 h to 
solubilize Drs2p. 400 μL of IgG Sepharose 6 Fast Flow beads (50% slurry in 50 mM 
potassium phosphate and 20% ethanol) pre-washed with 10 mL of wash buffer (40 mM 
Tris-HCl, pH 7.5/150 mM NaCl/10% glycerol/0.1% C12E9) was then added and rotated 
for 2 h, followed by a wash with 10 mL of wash buffer. The IgG beads were resuspended 
in 1 mL of TEV buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl/10% glycerol/0.1% 
C12E9/10 mM 2-mercaptoethanol/0.5 mM EDTA) with 100 units of AcTEV protease and 
Drs2p was released by rotating the mixture for 2 h at 16 C. 
In the second affinity step, Drs2p-TAPC was bound to 200 μL of calmodulin Sepharose 
4B beads in 5 mL of calmodulin binding buffer (40 mM Tris-HCl, pH 7.5/150 mM 
NaCl/10% glycerol/0.1% C12E9/1 mM imidazole/10 mM 2-mercaptoethanol/2 mM CaCl2) 
by rotating for 1 h, followed by a wash with 20 mL of calmodulin binding buffer, and was 
eluted with 1 mL of calmodulin elution buffer (40 mM Tris-HCl, pH 7.5/150 mM 
NaCl/10% glycerol/0.1% C12E9/6 mM EGTA). Similarly, TAPN-Drs2p was incubated with 
200 μL of Ni-NTA agarose beads in 5 mL of Ni2+ binding buffer (40 mM Tris-HCl, pH 
7.5/300 mM NaCl/10% glycerol/0.1% C12E9/20 mM imidazole/10 mM 2-mercaptoethanol) 
by rotating for 1 h, followed by a wash with 20 mL of Ni2+ binding buffer, and was eluted 
with 1 mL of Ni2+ elution buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl/10% 
glycerol/0.1% C12E9/200 mM imidazole). Protein eluates were stored at -20 C in the 
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presence of 50% glycerol. Recovery of Drs2p was determined using Odyssey Infrared 
Imaging System (LI-COR, Inc., Lincoln, NE) to quantify SimplyBlue-stained bands 
relative to a BSA standard curve. Purified Drs2p was assayed for ATPase activity in 
ATPase buffer (50 mM Tris-HCl, pH 7.5/100 mM NaCl/50 mM KCl/0.1% C12E9/4 mM 
Na+-ATP/10 mM MgCl2) at 37 C for 2 h, and released phosphate was measured 
colorimetrically using protocols previously described (Carter and Karl, 1982; Paterson et 
al., 2006; Zimmerman and Daleke, 1993). 
 
Section 2.3.3: Proteoliposome formation 
Proteoliposomes were formed by detergent removal using Bio-Beads SM-2 adsorption 
(Gummadi et al., 2003; Levy et al., 1990a; Levy et al., 1990b). All steps were performed 
at 4 C unless otherwise stated. Normally, 4 mg of lipid mixture (99% egg PC and 1% 
NBD-phospholipid) was dried under N2 stream and solubilized completely with 1 mL of 
1% C12E9 in reconstitution buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl) at room 
temperature. 1 mL of TEV buffer containing 20 μg of Drs2p purified by single-affinity 
purification (IgG Sepharose 6 Fast Flow) was gently mixed with the lipid solution, and 
the protein-lipid-detergent solution was incubated by rotation for 1 h before SM-2 beads 
addition. After addition of 100 mg of extensively-washed SM-2 beads and 6 h of 
incubation on an end-over-end rotator, a second portion of 200 mg of SM-2 beads was 
added and incubated for another 12 h without removing the original SM-2 beads. The 
supernatant containing proteoliposomes was then carefully removed and mixed with 500 
mg of fresh SM-2 beads for 3 h of incubation. The resulting proteoliposome was 
removed and stored at 4 C. 200 μL of proteoliposomes was mixed with 200 μL of 80% 
glycerol, and placed at the bottom of a glycerol step gradient consisting of 40% glycerol, 
30% glycerol (300 μL), 10% glycerol (400 μL) and reconstitution buffer (100 μL, top). 
The samples were centrifuged in a TLS-55 rotor (Beckman Coulter, Inc., Fullerton, CA) 
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at 50,000 rpm for 6 h, and fractions (200 μL each) were collected by piercing the bottom 
of the tube. The recovery of lipids for each fraction was calculated as (Fluorescence of 
NBD-phospholipid in each fraction) / (Initial fluorescence of total NBD-phospholipid used 
for reconstitution) x 100%, and Drs2p recovery was determined by (Drs2p quantified by 
SimplyBlue staining in each fraction) / (Initial Drs2p used for reconstitution) x 100%. For 
flippase assays, proteoliposome fractions containing both phospholipids and Drs2p were 
pre-treated with 10 mM dithionite for 3 min to quench most fluorescent NBD-
phospholipid in the outer leaflet of proteoliposomes. Treated proteoliposomes were re-
floated as described above to separate them from dithionite. 
 
Section 2.3.4: Flippase assay 
Flippase activity was defined by a change of interleaflet distribution of fluorescent lipid 
probes (NBD-phospholipids) in proteoliposomes measured using a dithionite-based 
quenching approach (McIntyre and Sleight, 1991). For each individual measurement, 10 
μL of proteoliposomes containing ~50 ng of Drs2p and ~10 nmol of phospholipids were 
incubated with either 5 mM Na+-ATP or Mg2+-ATP in 40 μL of flippase buffer (40 mM 
Tris-HCl, pH 7.5/200 mM NaCl) at 37 C. At 0 and 30 min of incubation, each sample was 
assayed for probe distribution. Samples were diluted to 1 mL with flippase buffer in a 
quartz cuvette and mixed by inverting the cuvette 10 times, and the total fluorescence 
(FT) was recorded for 30 s in an AB2 fluorometer (SLM Instruments, Inc.) (λex = 460 nm, 
λem = 534 nm) to obtain a stable baseline. Then, 10 μL of 1 M dithionite dissolved in 1 M 
Tris (pH 10) was added to the sample and mixed to quench the fluorescent probes in the 
outer leaflet of liposomes, and fluorescence was recorded until a stable line was 
obtained (120 s, FD). The sample was then solubilized by addition of 100 μL of 10% 
Triton X-100, and the background fluorescence (F0) was recorded for another 30 s. The 
percentage of NBD-phospholipid in the outer leaflet of proteoliposomes that is 
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accessible to dithionite quenching was calculated as (FT - FD) / (FT - F0) x 100% (defined 
as PO), and the percentage of NBD-phospholipid flipped to the outer leaflet over a 30-
min period was calculated as PO30min - PO0min. 
 
Section 2.4: Results 
Drs2p under its endogenous promoter is expressed in a low abundance estimated to be 
~4,000 molecules per cell in our wild-type strain (10 ng Drs2p/107 cells, data not shown). 
To increase the yield of Drs2p, DRS2 was overexpressed in its native host S. cerevisiae 
by substituting the strong glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter 
for its endogenous promoter (Figure 2-1A) (Janke et al., 2004). To facilitate purification, 
a tandem affinity purification (TAP) tag was integrated into the 3’ end of the DRS2 gene 
to express C-terminally TAP-tagged Drs2p (Drs2p-TAPC, Figure 2-1A and B) (Rigaut et 
al., 1999). Drs2p-TAPC was functional in vivo, since strains expressing DRS2-TAPC as 
the sole source of Drs2p grew at 20 C (Figure 2-2). Strains carrying loss of function drs2 
alleles cannot grow at 20 C or below (Chen et al., 1999; Hua et al., 2002; Ripmaster et 
al., 1993). Drs2p requires Cdc50p, a noncatalytic subunit and chaperone protein, for its 
export from the endoplasmic reticulum (ER) (Chen et al., 2006; Saito et al., 2004), so we 
also overexpressed CDC50 using the GPD promoter (Figure 2-1A). These modifications 
led to a 10-fold increase in Drs2p expression relative to wild-type cells (Figure 2-3). 
For purification of Drs2p-TAPC, a cell lysate prepared without detergent was 
centrifuged at 15,000 x g for 12 min to pellet ER membranes, along with any misfolded 
Drs2p-TAPC retained there by the quality control machinery. 1% C12E9 was used to 
solubilize Drs2p-TAPC from TGN membranes that remained in the supernatant (see 
Materials and Methods). As seen in Figure 2-1C, Drs2p-TAPC was successfully purified 
by the TAP procedure, and composed greater than 90% of protein in the final eluate 
(lane 4). Cdc50p was not detected in this preparation by SimplyBlue staining, but was  
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Figure 2-1. Expression and purification of Drs2p-TAPC. (A) Chromosomal organization of 
DRS2-TAPC and CDC50. (B) Schematic of Drs2p-TAPC modeled on the crystal structure 
of the sarcoplasmic reticulum Ca2+ ATPase 1 (SERCA1) in the E1·2Ca2+ conformation 
(Toyoshima et al., 2000). CBP, calmodulin binding peptide moiety; ProA, protein A 
moiety; TEV, tobacco etch virus. (C) Aliquots from a Drs2p-TAPC purification from strain 
XZY10b were subject to SDS-PAGE and the gel was stained with SimplyBlue. Lane 1, 
cell lysate; lane 2, proteins bound to the IgG beads; lane 3, proteins bound to the 
calmodulin beads; lane 4, final eluate. (D) ATPase activity of purified Drs2p-TAPC 
preparations. The control, vanadate (100 μM) and azide (1 mM) samples were assayed 
using 50 ng of Drs2p-TAPC purified from strain XZY10b (ATP2), and the atp2∆ sample 
was assayed using 100 ng of Drs2p-TAPC from strain XZY38b (atp2∆), deficient for the 
F1-ATPase. 
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Figure 2-2. Growth phenotype of yeast strains at 30 C (A) and 20 C (B). DRS2, (DRS2; 
atp2∆); DRS2-TAPC, (DRS2::TAPC; atp2∆); TAPN-DRS2, (TAPN::DRS2; atp2∆); drs2∆, 
(drs2∆; ATP2). Note that the drs2∆ strain grew better than others at 30 C due to its intact 
ATP2 gene (mitochondrial F1-ATPase), but it exhibited a growth defect at 20 C. 
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Figure 2-3. Overexpression of DRS2-TAPC and TAPN-DRS2 in yeast. (A) Yeast BY4742 
(WT, lane 1), XZY38b (DRS2-TAPC, lane 2) and XZY60m (TAPN-DRS2, lane 3) were 
grown in rich medium and harvested in mid-log phase (0.4-0.6 OD600/mL). The cell 
lysates were subjected to SDS-PAGE and western blotting. Primary antibodies were 
used at 1:2000 (anti-Drs2p) and 1:10000 (anti-G6PDH). Blotting for G6PDH served as a 
loading control. (B) Quantification of Drs2p overexpression in (A). Drs2p values were 
corrected for the loading control and defined as (Drs2p signal) / (G6PDH signal). The 
WT sample was defined as 1 unit (Arbitrary Unit, A.U.). 
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Table 2-1. Proteins identified in purified Drs2p-TAPC by MALDI-TOF mass spectrometry. 
Drs2p-TAPC was purified from strain XZY10b (ATP2). 
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identified by mass spectrometry (Table 2-1). Typically, 5% of Drs2p-TAPC in the cell 
lysate was recovered in the first affinity purification step (IgG column) and 1% was 
recovered in the second affinity step (calmodulin column), yielding 10 μg of Drs2p per 
liter of culture (~1011 cells). 
Robust ATPase activity was detected in the purified Drs2p-TAPC sample. However, 
this ATPase activity was insensitive to orthovanadate, a commonly used P-type ATPase 
inhibitor (Ding et al., 2000; Paterson et al., 2006), and was completely inhibited by 1 mM 
azide (Figure 2-1D). This result suggested that the ATPase activity was primarily 
catalyzed by contaminating mitochondrial F1-ATPase. Indeed, the α and β subunits of 
the F1-ATPase were detected by western blotting (Figure 2-4) and mass spectrometry 
(Table 2-1) as trace contaminants, but the specific activity of F1-ATPase is very high 
(150 μmol ATP hydrolyzed/min/mg) (Gause et al., 1981). To test if the activity was 
catalyzed by the F1-ATPase, the ATP2 gene encoding the catalytic β subunit of the F1-
ATPase was disrupted in the strain used for Drs2p-TAPC purification (Figure 2-4). No 
ATPase activity could be detected in Drs2p-TAPC preparations from the atp2∆ strain 
(Figure 2-1D), even though Drs2p-TAPC was recovered with a yield and purity 
comparable to that shown in Figure 2-1C. Other ATPases were also detected at trace 
levels (Table 2-1), but their activities were below the limit of detection in these 
preparations. Therefore, it appeared that purified Drs2p-TAPC was catalytically inactive 
in vitro. A variety of purification and assay conditions were tested for Drs2p-TAPC, 
including the addition of potential substrate lipids such as PS, but none of the conditions 
used yielded an active enzyme. However, moving the affinity tag from the C-terminus to 
the N-terminus of Drs2p (TAPN-Drs2p, Figure 2-5A and B), and modifying the TAP tag 
to contain a decahistidine as the second affinity module instead of the calmodulin 
binding peptide (Figure 2-5B), allowed purification of enzymatically active Drs2p. 
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Figure 2-4. Detection and disruption of mitochondrial F1-ATPase. Cell lysates from strain 
XZY10b (ATP2) (lane 1-2, 105 and 2 x 105 cells), XZY38b (atp2∆) (lane3-4, 105 and 2 x 
105 cells), and a purified Drs2p-TAPC sample (lane 5) (109 cells) were subjected to SDS-
PAGE and western blotting. Primary antibodies were used at 1:2000 (anti-Drs2p and 
anti-F1-ATPase). The antibody against the yeast F1-ATPase recognizes both α and β 
subunits (Puri et al., 2005), and was kindly provided by Dr. David Mueller (Rosalind 
Franklin University). Note that disruption of ATP2 gene (encoding the β subunit) also 
reduced expression of the α subunit. 
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Figure 2-5. Expression and purification of TAPN-Drs2p. (A) Chromosomal organization of 
TAPN-DRS2 and CDC50. (B) Schematic of TAPN-Drs2p. ProA, protein A moiety; His10, 
decahistidine moiety; TEV, tobacco etch virus. (C) Aliquots from a TAPN-Drs2p 
purification from strain XZY60m (atp2∆) were subject to SDS-PAGE and the gel was 
stained with SimplyBlue. Lane 1, cell lysate; lane 2, proteins bound to the IgG beads; 
lane 3, proteins bound to the Ni-NTA beads; lane 4, final eluate. (D) Comparison of 
TAPN-Drs2p and Drs2p-TAPC ATPase activity purified from strain XZY60m (atp2∆) and 
XZY38b (atp2∆), respectively. 
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TAPN-Drs2p was also purified from a strain that was deficient for the F1-ATPase and a 
comparable yield and purity was obtained (compare Figure 2-5C to Figure 2-1C). The 
TAPN-Drs2p preparation now displayed robust ATPase activity relative to Drs2p-TAPC 
(Figure 2-5D). The only significant difference between the two Drs2p preparations was 
the position of the tag (N-terminal versus C-terminal), indicating that the ATPase activity 
detected in the TAPN-Drs2p sample was catalyzed by Drs2p and not minor contaminants 
in the sample. Consistent with other P-type ATPases, the ATPase activity of TAPN-Drs2p 
was sensitive to orthovanadate with an IC50 of 5 μM and was resistant to azide (Figure 
2-6A and B). TAPN-Drs2p showed an optimal pH of 7.5 (Figure 2-6C), a Km of 1.5 ± 0.3 
mM for ATP (Figure 2-6D), and a Vmax of 0.45 ± 0.03 μmol Pi released/min/mg Drs2p 
(~70 ± 5 ATPs hydrolyzed/min/Drs2p, Figure 2-6D) under these assay conditions. The 
ATPase activity of TAPN-Drs2p was also Mg2+-dependent (Figure 2-6B), as reported for 
purified mammalian Atp8a1 (Ding et al., 2000; Paterson et al., 2006). 
To assess the oligomeric state of purified Drs2p, TAPN-Drs2p and Drs2p-TAPC were 
subjected to size exclusion chromatography. The majority of both Drs2 proteins eluted 
as a single peak at nearly the same volume (Figure 2-7A). Relative to protein standards 
(Figure 2-7B), the mass of TAPN-Drs2p was estimated to be 181 kDa and Drs2p-TAPC 
184 kDa, very close to their predicted monomer masses of 156 kDa and 160 kDa. To 
probe the molecular basis of Drs2p-TAPC inactivity, TAPN-Drs2p and Drs2p-TAPC were 
analyzed by circular dichroism (Figure 2-8). The spectra of the two proteins were 
strikingly different, suggesting possibly a difference between their tertiary structures. 
Importantly, the inactive Drs2p-TAPC did not seem to be more unstructured than the 
active TAPN-Drs2p, although with the caveat that the prediction for TAPN-Drs2p may not 
be accurate (Table 2-2). Although the molecular basis for its inactivity is not fully 
understood, Drs2p-TAPC served as an enzymatically-dead negative control in this study. 
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Figure 2-6. Characterization of purified Drs2p in 0.1% C12E9. (A) Sensitivity of TAPN-
Drs2p ATPase activity to orthovanadate (VO43−). (B) Mg2+ dependence of TAPN-Drs2p 
ATPase activity and its resistance to azide (1 mM). (B) pH profile of TAPN-Drs2p ATPase 
activity assayed as described in Materials and Methods but with varying buffers. pH 5.5 
and 6, 50 mM MES; pH 7, 8 and 9, 50 mM Tris-HCl. (C) Determination of the Km for ATP 
and Vmax of ATP hydrolysis for TAPN-Drs2p. Inset, double-reciprocal plot. Y-axis units of 
(A)-(D) = μmol Pi released/min/mg Drs2p. 
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Figure 2-7. Size exclusion chromatography of purified Drs2p. (A) TAPN-Drs2p and 
Drs2p-TAPC were solubilized in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl and 0.1% C12E9, 
and were analyzed by an ÄKTA FPLC system using a Superose 12 column from GE 
Healthcare. The column was pre-equilibrated with the same Drs2p buffer and samples 
were injected at 0 ml. The closed arrow head indicates the void volume (V0, 7.77 ml), 
and the three open arrow heads (from left to right) indicate the peaks of ferritin (440 kDa), 
catalase (232 kDa) and aldolase (158 kDa) standards, which were dissolved in the same 
Drs2p buffer and analyzed individually. (B) A molecular weight (MW) standard curve was 
constructed using protein standards (squares) from (A). The logarithm of the 
hydrodynamic radius of a protein is inversely linear to the partition coefficient of the 
protein, which is linear to its elution volume (Ve) in a given column (Davison, 1968; Irvine, 
1994; Tanford et al., 1974). Note that the logarithm of the molecular weight of proteins 
was approximately assumed to be linear to that of their hydrodynamic radii in this plot. 
The two crosses indicate the Ve/V0 values for Drs2p-TAPC and TAPN-Drs2p, respectively 
(from left to right), and were calculated to estimate their molecular weights in the purified 
samples. 
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Figure 2-8. Circular dichroism spectra of purified Drs2p. TAPN-Drs2p (40 μg/mL) and 
Drs2p-TAPC (38 μg/mL) were solubilized in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl and 
0.1% C12E9 in a 1 mm cell, and were scanned for absorbance using a Jasco J-810 
spectrometer. 
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Table 2-2. Secondary structure prediction from circular dichroism spectra (200-240 nm) 
of Drs2p by the K2D (Andrade et al., 1993) and K2D2 (Perez-Iratxeta and Andrade-
Navarro, 2008) web servers. 
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Purified TAPN-Drs2p was incorporated into PC liposomes via detergent-mediated 
reconstitution (see Materials and Methods). To improve reconstitution efficiency by 
increasing protein to lipid ratio, single-step affinity purified TAPN-Drs2p was used directly 
for reconstitution, because single-step affinity purification provided more Drs2p than the 
two-step purification, although with lower purity (Figure 2-9A, lane 0). After flotation of 
reconstituted samples in a glycerol step gradient, most TAPN-Drs2p was found in the top 
fractions and co-fractionated with phospholipids (Figure 2-9A, lane 5 and 6, and Figure 
2-9B). Importantly, most contaminating proteins from the single-step affinity purification 
remained at the bottom of the gradient and were well separated from the proteoliposome 
fractions (Figure 2-9A, lane 1 and 2). As determined by mass spectrometry, the 
proteoliposome fractions contained relatively pure TAPN-Drs2p, comparable to that 
obtained from the two-step TAP procedure (Table 2-3 and Table 2-1). Based on 
negative staining and visualization by electron microscopy, the size of proteoliposomes 
ranged from 25 to 75 nm in diameter, with a mean diameter of 40 nm (Figure 2-9C). A 
similar result was obtained when the proteoliposomes were visualized by cryo-electron 
microscopy (Figure 2-9D). The protein to lipid ratio was 1:200 (wt/wt) in the 
proteoliposome samples, and we estimated that there was one Drs2p molecule per 2-3 
liposomes. In our reconstituted samples, Drs2p was preferentially inserted into 
proteoliposomes with the ATPase domain facing outward as revealed by a protease 
protection assay (Figure 2-10). Any Drs2p reconstituted in the opposite orientation 
would not be stimulated by Mg2+-ATP present outside the proteoliposome. 
To assay for flippase activity, PS (potential substrate), PC or SM (control) analogues 
bearing a fluorescent NBD group on a short sn2 acyl chain (C6) was incorporated into 
PC proteoliposomes during reconstitution. The TAPN-Drs2p proteoliposomes were then 
assayed for flippase activity using dithionite, a membrane-impermeable quenching agent, 
to monitor the interleaflet distribution of NBD-phospholipid (see Materials and Methods).  
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Figure 2-9. Flotation of TAPN-Drs2p proteoliposomes in a glycerol gradient. (A) Fractions 
collected from the glycerol gradient were subject to SDS-PAGE and the gel was stained 
with SimplyBlue. Lane 0, the protein sample before reconstitution; lane 1-6, fractions 
(#1-6) collected from the bottom to the top of the gradient. (B) Recovery of Drs2p and 
phospholipid in each fraction relative to the starting material. (C) Electron micrograph of 
negative-stained proteoliposome sample from fraction #5. Scale bar, 50 nm. (D) Cryo-
electron micrograph of proteoliposome sample from fraction #5. Scale bar, 50 nm. 
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Table 2-3. Proteins identified in Drs2p proteoliposomes by MALDI-TOF mass 
spectrometry. 
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Figure 2-10. Protease protection assay of TAPN-Drs2p proteoliposomes using trypsin. 
Proteoliposomes were incubated with 0.001% (wt/vol) trypsin at 37 C for 5 min, and 
trypsin digestion was stopped by addition of trypsin inhibitors (5 mM benzamidine 
hydrochloride, 2.5 μM aprotinin, 40 μM leupeptin, 10 mM PMSF) before mixing with 
SDS-PAGE sample buffer. (A) After SDS-PAGE, a gel was stained with SimplyBlue. 
Lane 1, proteoliposomes alone; lane 2, proteoliposomes incubated with trypsin before 
addition of trypsin inhibitors; lane 3, proteoliposomes incubated with trypsin in the 
presence of trypsin inhibitors; lane 4, proteoliposomes incubated with trypsin in the 
presence of 0.1% Triton X-100; lane 5, trypsin only. (B) After SDS-PAGE, proteins in a 
gel from (A) were electrotransferred onto polyvinylidene difluoride (PVDF) membrane 
and Drs2p was detected by western blotting using a primary antibody (1:2000) that 
recognizes the ATPase domain of Drs2p. 
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To improve the sensitivity for detecting trans-bilayer flip, the NBD-phospholipid in the 
outer leaflet was pre-quenched with dithionite and the proteoliposomes were re-floated 
in a glycerol gradient to remove the dithionite. This treatment resulted in liposomes with 
most fluorescent NBD-phospholipid in the inner leaflet and increased the sensitivity for 
detecting flip of NBD-phospholipid to the outer leaflet. 
From preliminary experiments, we noticed that incubation of liposomes with ATP (Na+-
ATP) alone caused a small non-specific increase in accessibility of NBD-phospholipid to 
dithionite (Figure 2-11). To take this effect into account, we incubated the 
proteoliposomes with Na+-ATP, which is not hydrolyzed by TAPN-Drs2p (Figure 2-6B), 
as a background control in the flippase assay. As seen in Figure 2-12A, after a 30-min 
incubation, Na+-ATP caused a net ~3% increase in NBD-PS accessibility to dithionite 
(green trace versus black trace). While in the presence of Mg2+-ATP, significantly more 
NBD-PS (~7%) was accessible to dithionite (blue trace versus red trace). The increased 
quenching of NBD-PS was not caused by Mg2+ alone or contaminating Ca2+ (Figure 2-
11). NBD-PS was flipped across the liposome bilayer with a half-time of ~4 min (Figure 
2-12B), and the initial velocity was about 0.02 μmol NBD-PS flipped/min/mg Drs2p (~3 
NBD-PS flipped/min/Drs2p). As controls, no difference between the Mg2+-ATP and Na+-
ATP incubations was observed with TAPN-Drs2p proteoliposomes containing NBD-PC or 
NBD-SM instead of NBD-PS (Figure 2-12A and C), indicating that PS is the moiety that 
was recognized and translocated. Moreover, if Drs2p activity simply caused increased 
leakiness of the proteoliposome to dithionite, we would have observed enhanced 
quenching of the NBD-PC or NBD-SM probes. In other control experiments, no 
increased quenching was observed with protein-free liposomes (No Drs2p) containing 
NBD-PS (Figure 2-12C), or with proteoliposomes reconstituted with the enzymatically-
dead Drs2p-TAPC and NBD-PS (Figure 2-12C). These data demonstrated that the 
increased quenching (~4%) of NBD-PS in TAPN-Drs2p proteoliposome was mediated by  
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Figure 2-11. Flippase assay with TAPN-Drs2p proteoliposomes containing NBD-PS. 
Proteoliposomes were incubated with no addition (proteoliposomes alone), Na+-ATP (5 
mM), Mg2+ (5 mM), Mg2+-ATP (5 mM), or Mg2+-ATP (5 mM) plus EGTA (1 mM) at 37 C for 
30 min, and NBD-PS flipping was measured as described in Materials and Methods. 
Results were averaged from 4-6 independent experiments. 
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Figure 2-12. Reconstitution of NBD-PS flippase activity with TAPN-Drs2p 
proteoliposomes. (A) Dithionite quenching of NBD-PS (left panel) or NBD-PC (right 
panel) fluorescence in TAPN-Drs2p proteoliposomes before and after 30 min of 
incubation with Mg2+-ATP or Na+-ATP. Dithionite was added at 30 s to quench outer 
leaflet NBD-phospholipid and Triton X-100 was added at 150 s to quench remaining 
inner leaflet NBD-phospholipid. (B) Time course of NBD-PS translocation. Flippase 
assay was conducted as described in Materials and Methods, except that the incubation 
time varied from 0 to 60 min as indicated. Results were averaged from 4-6 independent 
experiments. (C) Flippase assay with liposomes containing TAPN-Drs2p, Drs2p-TAPC or 
no Drs2p and the indicated NBD-phospholipid was performed as described in Materials 
and Methods. The increase in outer leaflet NBD-phospholipid after a 30-min incubation 
with Mg2+-ATP or Na+-ATP was plotted. Results were averaged from 6-9 independent 
experiments. ***, P < 0.001. 
  
71 
a Mg2+-, ATP- and Drs2p-dependent flippase activity specific for the PS analogue. 
Furthermore, mass spectrometric studies revealed that the TAPN-Drs2p and the 
Drs2p-TAPC proteoliposomes contained a nearly identical protein composition (Table 2-
3). In both samples, Cdc50p was recovered as the second most abundant protein based 
on the number of peptides recovered. However, a relatively small number of Cdc50p 
peptides were recovered and Cdc50p was not apparent in the gels stained by 
SimplyBlue (Figure 2-1C and Figure 2-5C). Thus, it appears that the majority of Drs2p 
was not complexed with Cdc50p in the reconstituted samples. Other proteins recovered 
in low quantities, such as heat shock proteins and proteins involved in metabolism and 
protein synthesis, are very abundant proteins in yeast and are common contaminants of 
affinity purifications (Gould et al., 2004). Most importantly, the two proteoliposome 
samples were comparable in protein composition with the major difference being the 
placement of the TAP tag on Drs2p, indicating that Drs2p activity is responsible for the 
difference in the flippase activity between the two samples. 
 
Section 2.5: Discussion 
For more than a decade it has been proposed that Drs2p and the P4-ATPase family 
are phospholipid translocases or flippases, and several lines of evidence indicate that 
Drs2p is necessary for flipping NBD-labeled PS or PE analogues in isolated Golgi 
membranes and post-Golgi secretory vesicles (Alder-Baerens et al., 2006; Daleke, 2003; 
Graham, 2004; Natarajan et al., 2004; Pomorski et al., 2004; Tang et al., 1996). 
However, no in vitro reconstitution of flippase activity had been achieved with a purified 
P4-ATPase to test whether these pumps are sufficient to directly catalyze flippase 
activity. Towards this goal, we purified Drs2p from yeast, reconstituted it into 
proteoliposomes, and demonstrated an NBD-PS flippase activity with the purified and 
reconstituted enzyme. 
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In this study, Drs2p with affinity tags at either end (TAPN-Drs2p and Drs2p-TAPC) was 
purified. Surprisingly, although the two protein preparations were very comparable in 
yield and purity (Figure 2-1C and Figure 2-5C; Table 2-1 and Table 2-3), only TAPN-
Drs2p was catalytically active in vitro, whereas Drs2p-TAPC was enzymatically dead 
(Figure 2-5D and Figure 2-12C). However, both Drs2 proteins are functional in vivo, 
since they supported yeast growth at low temperatures (Figure 2-2). By contrast, Drs2p-
deficient cells exhibit a cold-sensitive growth defect (Chen et al., 1999; Hua et al., 2002; 
Ripmaster et al., 1993). Drs2p-TAPC appears to be folded well enough to have exited the 
ER, as our purification method should remove most of the ER-localized Drs2p. Based on 
size exclusion chromatography, both Drs2 proteins appear to be primarily monomeric in 
detergent solutions and do not differ significantly from each other in oligomeric states 
(Figure 2-7). Therefore, Drs2p-TAPC inactivity was not caused by aggregation of this 
protein. Moreover, no significant difference in stability and solubility was observed 
between TAPN-Drs2p and Drs2p-TAPC (Figure 2-5C and Figure 2-1C). However, the 
tertiary structure of TAPN-Drs2p seems to differ from that of Drs2p-TAPC as revealed by 
circular dichroism (Figure 2-8). Interestingly, the inactive Drs2p-TAPC was predicted to 
contain more ordered structural elements than TAPN-Drs2p (Table 2-2). Although the 
prediction for TAPN-Drs2p may not be accurate (Table 2-2), which may be caused by 
interference from residual imidazole, these data indicate that Drs2p-TAPC inactivity was 
probably not caused by denaturation of this protein. P-type ATPases undergo dramatic 
conformational changes during the catalytic cycle, and it is possible that Drs2p-TAPC is 
inactive because it is trapped in a single conformational state. Further work will be 
required to determine whether the loss of Drs2p-TAPC activity in vitro resulted from the 
position of the C-terminal TAP tag or from the calmodulin binding peptide versus the 
decahistidine module. 
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The ATPase activity of purified TAPN-Drs2p was Mg2+-ATP-dependent and 
orthovanadate-sensitive (Figure 2-6B and A), which are consistent with the properties 
of purified mammalian Atp8a1 (Ding et al., 2000; Paterson et al., 2006). The specific 
activity of TAPN-Drs2p was 0.45 ± 0.03 μmol Pi released/min/mg Drs2p (Vmax, Figure 2-
6D), and this activity is within the range of values reported for purified Atp8a1 (Ding et al., 
2000; Paterson et al., 2006). However, we observed only a mild increase of ~40% in 
ATPase activity of the purified TAPN-Drs2p in detergent solutions when incubated with 
PS, a potential phospholipid substrate for Drs2p, whereas no stimulation was observed 
for PC (Figure 2-13A). This stimulation level by PS is marginal compared to steep 
increases (greater than 10-fold) observed for purified mammalian Atp8a1 (Ding et al., 
2000; Paterson et al., 2006). Activation of Atp8a1 ATPase activity by PS suggests that 
PS is a native substrate for Atp8a1. The modest PS stimulation of TAPN-Drs2p sample 
may be due to co-purification of substrate phospholipid with Drs2p, such that the 
preparation is at near maximum activation. Another possibility is that the accessibility of 
the PS binding site of Drs2p to the externally added PS was poor in detergent solutions. 
Consistently, when purified TAPN-Drs2p was reconstituted into proteoliposomes 
containing varying amounts of PS (up to 20%), the ATPase activity of TAPN-Drs2p was 
stimulated up to ~400% (from 0.36 ± 0.04 to 1.28 ± 0.03 μmol Pi released/min/mg Drs2p, 
Figure 2-13B) with a Km for PS estimated to be 5.7 mol% by fitting the data to a 
hyperbolic Michaelis-Menten function. However, the specific activity of TAPN-Drs2p was 
relatively low compared to PS-activated bovine Atp8a1 (3-42 μmol Pi released/min/mg) 
(Ding et al., 2000; Moriyama and Nelson, 1988; Xie et al., 1989). Whether this difference 
reflects a species difference or whether only a portion of Drs2p molecules retained 
activity after purification remains to be determined. 
Upon reconstitution, the TAPN-Drs2p proteoliposome exhibited flippase activity that 
was specific for NBD-PS (Figure 2-12), because no activity was observed with the PC  
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Figure 2-13. Phospholipid stimulation of TAPN-Drs2p ATPase activity. (A) ATP activity of 
purified TAPN-Drs2p in 0.1% C12E9 was assayed in the presence of PS (POPS, 400 μM), 
PS (POPS, 400 μM) plus orthovanadate (80 μM), or PC (POPC, 400 μM). The stock 
solution for each phospholipid was prepared at 4 mM by complete solubilization of dried 
lipids in 2% C12E9. Phospholipids were incubated with TAPN-Drs2p for 10 min at room 
temperature before addition of ATP. (B) TAPN-Drs2p was reconstituted with indicated 
lipids as described in Materials and Methods except that the Bio-Beads SM-2 incubation 
time was reduced by 50% for incomplete removal of C12E9. Reconstituted samples were 
floated on a glycerol gradient and proteoliposomes were recovered as described in 
Materials and Methods. These proteoliposomes were leaky because dithionite quenched 
>95% of NBD fluorescence. ATPase activity of these TAPN-Drs2p proteoliposomes was 
assayed in the presence or absence of orthovanadate (80 μM). 
  
75 
and SM analogues (Figure 2-12A and C). TAPN-Drs2p was not the only protein present 
in the proteoliposome, although it was the major one (Figure 2-9A and Table 2-3). Mass 
spectrometry also identified several other proteins in low abundance, including Cdc50p 
(Table 2-3). Any of these proteins could potentially be responsible for the flippase 
activity independently or dependently of TAPN-Drs2p. However, the former possibility 
was ruled out because a control proteoliposome sample reconstituted with the 
enzymatically-dead Drs2p-TAPC showed no NBD-PS flippase activity (Figure 2-12C) 
and contained a protein composition almost identical to that of the TAPN-Drs2p 
proteoliposome (Table 2-3). These data argue strongly that Cdc50p and minor 
contaminants were incapable of catalyzing flippase activity without active Drs2p. 
However, our data are consistent with the possibility that Cdc50p may also be 
required for the flippase activity of Drs2p, because Cdc50p was present in the TAPN-
Drs2p proteoliposomes (Table 2-3). Moreover, recent work suggests that Cdc50p 
facilitates the catalytic cycle of Drs2p (Lenoir et al., 2009). In the current study, we 
estimated that around 40% of the liposomes would contain one Drs2p molecule if an 
equal distribution of Drs2p in liposomes is assumed. Drs2p seemed to be inserted 
preferentially into the proteoliposomes with its ATPase domain facing outward (Figure 2-
10). Therefore, at most, 40% of the liposomes would contain a Drs2p molecule that has 
access to externally applied Mg2+-ATP, and 40% would be the upper limit of NBD-PS 
translocation we could achieve under these conditions. We have observed a nearly 
saturated Mg2+-ATP-dependent flip of 4% NBD-PS (Figure 2-12), perhaps indicating that 
only 4% of the liposomes contain an active flippase. If the Drs2p-Cdc50p complex is 
essential for flippase activity, the molar concentration of Cdc50p would need to be at 
least 1/10 that of Drs2p to explain why we observed 1/10 the maximum expected activity. 
Based on mass spectrometric results, the number of Cdc50p peptides recovered in the 
TAPN-Drs2p proteoliposome was about 1/10 that of Drs2p (Table 2-3). Thus, it is 
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possible that the flippase activity reported here was catalyzed by Drs2p-Cdc50p 
complexes and that Drs2p alone is insufficient to drive flippase activity. Alternatively, it is 
possible that Cdc50p is not required and the suboptimal flippase activity in the 
proteoliposomes resulted from the physical restraint of small liposome size (40 nm in 
mean diameter, Figure 2-9C and D), an unequal distribution of Drs2p in 
proteoliposomes, a high percentage of inactive Drs2p molecules in the TAPN-Drs2p 
preparation, and/or the absence of other potential regulators of Drs2p activity. Further 
work will be required to determine the extent of Cdc50p contribution to flippase activity. 
Nonetheless, the studies reported here provide a critical step forward in the biochemical 
characterization of a phospholipid flippase and define the minimal flippase unit as a P4-
ATPase, perhaps in association with its noncatalytic subunit. 
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CHAPTER III 
 
EXPLORING THE BASIS OF DRS2-TAPC PROTEIN INACTIVITY: POTENTIAL AUTO- 
INHIBITION BY THE C-TERMINAL TAIL 
 
Section 3.1: Abstract 
Drs2p is a yeast type-IV P-type ATPase (P4-ATPase) and flippase that couples ATP 
hydrolysis to phospholipid translocation. Previous studies show that ATPase activity is 
retained with affinity-purified Drs2p using an N-terminal tandem affinity purification (TAP) 
tag (TAPN-Drs2p), but not in a comparable preparation using a C-terminal TAP tag 
(Drs2p-TAPC) (Zhou and Graham, 2009). However, both TAP-tagged Drs2 proteins are 
functional in vivo. Furthermore, the purified, inactive Drs2p-TAPC does not seem to be 
aggregated or denatured in detergent solutions, suggesting that there may be a 
biological reason for the inactivity of purified Drs2p-TAPC. In this chapter, further 
experiments were conducted to address potential causes of the Drs2p-TAPC inactivity. 
The N-terminal TAPN tag does not activate Drs2p, neither does the C-terminal TAPC tag 
inactivate it. Interestingly, the ATPase activity of purified Drs2p seems to be associated 
only with a C-terminally cleaved form of Drs2p. This proteolytic cleavage causes a partial 
or complete loss of the C-terminal tail in Drs2p, so the cleaved form is designated the 
“NoC” form. The “NoC” form was found only in the Drs2p samples purified using the 
TAPN tag but not the TAPC tag, as the “NoC” form of Drs2p also loses the TAPC tag and 
does not bind to the affinity column specific for the TAPC tag. The “NoC” form of Drs2p is 
estimated to be ~9 kDa smaller than Drs2p, and a potential cleavage site that generates 
the “NoC” form (the “NoC” cleavage site) was identified in the C-terminal tail of Drs2p by 
mass spectrometry. These data suggest that the intact Drs2p is auto-inhibited in vitro 
and the “NoC” form is released from this auto-inhibition, providing a molecular basis that 
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potentially underlies the activity difference between the purified TAPN-Drs2p and Drs2p-
TAPC. 
 
Section 3.2: Introduction 
P-type ATPases form a large protein family of membrane pumps that uses the energy 
derived from ATP hydrolysis to drive movement of various substrates, such as ions, 
across membranes against their chemical gradient. Most P-type ATPases have three 
cytosolic domains (A: actuator; N: nucleotide binding; P: phosphorylation) and ten 
transmembrane segments comprising the membrane domain (Kuhlbrandt, 2004). The 
molecular basis of the P-type ATPase catalytic cycle was primarily gained from the 
crystal structures of one P-type ATPase, the sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase 1 (SERCA1, Figure 3-1A), which has been crystallized in multiple 
conformational states (Toyoshima and Mizutani, 2004; Toyoshima et al., 2000; 
Toyoshima and Nomura, 2002; Toyoshima et al., 2004). For SERCA1 (Figure 3-1B), the 
catalytic cycle starts with the E1 state, in which the ATPase binds Ca2+ with high affinity 
from the cytosolic side followed by ATP binding to the N domain. Phosphoryl transfer 
from ATP to a conserved aspartic acid residue in the P domain induces the transition 
into the E1P state. Following release of ADP, rotation of the A domain triggers the E1P 
to E2P transition, which destroys the Ca2+ binding site and opens the lumenal gate for 
Ca2+ release. In the E2P state, the ATPase has a high affinity for the counter-ion 
substrate (H+), which binds from the lumenal side. Hydrolysis of the aspartylphosphate in 
the P domain and subsequent release of the phosphate induces a conformational 
change to the E2 state.  Release of the counter-ion substrate (H+) into the cytosol brings 
the protein back to the E1 state for next catalytic cycle. This catalytic cycle is thought to 
be a general model for all P-type ATPases, although some details may vary in some  
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Figure 3-1. Structure and catalytic cycle of the sarcoplasmic reticulum Ca2+ ATPase 1. 
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Figure 3-1. Structure and catalytic cycle of the sarcoplasmic reticulum Ca2+ ATPase 1 
(SERCA1). (A) Left panel: A ribbon representation of SERCA1 in the E1·2Ca2+ 
conformation (PDB ID: 1SU4) (from Toyoshima, 2009). Colors change gradually from 
the N-terminus (blue) to the C-terminus (red). Purple circles indicate the two bound Ca2+. 
A, actuator domain; N, nucleotide binding domain; P, phosphorylation domain; M, 
membrane domain. Dashed arrows indicate domain movement during the catalytic cycle. 
Bound ATP is shown in space-filling mode. Several α-helices such as A1 and A2 (A 
domain), and M1, M4, M5 and M10 (M domain) are indicated. Several key residues such 
as E183 (A domain, dephosphorylation), F487 and R560 (N domain, ATP binding), D351 
(P domain, phosphorylation site), and D703 (P domain, coordination) are also indicated. 
Right panel: A cartoon representation of the left panel rendered with Swiss-PdbViewer. 
(B) A cartoon illustrating the structural changes and domain movement of SERCA1 
during the catalytic cycle based on seven different conformational states determined by 
x-ray crystallography (from Toyoshima, 2009). This catalytic cycle is considered a 
general model for P-type ATPases (see text for details). 
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cases. For example, there is likely no counter-ion substrate for the plasma membrane 
proton pumps (Pedersen et al., 2007). 
P-type ATPases are divided into five subfamilies (type-I to type-V, or P1 to P5) based 
on sequence homology, and are further divided into subgroups according to substrate 
specificity (Axelsen and Palmgren, 1998; Kuhlbrandt, 2004) (Figure 3-2). For example, 
SERCA1 belongs to the P2A-ATPase class, and the plasma membrane proton pumps 
are P3A-ATPases. In addition to the common structural features shared by all P-type 
ATPases (the A, P, N domains and the transmembrane segments), some subgroups 
were found to have an additional regulatory cytosolic domain, called R domain, within 
the N-terminal or C-terminal tail of the protein (Carafoli, 1994; Kuhlbrandt, 2004; 
Palmgren, 2001; Portillo, 2000; Sze et al., 2000). The R domain usually serves as an 
auto-inhibitory element that limits the activity of the ATPase and removal of the R 
domain by limited proteolysis or genetic engineering activates the protein. Auto-inhibition 
was also shown to be relieved by various regulatory activities in the R domain. For 
example, the P2B-ATPase family comprising the plasma membrane Ca2+ pumps usually 
contains the R domain in the C-terminal tail (in animals) (Carafoli, 1994) or the N-
terminal tail (in plants) (Sze et al., 2000) that binds and inhibits the ATPase. Binding of 
calmodulin to the R domain of the P2B-ATPase displaces the auto-inhibitory tail and 
activates it for Ca2+ transport. Phosphorylation of serine or threonine residues in the R 
domain of P2B-ATPases was also found to regulate ATPase activity by disrupting 
calmodulin binding to the R domain, resulting in protein activation (in animals) or 
inactivation (in plants). Another subgroup possessing an auto-inhibitory R domain is the 
P3A-ATPase family, which comprises mostly plasma membrane proton pumps from 
plants and fungi (Palmgren, 2001; Portillo, 2000). The R domain for this family was 
found to be in the C-terminal tail of the protein, and phosphorylation of serine or 
threonine residues in the R domain of P3A-ATPases was required for displacement of  
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Figure 3-2. Phylogenetic tree of the P-type ATPase family. 
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Figure 3-2. Phylogenetic tree of the P-type ATPase family (modified from Kuhlbrandt, 
2004). Subfamilies cluster according to their substrate specificity. Type IA (P1A), 
bacterial Kdp-like K+ ATPases; type IB (P1B), heavy metal ion transporting ATPases; 
type IIA (P2A), sarcoplasmic/endoplasmic reticulum Ca2+ ATPases; type IIB (P2B), 
plasma membrane Ca2+ ATPases; type IIC (P2C), Na+/K+ ATPases and H+/K+ ATPases; 
type IID (P2D), eukaryotic Na+ ATPases; type IIIA (P3A), H+ ATPases; type IIIB (P3B), 
bacterial Mg2+ ATPases; type IV (P4), phospholipid flippases; type V (P5), eukaryotic P-
type ATPases with unknown substrate specificity. Representative genes presented in 
this phylogenetic analysis are color coded by species. Green, genes from Arabidopsis 
thaliana; orange, Caenorhabditis elegans; grey, Escherichia coli; dark blue, Homo 
sapiens; light blue, Methanobacterium thermoautotrophicum; yellow, Methanococcus 
jannaschii; purple, Synechocystis PCC6803; red, Saccharomyces cerevisiae. 
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the auto-inhibitory C-terminal tail. In plants, the activation of P3A-ATPases involves 
binding of 14-3-3 protein to the phosphorylated R domain, but the binding protein in 
yeast has not yet been identified, or perhaps the yeast pump has an activation 
mechanism distinct from that in plants. 
In addition to cis-regulation by the R domain, the activity of P-type ATPases can also 
be modulated by various trans regulators (Carafoli, 1994; Kuhlbrandt, 2004; Palmgren, 
2001; Portillo, 2000; Sze et al., 2000). The primary mechanisms of regulation are protein 
interactions, such as calmodulin binding for the P2B-ATPase Ca2+ pumps, 14-3-3 binding 
for the plant P3A-ATPase proton pumps, as well as phosphorylation and 
dephosphorylation of the R domain. Some protein regulators are also membrane 
proteins and may have a more intimate relationship with the P-type ATPase that they 
regulate. In this case, the P-type ATPase and its regulatory proteins are often deemed 
as a multi-subunit complex, with the P-type ATPase as the catalytic subunit and others 
the noncatalytic subunits. For example, SERCA1 of the P2A-ATPase family was found to 
associate tightly with a small integral membrane protein called phospholamban that 
when dephosphorylated binds and inhibits SERCA1 by stabilizing it in the E2 
conformation (Carafoli, 1994; Sze et al., 2000). Phosphorylation of phospholamban 
dissociates it from SERCA1 and results in SERCA1 activation. The best example of the 
hetero-oligomeric P-type ATPase complex is the P2C-ATPase family, comprising the 
Na+/K+ ATPases and the gastric H+/K+ ATPases (Geering, 2001; Kuhlbrandt, 2004). The 
functional unit of Na+/K+ ATPase consists of the catalytic α subunit (the P2C-ATPase) 
and two additional regulatory subunits, β (a type II membrane glycoprotein) and γ (a type 
I membrane protein of the FXYD family). The β subunit was found to be a chaperone 
that is essential for assembly, membrane insertion and proper localization of the catalytic 
α subunit, and both β and γ subunits were shown to regulate the Na+/K+ ATPase activity. 
Other than proteins, lipids may also be regulators for P-type ATPases. For instance, the 
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P2B-ATPase Ca2+ pump in erythrocytes was found to be stimulated by acidic 
phospholipids and unsaturated fatty acids (Carafoli, 1994). 
Drs2p is a P4-ATPase from the budding yeast Saccharomyces cerevisiae. In steady 
state, Drs2p is localized primarily to the trans Golgi network (TGN), and is involved in 
multiple protein trafficking pathways between the TGN, plasma membrane and 
endosomes (Muthusamy et al., 2009a; Zhou et al., 2010). Drs2p was also proposed to 
be a phospholipid flippase, an enzyme that transports specific phospholipid substrate 
across membranes to the cytosolic leaflet at the expense of ATP consumption (Daleke, 
2003; Graham, 2004; Pomorski et al., 2004). In recent years, Drs2p was found to be 
responsible for a PS flippase activity detected in isolated TGN membranes (Natarajan et 
al., 2004) and post-Golgi secretory vesicles (Alder-Baerens et al., 2006), as well as in 
proteoliposomes reconstituted with purified Drs2p (Zhou and Graham, 2009). 
Interestingly, like P2B- and P3A-ATPases, Drs2p also possesses a C-terminal tail 
predicted to be 137-aa long (Chantalat et al., 2004) (Figure 1-9), which was shown to 
contain a regulatory domain (R domain). Several features of the Drs2p R domain have 
been identified. One is a motif that binds to Gea2p, a guanine nucleotide exchange 
factor for ARF GTPases (Chantalat et al., 2004). Another feature of the R domain is a 
region homologous to a split PH domain that binds phosphatidylinositol 4-phosphate 
(PI4P) (Natarajan et al., 2009), a phospholipid that is enriched in the Golgi membranes 
and is important for vesicle-mediated protein transport from the TGN. In recent work 
from our laboratory, Drs2p flippase activity was found to be virtually abolished in TGN 
membranes isolated from yeast cells that are deficient for Gea2p and PI4P production 
(Natarajan et al., 2009). Moreover, addition of Gea2p and PI4P to these TGN 
membranes restored flippase activity. This result suggests that Drs2p is likely auto-
inhibited by its C-terminal tail in the absence of Gea2p and PI4P, both of which are 
positive regulators for Drs2p and stimulate its activity by binding to the Drs2p C-terminal 
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R domain. In addition, Kes1p, an oxysterol binding protein, was discovered to be a 
negative regulator of Drs2p flippase activity (Muthusamy et al., 2009b). Kes1p does not 
seem to bind Drs2p directly and may regulate Drs2p indirectly by modulating PI4P levels 
at the TGN. 
Another intriguing aspect of Drs2p is that this P4-ATPase (α subunit) requires a β 
subunit called Cdc50p for ER exit and proper localization (Chen et al., 2006; Saito et al., 
2004), as seen in the P2C-ATPase Na+/K+ pumps (Geering, 2001). However, other than 
being a chaperone, whether Cdc50p also plays a role in Drs2p function remains largely 
unknown. Recent work by Lenoir et al. brought several interesting observations to this 
issue (Lenoir et al., 2009). In that work, an N-terminally tagged Drs2p was affinity 
purified and a C-terminally tagged Cdc50p was found to be co-purified. The authors 
observed that a small portion of purified Drs2p molecules were capable of 
phosphorylation, and the percentage of Drs2p phosphorylation was higher in the 
Cdc50p-associated Drs2p population than in the monomeric Drs2p population. Hence, 
the authors suggested that Cdc50p is required for the phosphoenzyme intermediate 
formation of Drs2p during its catalytic cycle. Furthermore, using an in vivo split ubiquitin 
assay, a Drs2p mutant trapped in the E2P state was found to interact strongly with 
Cdc50p, whereas Drs2p mutants trapped in the E1 or E1P state did not interact with 
Cdc50p. Based on this observation, the authors suggested that the affinity of Cdc50p for 
Drs2p fluctuates during the Drs2p catalytic cycle. However, the conclusion that Cdc50p 
was required for the phosphoenzyme formation of Drs2p (E1 to E1P transition) but did 
not interact with Drs2p during this process seemed to add some complexity to this issue. 
In the previous chapter, I purified TAP-tagged Drs2p using either the N-terminal tag 
(TAPN-Drs2p) or the C-terminal tag (Drs2p-TAPC), and found that only TAPN-Drs2p 
retained ATPase activity after purification, despite the observation that both TAP-tagged 
Drs2 proteins are functional in vivo. The inactivity of purified Drs2p-TAPC did not seem to 
  
87 
result from protein denaturation or aggregation. In this chapter, further studies were 
pursued to address the cause of purified Drs2p-TAPC inactivity. A molecular mechanism 
that potentially underlies the Drs2p-TAPC inactivity is proposed and tested. In addition, 
preliminary studies on the contribution of Cdc50p to the ATPase activity of purified Drs2p 
are presented. 
 
Section 3.3: Materials and Methods 
 
Section 3.3.1: Reagents 
IgG Sepharose 6 Fast Flow, calmodulin Sepharose 4B, and ATP (>99% purity) were 
from GE Healthcare. Ni-NTA agarose was from Qiagen. AcTEV protease and 
SimplyBlue SafeStain (Coomassie G-250) were from Invitrogen, and Triton X-100 was 
from Anatrace. Antibodies used in this study were rabbit primary antibodies against 
Drs2p, the decahistidine (His10) tag (Santa Cruz), and the calmodulin binding peptide 
(CBP) tag (GenScript), and an Alexa Fluor 680-labeled goat secondary antibody against 
rabbit IgG (Invitrogen). 
 
Section 3.3.2: Media and strains 
Yeast cells were grown in standard rich medium (1% yeast extract/2% peptone/2% 
dextrose) or synthetic minimal media containing required supplements (Sherman, 1991), 
and the nutrients were doubled in cell cultures for protein purification purposes. 
Yeast strains used for protein purification were XZY38b (MATa his3 leu2 ura3 met15 
PGPD::DRS2::TAPC PGPD::CDC50 atp2∆::URA3), XZY60m (MATα his3 leu2 ura3 lys2 
PGPD::TAPN::DRS2 PGPD::CDC50 atp2∆::URA3), XZY84 (MATa his3 leu2 ura3 met15 
PGPD::CDC50::TAPC pRS425-PGPD::TAPN::DRS2), and XZY85 (MATα his3 leu2 ura3 lys2 
PGPD::CDC50 atp2∆::URA3 pRS425-PGPD::TAPN::DRS2:TAPC), where TAPC encodes the 
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CBP-TEV protease cleavage site-protein A tag, and TAPN encodes the protein A-TEV 
protease cleavage site-His10 tag. 
 
Section 3.3.3: Protein purification 
TAP-tagged Drs2p was affinity purified using a TAP procedure described previously 
with some modifications (Zhou and Graham, 2009). Briefly, yeast cells were cultured to 
near saturation (10-15 OD600/mL in rich media and 4-6 OD600/mL in minimal media) at 30 
C, harvested and lysed by an EmulsiFlex-C3 High Pressure Homogenizer (Avestin). The 
cell lysate was centrifuged at 15,000 x g for 12 min, and 20% of Triton X-100 was added 
to the supernatant to a final concentration of 1% to solubilize Drs2p. TAP-tagged Drs2p 
was then purified using an IgG column plus either a Ni2+ column (for TAPN) or a 
calmodulin column (for TAPC). In the experiments that Drs2p was first purified using the 
TAPN tag and then different Drs2p populations were separated using the TAPC tag, the 
procedure was a combination of the TAPN purification plus the second affinity step (the 
calmodulin column) of the TAPC purification. 
All purified Drs2p samples were centrifuged in the Microcon YM-100 filter (Millipore) at 
13,000 x g for 15 min at 4 C to near dryness, and resuspended in the desired amount of 
storage buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl/40% glycerol/0.1% Triton X-100) 
to store at -20 C. Recovery of Drs2p was determined using Odyssey Infrared Imaging 
System (LI-COR) to quantify SimplyBlue-stained bands relative to a BSA standard curve. 
 
Section 3.3.4: ATPase assay 
Purified Drs2p was assayed for ATPase activity in ATPase buffer (50 mM Tris-HCl, pH 
7.5/100 mM NaCl/50 mM KCl/1 mM NaN3/0.1% Triton X-100/4 mM Na+-ATP, pH 7.5/10 
mM MgCl2) at 37 C for 2 h, and released phosphate was measured colorimetrically using 
a modified protocol previously described (Carter and Karl, 1982; Paterson et al., 2006; 
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Zimmerman and Daleke, 1993). Briefly, the volume of the sample was brought to 275 μL 
with deionized water, and the ATPase reaction was stopped by addition of 150 μL of 
molybdate solution (2 M HCl/50 mM Na2MoO4) and 75 μL of malachite green solution 
(0.042% malachite green in 1% polyvinyl alcohol solution). The sample was mixed for 2 
min before addition of 500 μL of citric acid (7%) or H2SO4 (7.8%), and the optical density 
at 660 nm was read at 30 min after addition of the citric acid solution. The amount of 
released phosphate was determined by a phosphate standard curve constructed in the 
same ATPase buffer. 
 
Section 3.3.5: Western blotting 
Western blotting was performed as previously described (Chen et al., 1999). The 
primary antibodies used were rabbit anti-Drs2p (1:2000), anti-His10 (1:200), and anti-
CBP (1:500) antibody. The secondary, Alexa Fluor 680-labeled goat anti-rabbit IgG 
antibody was used at 1:2000. Western blots were imaged with Odyssey Infrared Imaging 
System (LI-COR). 
 
Section 3.3.6: Mass spectrometry 
Protein samples were subjected to SDS polyacrylamide gel electrophoresis and the 
protein bands of interest were excised. The protein sample was then in-gel digested with 
trypsin, and was loaded onto an ABI Voyager 4700 MALDI-TOF-TOF system (Applied 
Biosystems) and analyzed by tandem mass spectrometry (MS-MS). 
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Section 3.4: Results 
 
Section 3.4.1: The content of the tag does not seem to cause the difference in 
                        ATPase activity between purified TAPN-Drs2p and Drs2p-TAPC. 
In a previous study, both TAPN-Drs2p and Drs2p-TAPC were affinity purified with 
comparable yields and purities as determined by Coomassie staining and mass 
spectrometry. Although both TAP-tagged Drs2p forms appeared to be functional in vivo, 
only TAPN-Drs2p retained ATPase activity after purification, whereas the purified Drs2p-
TAPC was inactive. The purified Drs2p-TAPC did not seem to be aggregated or 
denatured compared to TAPN-Drs2p when analyzed by size exclusion chromatography 
and circular dichroism spectroscopy (Zhou and Graham, 2009), suggesting that the 
inactivity of purified Drs2p-TAPC may have a biologically relevant cause. 
The major molecular difference between the purified TAPN-Drs2p and Drs2p-TAPC 
was that the former has a decahistidine (His10, part of the TAPN) tag appended to the N-
terminus of Drs2p versus a calmodulin binding peptide (CBP, part of the TAPC) tag 
appended to the C-terminus of Drs2p in the latter (Figure 2-5B and Figure 2-1B). It is 
possible that the content of the tag (His10 vs. CBP) or the position of the tag (N- vs. C-) 
caused the difference in ATPase activity of purified Drs2 proteins. To address this issue, 
a dual-TAP-tagged Drs2p (TAPN-Drs2p-TAPC) was engineered in a multicopy (2μ) 
plasmid and overexpressed by the glyceraldehyde-3-phosphate dehydrogenase (GPD) 
promoter (Figure 3-3A and B). 
TAPN-Drs2p-TAPC was affinity purified using either the TAPN tag or the TAPC tag, and 
the protein yield and purity was comparable between the two preparations as judged by 
Coomassie staining (Figure 3-3C, lane 3 and 4). Theoretically, both preparations should 
contain Drs2p of the same molecular composition, i.e. TAPN-Drs2p-TAPC (more 
precisely, His10-Drs2p-CBP). Indeed, Drs2p from both preparations appeared as a single 
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Figure 3-3. Expression and purification of TAPN-Drs2p-TAPC. (A) Genetic organization of 
TAPN-DRS2-TAPC and CDC50. TAPN-DRS2-TAPC was expressed from a 2μ plasmid 
and CDC50 was from the chromosome. (B) Schematic of TAPN-Drs2p-TAPC modeled on 
the crystal structure of SERCA1 in the E1·2Ca2+ conformation (Toyoshima et al., 2000). 
ProA, protein A moiety; His10, decahistidine moiety; CBP, calmodulin binding peptide 
moiety; TEV, tobacco etch virus. (C) Purified TAPN-Drs2p-TAPC from strain XZY85 
(atp2∆) using the TAPN tag (lane 1) or TAPC tag (lane 2) were subject to SDS-PAGE and 
the gel was stained with SimplyBlue. (D) Proteins in a gel from (C) were 
electrotransferred to polyvinylidene difluoride (PVDF) membrane for western blotting. 
The primary antibody against Drs2p was used at 1:2000. The upper arrow head 
indicates the intact TAPN-Drs2p-TAPC form and the lower arrow head indicates a minor 
band with faster mobility (the “NoC” form). Note that there was another minor band 
below the two arrow heads. (E) ATPase activity of purified TAPN-Drs2p-TAPC 
preparations. TAPN-Drs2p and Drs2p-TAPC were purified from strains XZY60m (atp2∆) 
and XZY38b (atp2∆), respectively, as previously described. 
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band corresponding to the size of TAPN-Drs2p-TAPC on a Coomassie-stained protein gel 
(Figure 3-3C, lane 3 and 4), suggesting that the bulk of purified TAPN-Drs2p-TAPC using 
either tag was in the same form as expected. However, ATPase activity was only 
detected in the TAPN-Drs2p-TAPC sample purified using the TAPN tag, but not the TAPC 
tag (Figure 3-3E). These data suggest that the presence of the N-terminal His10 tag or 
the C-terminal CBP tag did not directly cause activation or inactivation of Drs2p, 
respectively. Rather, it is more likely the position of the tag and a reason that is inherent 
to the C-terminal purification method that has caused Drs2p-TAPC to be inactive after 
purification. 
 
Section 3.4.2: A cleaved form of Drs2p is present only in the TAPN-Drs2p-TAPC 
  sample purified using the TAPN tag, but not the TAPC tag. 
Although the N-terminally purified TAPN-Drs2p-TAPC appeared to be the same as the 
C-terminally purified one based on Coomassie staining, a difference between the two 
preparations was revealed by western blotting. Interestingly, a minor form of Drs2p with 
mobility faster than that of TAPN-Drs2p-TAPC was detected in the TAPN-Drs2p-TAPC 
sample purified using the TAPN tag, but not the TAPC tag (Figure 3-3D), suggesting that 
it is a C-terminally cleaved form of Drs2p. Indeed, this cleaved TAPN-Drs2p-TAPC 
remained immunoreactive with an antibody recognizing the His10 tag (part of the TAPN), 
but could not be detected by an antibody that recognizes the CBP tag (part of the TAPC) 
(Figure 3-4A, lane 2 and 5). Because the cleavage resulted in a partial or complete loss 
of the C-terminal tail of Drs2p, this cleaved form of Drs2p was designated the “NoC” 
form. 
The “NoC” form of TAPN-Drs2p-TAPC was estimated to compose ~10% of the total 
Drs2p molecules in the N-terminally purified TAPN-Drs2p-TAPC sample by measuring the 
intensity of bands on western blots (Figure 3-3D, lane 1; Figure 3-4A, lane 7). Based on  
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Figure 3-4. Partial separation of the “NoC” form from the intact form in purified TAPN-
Drs2p-TAPC by calmodulin column. (A) Purified TAPN-Drs2p-TAPC before separation 
(lane 1, 4 and 7), the unbound fraction from the calmodulin column (lane 2, 5, and 8), 
and the bound and eluted fraction (lane 3, 6, and 9) were subjected to SDS-PAGE and 
western blotting. Primary antibodies were used at 1:200 (anti-His10), 1:500 (anti-CBP) 
and 1:2000 (anti-Drs2p). The upper arrow head indicates the intact TAPN-Drs2p-TAPC 
form and the lower arrow head indicates the “NoC” form. Note that the “NoC” form is a 
very weak band in lane 2. (B) The three samples ordered as in (A) were analyzed by 
SDS-PAGE and the gel was stained with SimplyBlue. Arrow heads indicate the two 
forms of TAPN-Drs2p-TAPC as in (A). (C) ATPase activity was assayed with purified 
TAPN-Drs2p-TAPC before separation and the two fractions after separation. 
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mobility of proteins on western blots (Figure 3-4A, lane 2 and 8), the “NoC” form of 
TAPN-Drs2p-TAPC was estimated to be ~15 kDa smaller than the intact form of TAPN-
Drs2p-TAPC, which corresponds to an ~9 kDa loss in the C-terminal tail of Drs2p. 
The C-terminal tail of Drs2p has been suggested to contain an R domain that auto-
inhibits Drs2p (Natarajan et al., 2009). It is possible that only the “NoC” form of Drs2p, 
which was recovered only in the N-terminal purifications, was active, and that it was the 
“NoC” form of Drs2p that conferred ATPase activity in the purified samples. 
 
Section 3.4.3: The ATPase activity is associated with the “NoC” form of TAPN- 
  Drs2p-TAPC in purified samples. 
To test if the “NoC” form of Drs2p was responsible for the ATPase activity detected in 
the purified Drs2p samples, the “NoC” form was partially separated from the intact form 
in an N-terminally purified TAPN-Drs2p-TAPC preparation. Because the “NoC” form of 
TAPN-Drs2p-TAPC lost the C-terminal tag (the CBP tag of the TAPC) but the intact form 
retained it, these two TAPN-Drs2p-TAPC forms were separated by binding to a 
calmodulin column. The unbound fraction was enriched in the “NoC” form of TAPN-
Drs2p-TAPC (~30% of total Drs2p, Figure 3-4A, lane 8), whereas the bound and eluted 
fraction contained very little “NoC” form (<4% of total Drs2p, Figure 3-4A, lane 9). 
Consistently, the fraction enriched in the “NoC” form of TAPN-Drs2p-TAPC displayed a 
specific ATPase activity 3-4 fold higher than that of the initial preparation before the 
separation (Figure 3-4C). In contrast, the eluted fraction free of the “NoC” form was 
almost devoid of ATPase activity (Figure 3-4C). These data suggest that the ATPase 
activity of purified TAPN-Drs2p-TAPC coincided with the “NoC” form and that the intact 
form of Drs2p was inactive after purification, furthering supporting that the “NoC” form of 
TAPN-Drs2p-TAPC was responsible for the observed ATPase activity. 
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Section 3.4.4: A potential cleavage site that generates the “NoC” form of TAPN- 
  Drs2p-TAPC is identified by mass spectrometry. 
In the fraction enriched in the “NoC” form of TAPN-Drs2p-TAPC, Drs2p appeared as a 
doublet on Coomassie-stained gels (Figure 3-4B, lane 2), corresponding to the intact 
and the “NoC” form of TAPN-Drs2p-TAPC. To map the cleavage site that generates the 
“NoC” form (the “NoC” cleavage site) and identify the C-terminal end sequence of the 
“NoC” form of Drs2p (the “NoC” terminus), the band with faster mobility corresponding to 
the “NoC” form was excised and digested with trypsin for a mass spectrometric analysis. 
The eluted fraction contained little “NoC” form was also run on a gel and the protein 
band corresponding to the intact form of TAPN-Drs2p-TAPC was excised as a control for 
the mass spectrometric identification (Figure 3-4B, lane 3). If the “NoC” cleavage site 
was not a trypsin recognition site, that is, if the cleavage did not take place after a basic 
residue (R or K), the “NoC” form of Drs2p would produce a novel peptide containing the 
“NoC” terminus when digested with trypsin, which would not appear in the control 
sample containing the intact Drs2p. However, if the cleavage happened right after a 
basic residue, the peptide that contains the “NoC” terminus would be indistinguishable 
from that generated by trypsin digestion. In this case, different proteases will be needed 
to digest the protein samples for mass spectrometry. 
The initial attempt with trypsin digestion to identify a novel peptide without a basic 
residue at the C-terminal end was partially successful. Because the last 57-aa region 
(1299-1355) of the predicted Drs2p C-terminal tail (1219-1355) lacks sufficient basic 
residues (Figure 1-9A), this region was not recovered in either the “NoC” sample or the 
control. Therefore, it was not known if the “NoC” cleavage site resides in this region. 
However, the “NoC” form was estimated to miss a sequence of ~9 kDa in size (~80-aa) 
of the C-terminus of Drs2p, suggesting that the “NoC” cleavage site was likely not in the 
C-terminal 57-aa region of Drs2p (1299-1355). The protein sequence coverage at the C-
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terminus was the same for the “NoC” sample and the control, both of which were 
covered to residue 1298, indicating a contamination of the intact TAPN-Drs2p-TAPC in 
the “NoC” sample. However, a novel peptide ending with a glutamine residue at position 
1254 (Q1254) was discovered in the “NoC” sample but not in the control sample. 
It is possible that the Q1254-Q1255 sequence was the potential “NoC” cleavage site. 
If the “NoC” form of Drs2p ended with Q1254, the “NoC” form would lose a 101-aa long 
sequence from the C-terminus of Drs2p (Figure 1-9A), resulting in a loss of ~11 kDa in 
size. This value was close to that estimated by the protein mobility measurement. 
However, because non-traditional peptides in mass spectrometry may also arise from 
non-tryptic events, whether the Q1254 residue was the true C-terminal end of the “NoC” 
form of Drs2p will require further mass spectrometric studies with different protease 
digestion. 
 
Section 3.4.5: Cdc50p preferentially binds inactive Drs2p in purified samples. 
In both purified TAPN-Drs2p and Drs2p-TAPC samples, Cdc50p was co-purified at a 
substoichiometric concentration relative to Drs2p (Table 2-3 and Table 2-1), suggesting 
that the purified Drs2p was a mixed population of Drs2p monomers and Drs2p/Cdc50p 
complexes. Although the role that Cdc50p plays in Drs2p activity was unclear, Cdc50p 
did not confer ATPase activity to the inactive, purified Drs2p-TAPC. To further assess the 
contribution of Cdc50p to the ATPase activity of purified TAPN-Drs2p, Cdc50p was fused 
with the TAPC tag at the C-terminus (Cdc50p-TAPC) and was overexpressed along with 
TAPN-Drs2p by the GPD promoter (Figure 3-5A and B). The purified TAPN-Drs2p 
sample was then loaded on a calmodulin column to separate the TAPN-Drs2p/Cdc50p-
TAPC complex from the TAPN-Drs2p monomer. Fractions were collected and analyzed 
for Drs2p and Cdc50p by western blotting to estimate relative abundance of the TAPN-
Drs2p/Cdc50p-TAPC complex in each fraction (Figure 3-5C and D). Only the  
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Figure 3-5. Partial separation of TAPN-Drs2p/Cdc50p-TAPC complex from TAPN-Drs2p 
monomer in purified TAPN-Drs2p by calmodulin column. (A) Genetic organization of 
TAPN-DRS2 and CDC50-TAPC. TAPN-DRS2 was expressed from a 2μ plasmid and 
CDC50-TAPC was from the chromosome. (B) Schematic of TAPN-Drs2p and Cdc50p-
TAPC. ProA, protein A moiety; His10, decahistidine moiety; CBP, calmodulin binding 
peptide moiety; TEV, tobacco etch virus. (C) Purified TAPN-Drs2p before separation 
(lane 1), the unbound fraction from the calmodulin column (lane 2), and the bound and 
eluted fraction (lane 3) were subjected to SDS-PAGE and western blotting. Primary 
antibodies were used at 1:200 (anti-His10) and 1:500 (anti-CBP). The upper arrow head 
indicates the intact TAPN-Drs2p form and the lower arrow head indicates the “NoC” form. 
(D) Estimation of the percentage of Cdc50p-complexed Drs2p according to (C). The 
abundance of Cdc50p relative to Drs2p was defined as Cdc50p signal (α-CBP) / Drs2p 
signal (α-His10) in (C), and the bound fraction in (C) lane 3 was defined to be 1:1 in 
Cdc50p:Drs2p (mol/mol), i.e. 100% TAPN-Drs2p/Cdc50p-TAPC complex. Values for the 
other two samples were normalized. (E) ATPase activity was assayed with purified 
TAPN-Drs2p before separation and the two fractions after separation. 
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TAPN-Drs2p/Cdc50p-TAPC complex would bind and be eluted from the calmodulin 
column because of the interaction of the TAPC tag (the CBP module) with the column, so 
the eluted fraction contained purely the TAPN-Drs2p/Cdc50p-TAPC complex (100%). In 
contrast, the unbound fraction was enriched in the TAPN-Drs2p monomer and contained 
fewer TAPN-Drs2p/Cdc50p-TAPC complexes (~6%). The original Drs2p preparation 
before separation contained an intermediate level of the TAPN-Drs2p/Cdc50p-TAPC 
complex (~20%). 
Interestingly, we observed an inverse correlation between ATPase activity and the 
percentage of the TAPN-Drs2p/Cdc50p-TAPC complex in the samples (Figure 3-5E). 
The eluted fraction containing 100% of the TAPN-Drs2p/Cdc50p-TAPC complex showed 
ATPase activity lower than that before separation (~20%), and was lower than that of the 
unbound fraction (~6%). These data suggest that the Drs2p molecules that Cdc50p 
preferentially binds in purified samples were less active, and that the active Drs2p 
molecules in purified samples may not require Cdc50p for ATPase activity. 
 
Section 3.5: Discussion 
The observation that Drs2p purified using affinity tags at different termini showed 
different ATPase activities was intriguing. This phenomenon was originally observed 
between TAPN-Drs2p and Drs2p-TAPC, and ATPase activity was only detected in the N-
terminally purified TAPN-Drs2p (Zhou and Graham, 2009). However, Drs2p-TAPC was 
functional in vivo, and did not seem to be unstructured or aggregated in vitro (Zhou and 
Graham, 2009). Furthermore, the tag itself was unlikely the direct cause of the different 
ATPase activity between the purified TAPN-Drs2p and Drs2p-TAPC, because a dual-
TAP-tagged Drs2p (TAPN-Drs2p-TAPC) was also active in N-terminally purified samples, 
but remained dead when C-terminally purified (Figure 3-3E). Since high concentrations 
of imidazole and EDTA/EGTA seem to inhibit Drs2p ATPase activity (data not shown), to 
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avoid an effect of different elution buffers, the buffers for storage of TAPN-Drs2p-TAPC 
purified using either tag were exchanged to the same buffer (see Materials and 
Methods). Moreover, a physical binding interaction between the C-terminal tag and a 
column did not inactivate Drs2p, because the TAPC tag should also bind the IgG column 
during the first affinity step when TAPN-Drs2p-TAPC was N-terminally purified. These 
findings suggest that there may be a mechanistic reason underlying the inactivity of the 
C-terminally purified Drs2p. 
The C-terminal tail of Drs2p was suggested to contain an R domain that inhibits Drs2p 
flippase activity in isolated TGN membranes when stimulators, such as Gea2p and PI4P, 
are absent (Natarajan et al., 2009). One possible explanation for the inability to detect 
ATPase activity in purified Drs2p-TAPC was that every Drs2p-TAPC molecule recovered 
had to have an intact C-terminal tail, which inhibits Drs2p. On the other hand, the TAPN-
Drs2p sample may contain some TAPN-Drs2p molecules that have lost the C-terminal 
tail and become constitutively active. In support of this possibility, the “NoC” form of 
Drs2p was identified only in the N-terminally, but not the C-terminally, purified Drs2p 
preparations (Figure 3-3D). Furthermore, ATPase activity was found to associate only 
with fractions containing the “NoC” form and became undetectable when the “NoC” form 
of Drs2p was depleted (Figure 3-3E). It would be interesting to see if addition of Gea2p 
and PI4P to purified Drs2p-TAPC would activate ATPase activity, although incubation of 
PI4P alone with purified Drs2p-TAPC in detergent solutions did not yield detectable 
ATPase activity (data not shown). It is possible that intact Drs2p requires a membrane 
environment for proper regulation by stimulators, and this possibility can be tested with 
reconstituted Drs2p-TAPC in proteoliposomes. 
A potential “NoC” terminus (Q1254) was also identified by a mass spectrometric 
analysis of trypsinized Drs2 proteins. The Q1254 residue resides in the Gea2p 
interacting region of the Drs2p R domain, which is followed by, and partially overlapped 
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by, the PI4P binding site (Figure 1-9A). In the R domain of P2B-ATPases, the regulator 
(calmodulin) binding site also binds to the ATPase itself and causes auto-inhibition 
(Carafoli, 1994; Sze et al., 2000). Analogous to the P2B-ATPase R domain, the regulator 
(Gea2p and PI4P) binding region of the Drs2p R domain may also bind to Drs2p and 
inhibit its activity. The Drs2p “NoC” form ending with the Q1254 residue would lose both 
the Gea2p interacting region and the PI4P binding site, and perhaps the auto-inhibition 
as well. However, there may be more than one “NoC” terminus. Supportively, at least 
two minors bands with faster mobility than that of intact TAPN-Drs2p-TAPC were 
observed on the western blots in Figure 3-3D and Figure 3-4A. Some “NoC” termini 
may not be recognized in this mass spectrometric identification using trypsin. For 
example, because the Gea2p interacting region and the PI4P binding site of the Drs2p R 
domain are extremely rich in basic residues (Figure 1-9A), any “NoC” terminus that 
ends with a basic residue would be indistinguishable from that generated by trypsin 
digestion and would be missed. A different protease digestion for mass spectrometry will 
be helpful in addressing this issue. 
Affinity purified Drs2p was found to have Cdc50p co-purified at a substoichiometric 
concentration relative to Drs2p (Zhou and Graham, 2009), which was also observed 
recently by Lenoir et al. (Lenoir et al., 2009). In my purified samples, Cdc50p seemed to 
bind preferentially to the inactive Drs2p molecules (Figure 3-5D and E). Interestingly, 
Lenoir et al. found that Cdc50p interacted strongly with Drs2p trapped in the E2P state, 
but did not interact with Drs2p in its E1 or E1P state (Lenoir et al., 2009). These data 
suggest that the inactive, purified Drs2p (probably auto-inhibited) was likely in the E2P 
state, and had a higher affinity for Cdc50p than Drs2p in other conformational states 
such as E1 or E1P. This conformation-dependent association of Drs2p with Cdc50p may 
reflect a mechanism for quality control of Drs2p at the ER. Perhaps only fully functional 
Drs2p capable of proceeding to the E2P state and being auto-inhibited will be allowed to 
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associate with Cdc50p for ER exit. Upon arrival at the TGN, Drs2p is then activated by 
regulators, such as Gea2p and PI4P (Figure 1-9B). On the other hand, the Drs2p 
molecules that Cdc50p did not preferentially bind in the purified sample had higher 
ATPase activity (Figure 3-5D and E). Consistently, the “NoC” form of Drs2p was also 
detected primarily in the Drs2p monomer fraction (Figure 3-5C, lane 2), but much 
weaker in the fraction enriched in the Drs2p/Cdc50p complex form (Figure 3-5C, lane 3). 
These data suggest that the active, purified Drs2p (probably the “NoC” form) may not 
require Cdc50p for ATPase activity, although Cdc50p may be part of a regulatory 
machinery for Drs2p in vivo. 
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CHAPTER IV 
 
FORMATION AND OBSERVATION OF GIANT UNILAMELLAR VESICLES 
 
Section 4.1: Abstract 
Drs2p is a yeast flippase that translocates specific phospholipid substrates across a 
membrane bilayer to the cytosolic leaflet, which is proposed to be a driving force that 
promotes membrane deformation and vesicle budding. A direct approach to test this 
hypothesis is to reconstitute membrane bending and vesicle formation in chemically 
defined artificial membranes containing purified Drs2p. However, the Drs2p 
proteoliposomes generated by detergent-mediated reconstitution are too small (40 nm in 
diameter) to be amenable to morphological studies (Zhou and Graham, 2009). A 
promising means to overcome the physical restraint and technical hurdles imposed by 
the small size of the proteoliposomes is to convert them into giant unilamellar vesicles 
(GUVs). GUVs are normally 5-100 μm in diameter, and their morphological changes 
induced by various manipulations can be easily observed under an optical microscope in 
real-time (Farge and Devaux, 1992; Papadopulos et al., 2007). This chapter describes a 
preliminary study on the methods of converting small, protein-free liposomes to GUVs, 
and observation of induced morphological changes of these GUVs. This information lays 
the ground for generation of Drs2p GUVs and subsequent morphological studies. 
 
Section 4.2: Introduction 
There are three major types of vesicles that mediate intracellular protein transport, 
namely COPI-, COPII-, and clathrin-coated vesicles (Kirchhausen, 2000b). Proteins 
traffic from the endoplasmic reticulum (ER) to the Golgi through COPII-coated vesicles, 
whereas COPI-coated vesicles mediate the retrograde transport from the Golgi back to 
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the ER. Clathrin-coated vesicles carry proteins between the trans Golgi network (TGN), 
the plasma membrane and endosomes. Vesicle budding of all three major types has 
been reconstituted from protein-free liposomes with addition of only cytosolic proteins 
such as coats and some accessory proteins (Matsuoka et al., 1998; Spang et al., 1998; 
Takei et al., 1998), indicating that these cytosolic factors alone are sufficient to drive 
vesicle formation. However, vesicle budding in vivo takes place in a tightly regulated 
temporal and spatial manner and cytosolic factors may not fully satisfy this layer of 
regulation. Furthermore, in vitro vesicle budding appears to be very inefficient and may 
occur at a rate much slower than that needed in vivo (Kinuta et al., 2002). Therefore, 
membrane factors such as phospholipids and membrane proteins likely make important 
contributions to this process in vivo. For example, Drs2p is a membrane protein that is 
suggested to directly facilitate the vesicle budding process (Graham, 2004; Pomorski et 
al., 2004). 
Drs2p is a yeast flippase localized primarily at the TGN that translocates 
phosphatidylserine (PS) and probably phosphatidylethanolamine (PE) from the lumenal 
leaflet to the cytosolic leaflet of TGN membranes (Natarajan et al., 2009; Natarajan et al., 
2004). This directional movement of phospholipids is proposed to cause an imbalance in 
phospholipid number and surface area between the two leaflets and result in membrane 
bending toward the cytosolic leaflet (Sheetz and Singer, 1974), which is an essential 
step in vesicle formation. In support of this hypothesis, yeast cells deficient for Drs2p 
were found to be defective in forming a subset of clathrin-coated vesicles from the TGN 
(Chen et al., 1999; Gall et al., 2002). However, a direct test of the hypothesized role of 
Drs2p flippase activity on driving membrane deformation and vesicle budding in a 
biochemically defined membrane system remains to be pursued. 
The main difficulty in reconstituting vesicle budding from the Drs2p proteoliposomes is 
that they are smaller, an average 40 nm in diameter (Zhou and Graham, 2009), than 
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vesicles formed in vivo (50-100 nm) (Kirchhausen, 2000b). Any potential morphological 
changes of these small liposomes induced by phospholipid movement would be 
restrained and difficult to observe. The best way to overcome this difficulty is to convert 
the small, preformed Drs2p proteoliposomes into giant unilamellar vesicles (GUVs, 5-
100 μm in diameter). Because GUVs are big, vesicle budding will be more feasible. 
Moreover, GUVs can be observed directly under an optical microscope in real-time for 
morphological studies. Shape changes of GUVs have been successfully documented 
when the phospholipid number of the GUV bilayer was manipulated by various means. 
For example, pH-induced movement of phospholipids to the outer leaflet or external 
addition and incorporation of phospholipids to the outer leaflet were shown to induce 
tubulation and vesicle budding in GUVs (Farge and Devaux, 1992; Papadopulos et al., 
2007). 
Several techniques are available for conversion of small vesicles to GUVs. One 
technique is the uncontrolled swelling method (Criado and Keller, 1987; Manley and 
Gordon, 2008), in which small vesicles are dehydrated followed by rehydration of the 
dried lipid film to form giant vesicles. An alternative to this technique is the controlled 
swelling method, or the electroformation method (Farge and Devaux, 1992; Girard et al., 
2004; Manley and Gordon, 2008; Mathivet et al., 1996; Papadopulos et al., 2007), in 
which dried lipid vesicles swell to form GUVs in an AC electric field. Each method has its 
own advantages and shortcomings. The uncontrolled swelling method is simple and 
quick, and compatible with most buffers, but the giant vesicles formed are very 
heterogeneous with a high percentage of multilamellar structures. In contrast, the 
electroformation method produces relatively homogeneous GUVs, but buffers and ions 
are only allowed at very low concentrations during electroformation. Another technique 
to convert small proteoliposomes to protein-containing GUVs involves fusion of 
preformed proteoliposomes either to each other or to preformed protein-free GUVs, 
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which usually requires special fusogenic lipids (e.g. palmitoylhomocysteine) (Connor et 
al., 1984), peptides (e.g. WAE, a synthetic undecameric peptide) (Kahya et al., 2001; 
Pecheur et al., 1997), and proteins (e.g. SNAREs) (Ohya et al., 2009; Tareste et al., 
2008). Because this method adds new components and complexity to the GUV system, I 
focused on the first two swelling methods to generate GUVs from small vesicles. At the 
current stage, GUVs were formed from protein-free liposomes under conditions that 
should maintain native protein structures (Girard et al., 2004; Papadopulos et al., 2007), 
and future studies will be expanded to generate Drs2p-containing GUVs from preformed 
Drs2p proteoliposomes. 
 
Section 4.3: Materials and Methods 
 
Section 4.3.1: Reagents 
Polyoxyethylene 9-lauryl ether (C12E9) was from Sigma-Aldrich, and Bio-Beads SM-2 
was from Bio-Rad. Phospholipids and fluorescent derivatives were from Avanti Polar 
Lipids and were DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), DOPG (1,2-dioleoyl-
sn-glycero-3-phospho-(1'-rac-glycerol)), DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-
serine), and NBD-PC (1-palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]-
hexanoyl]-sn-glycero-3-phosphocholine). Lipids were dissolved in chloroform and stored 
at -20 C. 
 
Section 4.3.2: Formation of protein-free liposomes 
Protein-free liposomes were formed by detergent removal method as described in 
chapter II with some modifications (Zhou and Graham, 2009). Briefly, 2 μmol of lipid 
mixture of a desired composition was dissolved in chloroform and the organic solvent 
was evaporated thoroughly. The dried lipid film was solubilized completely in 1 mL of 
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0.75% C12E9 in reconstitution buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl) and 200 mg 
of extensively washed Bio-Beads SM-2 was added. The mixture was incubated on an 
end-over-end rotator for 6 h at 4 C and another 200 mg of SM-2 beads was added for 
another 12 h of rotation. The solution of the mixture was then transferred to a clean tube 
and 400 mg of fresh SM-2 beads was added. After 6 h of rotation, the cloudy solution 
containing liposomes was carefully removed and stored at 4 C. 
 
Section 4.3.3: Formation of giant vesicles by uncontrolled swelling 
The uncontrolled swelling method was performed as previously described (Criado and 
Keller, 1987; Manley and Gordon, 2008). Briefly, 5 μL of preformed liposomes (2 mM 
lipid) was deposited as an 8 mm circle on a glass slide and was dried in a desiccator for 
3 h at 4 C. 20 μL of rehydration buffer (40 mM Tris-HCl, pH 7.5/150 mM NaCl) was 
added gently to cover the dried lipid spot and the glass slide was placed in a sealed petri 
dish containing a wet paper pad for 1 h at room temperature. The newly formed giant 
vesicles were transferred to a glass vial using a pipette tip with a large opening and 
stored at room temperature. 
 
Section 4.3.4: Formation of giant vesicles by electroformation 
GUVs were generated using an electroformation method modified from a previously 
described protocol (Girard et al., 2004; Papadopulos et al., 2007). Generally, 5 μL of 
preformed liposomes (2 mM lipid) was carefully deposited on the conductive side of one 
indium tin oxide (ITO) slide, and was dried in a desiccator for 3 h at 4 C. A nitrile O-ring 
(12 mm diameter x 1 mm height) was then placed around the dried lipid spot to form a 
little chamber. After carefully filling the chamber with 100 μL of electroformation buffer (1 
mM Tris-HCl, pH 7.5/100 mM sucrose), the chamber was sealed with another ITO slide 
by clamping the two slides together. The two ITO slides were assembled in the way that 
  
107 
their conductive sides face each other and are separated by the O-ring chamber. After 
assembly, the conductive glasses were connected to the electrodes of a function 
generator. For electroformation, an AC electric field of 1 V was applied across the O-ring 
chamber for 4 h at room temperature at 12 Hz frequency. To detach GUVs from glass, 
the AC field was elevated to 2 V for 30 min at room temperature at 4 Hz frequency. 
GUVs were then transferred to a glass vial using a pipette tip with a large opening and 
stored at room temperature. 
 
Section 4.4: Results and Discussion 
Giant vesicles were formed by either the uncontrolled swelling method or the 
electroformation technique, and were usually 10-50 μm in diameter. As reported 
previously, giant vesicles generated by uncontrolled swelling were heterogeneous in size 
and morphology (Manley and Gordon, 2008). Most structures were multilamellar with 
complex shapes (Figure 4-1A and B). By contrast, the electroformation method 
generated a relatively uniform population of round-shaped vesicles that seemed to be 
unilamellar (Figure 4-1C). Therefore, the electroformation method is more efficient in 
generating GUVs that are suitable for morphological studies. 
As a proof of principle, shape changes were induced in the protein-free GUVs and 
observed under an optical microscope equipped with DIC and fluorescence optics. In 
one experiment, the giant vesicles (90% DOPC/9% DOPG/1% NBD-PC) formed by 
uncontrolled swelling were transferred to a solution with the same osmolarity but a 
higher pH. A pH gradient was shown to induce accumulation of some lipids, such as 
phosphatidylglycerol (PG) and phosphatidic acid (PA), to the more basic side and cause 
morphology changes of GUVs such as tubulation and vesicle budding (Farge and 
Devaux, 1992). As shown in Figure 4-2, a giant vesicle was observed undergoing shape 
transition from a two-connected-vesicle structure to a three-connected-vesicle one. In 
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another example, a GUV (90% DOPC/10% DOPS) generated by electroformation was 
observed on a microscope slide without a cover slip. The GUV remained its original 
round shape for ~20 min and then started to change its shape (shrinkage) (Figure 4-3), 
which was probably due to an apparent evaporation of the solution on the slide. These 
preliminary observations confirm that morphology changes can be easily observed with 
GUVs, and the GUV is an excellent platform to study the relationship between flippase 
activity, membrane curvature, and vesicle budding. 
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Figure 4-1. Formation of giant vesicles by swelling methods. Giant vesicles were formed 
by the uncontrolled swelling method (A and B, 90% DOPC/9% DOPG/1% NBD-PC) or 
the electroformation method (C, 90% DOPC/10% DOPS), and were observed under an 
optical microscope. DIC, differential interference contrast; fluorescence, green 
fluorescence emitted by the NBD fluorophore (λex = 460 nm; λem = 534 nm). Scale bar, 5 
μm. 
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Figure 4-2. Shape change of giant vesicles induced by pH gradient. (A) A giant vesicle 
(90% DOPC/9% DOPG/1% NBD-PC) formed by uncontrolled swelling at pH 7.5 was 
transferred to a pH 10 solution without changing osmolarity. Images were taken at 1-min 
interval. DIC, differential interference contrast. Scale bar, 5 μm. (B) A fluorescence (NBD 
fluorophore) image was taken between 1 and 2 in (A). Scale bar, 5 μm. 
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Figure 4-3. Shape change of giant unilamellar vesicles (GUVs) induced by osmolarity 
gradient. A GUV (90% DOPC/10% DOPS) formed by electroformation was observed 
using a 20x objective without using a cover slip. Images were taken at 5-min interval. At 
the time of taking images 5 and 6, substantial evaporation of the sample on the slide 
was noticed. DIC, differential interference contrast. Scale bar, 5 μm. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The plasma membrane of eukaryotic cells has been known to be asymmetric in lipid 
composition since Bretscher described it in the early 1970s (Bretscher, 1973). Normally, 
the extracellular leaflet is enriched in choline-containing phospholipids such as 
phosphatidylcholine (PC) and sphingomyelin (SM), whereas the cytosolic leaflet is 
enriched in amine-containing phospholipids including phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) (Bretscher, 1973; Daleke, 2003; Devaux, 1992; Graham, 
2004; Menon, 1995; Pomorski et al., 2004). Because of their hydrophilic head groups, 
phospholipids diffuse very slowly across a membrane bilayer. Hence, asymmetrical 
biosynthesis of phospholipids at the endoplasmic reticulum (ER) could explain 
membrane asymmetry at the plasma membrane. However, the phospholipid distribution 
of the ER membrane appears to be symmetric due to the presence of ER flippases, a 
class of energy-independent, non-selective lipid transporters that allows bidirectional 
movement of newly-synthesized phospholipids to equilibrate between the two leaflets of 
the ER for membrane growth (Daleke, 2003; Devaux, 1992; Graham, 2004; Menon, 
1995; Pomorski et al., 2004). Therefore, as Bretscher envisioned, there must be a 
mechanism to generate membrane asymmetry, but at a post-ER level. 
Unidirectional, active translocation of phospholipids by proteins called flippases is 
proposed to play an important role in the generation of membrane asymmetry (Daleke, 
2003; Graham, 2004; Pomorski et al., 2004). Flippases are energy-consuming, integral 
membrane transporters that move phospholipid substrates across membranes from the 
extracellular leaflet or the topologically equivalent lumenal leaflet to the cytosolic leaflet. 
The first flippase activity documented experimentally was the aminophospholipid 
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translocase activity in human red blood cells (Daleke and Huestis, 1985; Seigneuret and 
Devaux, 1984). Since then, a goal has been to identify the flippase through purifying the 
protein and reconstituting its flippase activity in artificial membranes. Several lines of 
evidence from studies on the bovine chromaffin granule aminophospholipid translocase 
suggested that this enzyme belongs to a subclass of P-type ATPases, the type-IV P-type 
ATPases (P4-ATPases) (Moriyama and Nelson, 1988; Tang et al., 1996; Zachowski et 
al., 1989). A P4-ATPase, ATPase II/Atp8a1, was suggested to be responsible for the 
flippase activity in bovine chromaffin granules (Moriyama and Nelson, 1988; Tang et al., 
1996; Zachowski et al., 1989). However, there was no report of successful reconstitution 
of flippase activity with any purified P4-ATPase, even with purified, active ATPase 
II/Atp8a1 from multiple sources (Ding et al., 2000; Moriyama and Nelson, 1988; 
Paterson et al., 2006; Xie et al., 1989). The closest achievement to this goal was made 
in 1994, when the Devaux group purified a Mg2+-ATPase from human red blood cells, 
reconstituted this protein into liposomes and detected flippase activity toward spin-
labeled PS and PE analogues (Auland et al., 1994). However, the identity of this 
mysterious Mg2+-ATPase remains unknown today. It is possible that the reconstituted 
Mg2+-ATPase from human red blood cells is ATPase II/Atp8a1, since ATPase II/Atp8a1 
was found to be expressed in murine red blood cells (Soupene and Kuypers, 2006). 
Other candidates for this Mg2+-ATPase include ABCB6 and Atp8a2, which were also 
detected in human erythrocytes and are PS-stimulatable (Daleke, 2008). Further work is 
required to test these possibilities. 
On the other hand, studies on P4-ATPases from budding yeast provided additional 
evidence that these pumps are flippases. Yeast P4-ATPases, including Drs2p, Dnf1p, 
Dnf2p, and Dnf3p, were shown to be required for flippase activity detected in the plasma 
membrane (Pomorski et al., 2003; Riekhof and Voelker, 2006; Stevens et al., 2008), 
secretory vesicles (Alder-Baerens et al., 2006), and the trans-Golgi network (TGN) 
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(Natarajan et al., 2009; Natarajan et al., 2004). The most convincing genetic evidence 
came from a study on Drs2p, which is a yeast homolog of mammalian ATPase II/Atp8a1 
and is localized primarily to the TGN (Chen et al., 1999; Hua et al., 2002; Tang et al., 
1996). Isolated TGN membranes containing a temperature-sensitive mutant form of 
Drs2p as sole source of Drs2p translocated a PS analogue bearing a fluorescent 7-nitro-
2-1,3-benzoxadiazol-4-yl (NBD) group on a short sn2 acyl chain (NBD-PS), but not NBD-
PC, to the cytosolic leaflet at permissive temperature (Natarajan et al., 2004). 
Inactivation of this mutant Drs2p at higher temperature abolished the NBD-PS flippase 
activity. In this experiment, altering a single protein (Drs2p) directly affected flippase 
activity, suggesting that Drs2p is coupled directly to this activity. Translocation of NBD-
PS but not NBD-PC argues that it is the phospholipid rather than the NBD moiety that is 
recognized. However, there is more than one explanation for this observation. One 
possibility is that Drs2p pumps phospholipid substrates directly across membrane bilayer. 
Alternatively, Drs2p may pump an unidentified ion into the TGN to generate an ion 
gradient, which is then coupled by another transporter (an unidentified symporter) to 
phospholipid translocation. 
Therefore, to seek a direct test on the candidacy of P4-ATPases as flippases, in the 
current study, I purified Drs2p, reconstituted it into artificial membranes, and tested if 
flippase activity could be detected. Reconstitution of a flippase has proven to be 
challenging. After many failed attempts, I succeeded finally in reconstituting the Drs2p 
flippase activity (Zhou and Graham, 2009). In the whole process, from the start of Drs2p 
expression to the end of flippase assay, optimization of every step proved to be critical to 
the final success. 
The prerequisite of Drs2p reconstitution is to obtain pure, active Drs2p. Much useful 
information was obtained from purification of another P4-ATPase, ATPase II/Atp8a1. 
Bovine and murine ATPase II/Atp8a1 has been heterologously expressed in insect cells 
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and purified to apparent homogeneity with active protein in regard to ATPase activity 
(Ding et al., 2000; Paterson et al., 2006), but its reconstitution has not been reported. 
Several factors may account for the inability to reconstitute ATPase II/Atp8a1. First, 
perhaps a necessary β subunit was missing from the heterologous expression system. 
Many P4-ATPases were shown to require a noncatalytic β subunit for ER exit and proper 
localization (Chen et al., 2006; Furuta et al., 2007; Paulusma et al., 2008; Perez-Victoria 
et al., 2006; Poulsen et al., 2008; Saito et al., 2004). For example, Drs2p requires 
Cdc50p for function in vivo. Although the β subunit for ATPase II/Atp8a1 has not been 
identified, it is possible that ATPase II/Atp8a1 still requires one. Without co-expression of 
its β subunit, ATPase II/Atp8a1 expressed in a heterologous expression system may be 
folded well enough to exert ATPase activity, but insufficiently for flippase activity. 
Another possibility is that the β subunit is essential for the flippase activity of ATPase 
II/Atp8a1, but is dispensable for its ATPase activity. Second, a heterologous expression 
system may not be optimal for ATPase II/Atp8a1 production. Although purified ATPase 
II/Atp8a1 displayed ATPase activity, it is difficult to determine if this P4-ATPase 
remained biologically active during heterologous expression. For example, its flippase 
activity may be compromised when ATPase II/Atp8a1 was expressed in insect cells. 
Third, the purification process of ATPase II/Atp8a1 may perturb the protein folding, 
especially the organization of transmembrane segments, and yield protein preparations 
that lose flippase activity, or preparations with a high percentage of inactive protein. 
To avoid these potential shortcomings, I chose to overexpress Drs2p and its β subunit, 
Cdc50p, in its native host, budding yeast. Because Drs2p was slightly modified with 
affinity tags, another advantage of using budding yeast is that the tagged Drs2p protein 
can be easily tested for biological activity by assessing its ability to support Drs2p-
dependent growth at low temperature (Chen et al., 1999; Hua et al., 2002; Ripmaster et 
al., 1993). 
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Overexpression of Drs2p and Cdc50p was initially attempted using two multicopy 2μ 
vectors harboring the DRS2 and CDC50 gene (data not shown). However, the 
expression and recovery of Drs2p was not ideal in this system, and the yield of Drs2p 
per liter of culture was estimated to be on the scale of 0.1 μg, which was too low for 
reconstitution experiments. To improve Drs2p production, several other means were 
tested, and the yield of Drs2p was found to be effectively elevated by substituting the 
strong glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter for the endogenous 
promoter of both DRS2 and CDC50 in the yeast chromosome. Although the GPD 
promoter is estimated to be 40+ fold stronger than the endogenous DRS2 promoter, 
overexpression of Drs2p under this experimental condition was ~10 fold greater than the 
endogenous level, probably due to the limitation of internal membrane capacity and the 
ER quality control system. One advantage of using this chromosome-integrated Drs2p 
expression cassette over a plasmid-borne one is that cells can be cultured in rich media 
instead of synthetic selective media. Rich media usually allow cells to grow to a higher 
density, and sufficient starting material was found to be a very important factor to 
successful Drs2p purification. 
To facilitate protein purification, I first engineered a tandem affinity purification (TAP) 
tag at the C-terminus of Drs2p (Drs2p-TAPC). The TAPC tag contains a protein A moiety 
(ProA) and the calmodulin binding peptide (CBP) as the first and second affinity module, 
respectively, separated by the tobacco etch virus (TEV) protease cleavage site (TAPC = 
-CBP-TEV-ProA). Drs2p-TAPC seemed to be active when expressed in vivo, because it 
supported cell growth at 20 C which requires functional Drs2p (Chen et al., 1999; Hua et 
al., 2002; Ripmaster et al., 1993). For Drs2p-TAPC purification, a cell lysate was 
centrifuged at 15,000 X g for 12 min prior to detergent addition to pellet ER membranes 
and the supernatant containing the TGN proceeded to purification. Thus, any misfolded 
Drs2p-TAPC retained in the ER by the quality control system was discarded and only 
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those molecules that are folded properly and have exited the ER were recovered and 
purified. Normally, the yield of TAP-purified Drs2p from 1 liter of culture was in the range 
of 1-10 μg. 
Robust ATPase activity was detected in Drs2p-TAPC preparations. However, this 
activity showed no sensitivity to orthovanadate, a commonly used inhibitor for P-type 
ATPases, which raised a concern of contamination. To test if this activity was catalyzed 
by Drs2p-TAPC, I attempted to express and purify an ATPase-dead mutant of Drs2p, 
Drs2p(D560N), in the same C-terminally TAP-tagged form (data not shown). The original 
plan was to knock in the D560N mutation in the strain overexpressing Drs2p-TAPC, but 
this approach unfortunately failed. Instead, I moved DRS2-TAPC along with the GPD 
promoter to a 2μ plasmid, and generated the D560N mutation on that plasmid. Both 
Drs2p-TAPC and Drs2p(D560N)-TAPC were purified from the 2μ system, although the 
yield of Drs2p(D560N)-TAPC was lower compared to that of Drs2p-TAPC. ATPase 
activity was detected in the Drs2p-TAPC sample, but was absent from the 
Drs2p(D560N)-TAPC preparation, suggesting that this ATPase activity was catalyzed by 
Drs2p-TAPC, even though it was insensitive to orthovanadate. 
However, the ATPase activity in Drs2p-TAPC preparations was found later to be 
sensitive to azide, an inhibitor for the mitochondrial F1-ATPase. This observation argued 
strongly against my previous conclusion and suggested a contamination with the F1-
ATPase. To test if the ATPase activity in the Drs2p-TAPC sample was catalyzed by the 
F1-ATPase, I deleted the ATP2 gene, which encodes the catalytic subunit of the F1-
ATPase, in the strain overexpressing Drs2p-TAPC. From the atp2∆ strain, Drs2p-TAPC 
was purified with a yield and purity comparable to that from its isogenic mother strain. 
However, no ATPase activity could be detected in this Drs2p-TAPC preparation, 
indicating that the ATPase activity detected previously was indeed catalyzed by the 
contaminating F1-ATPase and that purified Drs2p-TAPC seems to be catalytically 
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inactive. These data also suggested that the contaminants present in the Drs2p-TAPC 
preparation and the Drs2p(D560N)-TAPC preparation were different, thus making 
purified Drs2p(D560N) an imperfect control for purified Drs2p. 
Many purification and assay conditions were tested for Drs2p-TAPC but none yielded 
an active enzyme. The conditions tested included purifying Drs2p-TAPC with different 
detergents and assaying ATPase activity in different pH buffers, at different 
temperatures, in the presence of various ions, and by addition of various phospholipids 
including PS and PI4P (data not shown). To troubleshoot this inactive preparation of 
Drs2p-TAPC, I engineered a different TAP tag at the N-terminus of Drs2p (TAPN-Drs2p). 
The TAPN tag differs from the TAPC tag in that it contains decahistidine (His10) instead of 
CBP as the second affinity module (TAPN = ProA-TEV-His10-). TAPN-Drs2p was also 
overexpressed by the GPD promoter along with Cdc50p in a strain background that is 
deficient for the ATP2 gene, and like Drs2p-TAPC, TAPN-Drs2p was functional in vivo. 
Purification of TAPN-Drs2p yielded preparations with a purity and yield comparable to 
that of Drs2p-TAPC, but the difference is that ATPase activity could be detected with 
purified TAPN-Drs2p but not purified Drs2p-TAPC. 
To probe the difference between TAPN-Drs2p and Drs2p-TAPC that is responsible for 
their difference in ATPase activity, both Drs2 proteins were analyzed by size exclusion 
chromatography to determine their oligomeric states. One possibility was that different 
oligomeric states of Drs2p could affect its activity. However, the majority of both TAPN-
Drs2p and Drs2p-TAPC seemed to be monomeric in detergent solutions, arguing against 
this possibility. Another possibility could be that the Drs2p-TAPC structure was severely 
perturbed during purification. To test this possibility, both Drs2 proteins were subjected 
to circular dichroism analysis. Indeed, the circular dichroism spectra of the two Drs2 
proteins were found to be different in the far-UV region, suggesting possibly a difference 
in the overall structure between TAPN-Drs2p and Drs2p-TAPC. However, purified Drs2p-
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TAPC did not seem to be more unstructured than TAPN-Drs2p. Therefore, the inactivity of 
purified Drs2p-TAPC was not caused simply by aggregation or denaturation of this 
protein, and there is probably a biologically relevant mechanism underlying this 
observation. 
From a molecular perspective, one apparent difference between TAPN-Drs2p and 
Drs2p-TAPC is their TAP tags, in both tag position and tag content. It is possible that it 
was the His10 of the TAPN tag versus the CBP of the TAPC tag, or the position of the tag 
that caused the difference in ATPase activity between the two Drs2 proteins. To test 
these possibilities, Drs2p was fused with TAP tags at both the N-terminus and the C-
terminus (TAPN-Drs2p-TAPC), and purified using either TAP tag. To avoid any effect of 
different buffers, purified Drs2p samples were stored in the same buffer. Although these 
two Drs2p preparations should contain the same TAPN-Drs2p-TAPC, only the one 
purified using the TAPN tag showed ATPase activity, whereas the other remained 
inactive. These data suggest that the His10 of the TAPN tag did not activate Drs2p, and 
neither did the CBP of the TAPC tag inactivate it. Moreover, because the TAPC tag also 
binds to the IgG column during the N-terminal TAPN purification, a physical interaction of 
the C-terminus with a column did not cause inactivation of Drs2p. To further test the tag 
position influence on Drs2p activity, different affinity tags need to be engineered at either 
terminus of Drs2p. For example, the TAPN tag can be fused to the C-terminus of Drs2p, 
or the TAPC tag can be moved to its N-terminus. If ATPase activity would still be 
detected only in the Drs2p preparation using the N-terminal tag, but not the C-terminal 
tag, it would suggest that the position of affinity tags was the cause of the activity 
difference between purified TAPN-Drs2p and Drs2p-TAPC. Although this notion has not 
been fully tested, evidence described below from my data indicates that it may be true. 
When TAPN-Drs2p-TAPC was purified, interestingly, a cleaved form (the “NoC” form) 
was discovered in the preparation using the TAPN tag, but not the TAPC tag. The 
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cleavage of TAPN-Drs2p-TAPC seems to take place in the C-terminal tail of Drs2p (thus 
giving the term “NoC”), because the “NoC” form of TAPN-Drs2p-TAPC immunoreacted 
with the anti-His10 antibody, but not the anti-CBP antibody. The C-terminal tail of Drs2p 
has been suggested to be an auto-inhibitory domain, and Drs2p flippase activity was 
shown to be stimulated by binding of regulators, such as Gea2p and phosphatidylinositol 
4-phosphate (PI4P), to its C-terminal tail (Natarajan et al., 2009). Therefore, partial or 
complete loss of the C-terminal tail could possibly bypass the requirement of regulators 
for Drs2p activity and release Drs2p from its auto-inhibition. Although the cause of Drs2p 
cleavage is not yet known, the “NoC” form of Drs2p may provide a molecular explanation 
for Drs2p-TAPC inactivity, because this “NoC” form could be recovered only in 
purifications using the N-terminal, but not the C-terminal, TAP tag. Therefore, the 
position of affinity tags could be responsible for the activity difference between purified 
TAPN-Drs2p and Drs2p-TAPC, because these tags determine whether the “NoC” form of 
Drs2p was included in or excluded from the purification. 
The “NoC” form of TAPN-Drs2p-TAPC was estimated to compose ~10% of total Drs2p 
molecules in purifications using the TAPN tag. Because the intact form of TAPN-Drs2p-
TAPC retained the TAPC tag (the CBP module) but the “NoC” form did not, these two 
forms of Drs2p were separated using the CBP interaction with a calmodulin column. The 
unbound Drs2p fraction was enriched in the TAPN-Drs2p-TAPC “NoC” form, which 
represented ~30% of the total Drs2p molecules. In contrast, the Drs2p sample eluted 
from the calmodulin column contained very little “NoC” form. Consistent with our 
hypothesis, the Drs2p fraction enriched of the TAPN-Drs2p-TAPC “NoC” form showed a 
specific ATPase activity higher than that before separation, whereas the Drs2p sample 
containing no “NoC” form of TAPN-Drs2p-TAPC showed almost no activity. Based on 
mobility of proteins on western blots, the “NoC” form of TAPN-Drs2p-TAPC was estimated 
to be ~15 kDa smaller than the intact form. Meanwhile, a mass spectrometric analysis of 
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both intact and “NoC” form of TAPN-Drs2p-TAPC revealed a potential cleavage site in the 
C-terminal tail of Drs2p at position 1254-1255 (Q-Q), which generates a “NoC” form of 
TAPN-Drs2p-TAPC that is 17.5 kDa smaller than the intact protein, very close to the 
experimental value. Currently, a stop codon as well as the factor Xa protease site 
(IEGR|X) is being engineered at the potential cleavage site to test if the intact form of 
Drs2p is auto-inhibited and if only the “NoC” form of Drs2p is active in vitro. Nevertheless, 
although the molecular basis of Drs2p-TAPC inactivity was not completely resolved, it 
served as a valuable negative control for the reconstitution experiments. 
The ATPase activity of purified TAPN-Drs2p was Mg2+-ATP-dependent and 
orthovanadate-sensitive, consistent with the properties of purified mammalian ATPase 
II/Atp8a1 (Ding et al., 2000; Moriyama and Nelson, 1988; Paterson et al., 2006; Xie et al., 
1989). However, these properties are shared by most P-type ATPases, and we were 
concerned that a very abundant P-type ATPase proton pump called Pma1p may 
contaminate our TAPN-Drs2p preparation. Indeed, Pma1p was detected as a trace 
contaminant by mass spectrometry, and was the only other P-type ATPase detected in 
the TAPN-Drs2p sample. However, Pma1p has an optimal pH of 5.8 (Decottignies et al., 
1994; Dufour and Goffeau, 1980), whereas the ATPase activity of purified TAPN-Drs2p 
peaks at pH 7.5, indicating that it was not Pma1p that catalyzed this ATPase activity. 
Moreover, Pma1p and other ATPases were also found at trace levels in the inactive 
Drs2p-TAPC preparation, further confirming that active TAPN-Drs2p was responsible for 
ATPase activity. 
The Km of purified TAPN-Drs2p for ATP was1.5 ± 0.3 mM, indicating a relatively low 
affinity for ATP compared with many other purified P-type ATPases (Desrosiers et al., 
1996; Moriyama and Nelson, 1988; Paterson et al., 2006). The nature of this low affinity 
could result from a suboptimal interaction between Drs2p and ATP in detergent solutions, 
or it could be a regulatory means for Drs2p activity. It is possible that the biological 
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processes that Drs2p is involved in (e.g. vesicular transport) are more actively engaged 
when energy is adequate, usually happening during the vegetative growth phase of cells. 
But when energy becomes limiting, the lower activity of Drs2p could save ATP for other 
cellular processes. 
Purified TAPN-Drs2p showed a Vmax of 0.45 ± 0.03 μmol Pi released/min/mg Drs2p at 
pH 7.5 and 4 mM ATP, which is low relative to the values reported for other purified P-
type ATPases, which can extend up to 75 μmol Pi released/min/mg (Desrosiers et al., 
1996). One reason could be that the substrate for Drs2p was missing in the assay. 
Surprisingly, I observed only a mild increase of ~40% in ATPase activity of purified 
TAPN-Drs2p when incubated with PS, a phospholipid substrate for Drs2p, in detergent 
solutions. This stimulation was weak compared with the steep increase (greater than 10-
fold) observed for purified mammalian ATPase II/Atp8a1. One possibility is co-
purification of substrate phospholipid with Drs2p, so that TAPN-Drs2p was at nearly 
maximum activation. Another cause may be that the delivery of PS to Drs2p was very 
inefficient in detergent solutions. To test these possibilities, purified TAPN-Drs2p was 
incorporated into artificial membranes containing different amounts of PS (0-20%). To 
eliminate potential curvature restraint imposed by PS movement, these artificial 
membranes were made leaky by incomplete removal of detergent so that phospholipids 
could diffuse freely across membrane bilayer. In membranes containing no PS, TAPN-
Drs2p showed ATPase activity (0.36 ± 0.04 μmol Pi released/min/mg Drs2p) comparable 
to that in detergent solutions. With increasing PS concentration, the ATPase activity of 
TAPN-Drs2p was stimulated up to ~400% (1.28 ± 0.03 μmol Pi released/min/mg Drs2p; 
20% PS) in a dose-dependent manner. These data confirm that there was a PS-
stimulatable TAPN-Drs2p pool in purified samples. However, whether the ATPase activity 
without externally added PS reflected basal activity of the PS-stimulatable TAPN-Drs2p 
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or full activity of a population of TAPN-Drs2p molecules that had PS co-purified remains 
to be determined. 
Even with PS stimulation, the ATPase activity of TAPN-Drs2p was relatively low 
compared with PS-activated bovine ATPase II/Atp8a1 (3-42 μmol Pi released/min/mg) 
(Ding et al., 2000; Moriyama and Nelson, 1988; Xie et al., 1989). However, if the 
ATPase activity of purified TAPN-Drs2p was solely conveyed by the “NoC” form of Drs2p 
as hypothesized above, the actual specific ATPase activity of Drs2p should be 10-fold 
greater (5-10 μmol Pi released/min/mg Drs2p), assuming that the “NoC” form comprises 
10% of total Drs2p. 
One intriguing aspect of the Drs2p ATPase activity is the contribution of Cdc50p. 
Drs2p requires Cdc50p association to exit the ER and proceed to the TGN (Chen et al., 
2006; Saito et al., 2004), but whether the chaperone role is the sole function of Cdc50p 
or whether Cdc50p contributes directly to the ATPase activity of Drs2p is yet to be 
determined. Because Cdc50p was also recovered in the purified TAPN-Drs2p sample, 
although at a substoichiometric concentration relative to Drs2p, it was possible that 
Drs2p requires Cdc50p for ATPase activity. To test this possibility, I took advantage of 
the two different TAP tags and engineered TAPN-Drs2p and Cdc50p-TAPC, and 
expressed them simultaneously. After purifying TAPN-Drs2p, the protein preparation 
contained a mixed population of the TAPN-Drs2p monomeric form and the TAPN-
Drs2p/Cdc50p-TAPC complex form. These two populations of Drs2p were then 
separated by the TAPC tag on Cdc50p, using the CBP interaction with a calmodulin 
column. The fraction eluted off the calmodulin column was enriched in the TAPN-
Drs2p/Cdc50p-TAPC complex form (assuming 100%), but it had the lowest ATPase 
activity. Meanwhile, the unbound fraction contained few complex molecules (~6%), but 
showed the highest ATPase activity. The mixed population before separation displayed 
an intermediate level of the complex form (~20%) as well as ATPase activity. These data 
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suggest that purified TAPN-Drs2p may not require Cdc50p for ATPase activity in vitro. 
However, there was still some Cdc50p-TAPC in the unbound fraction that was enriched 
in the TAPN-Drs2p monomeric form. Therefore, the possibility that Cdc50p contributes to 
the Drs2p ATPase activity cannot be ruled out completely and requires further test. 
Interestingly, these data also showed that the TAPN-Drs2p molecules that were bound 
preferentially by Cdc50p-TAPC and eluted in the complex form seemed to be less active. 
Taking the “NoC” form of Drs2p into consideration, it is possible that Cdc50p-TAPC has 
higher affinity for the intact form of TAPN-Drs2p (auto-inhibited potentially in a single 
conformational state) but lower affinity for the “NoC” form of TAPN-Drs2p (active). This 
hypothesis received experimental support in that the “NoC” form of TAPN-Drs2p was 
readily detected by western blotting in the unbound fraction enriched in the TAPN-Drs2p 
monomeric form, but much weaker in the eluted fraction containing primarily the TAPN-
Drs2p/Cdc50p-TAPC complex form. 
Furthermore, the notion that Cdc50p preferentially binds a particular conformational 
state of Drs2p is also consistent with a recent report by Lenoir et al. (Lenoir et al., 2009). 
In that work, Cdc50p was found to bind most tightly to the E2P state of Drs2p. It is very 
possible that the E2P state is where the intact Drs2p (such as purified Drs2p-TAPC) is 
normally trapped, even in vivo. This may be part of the quality control mechanism for 
Drs2p at the ER that allows only properly folded Drs2p capable of phosphorylation (and 
trapped in the E2P state) to associate with Cdc50p for ER exit. The observation that the 
Drs2p(D560N) mutant form, which is incapable of phosphorylation, was found to be 
largely retained in the ER is consistent with this speculation. After ER exit, Drs2p may 
keep itself in the E2P state (auto-inhibited) until being activated by its regulators, such as 
Gea2p and PI4P, through binding to its C-terminal tail. Cdc50p and other molecules may 
also be part of this regulatory machinery for the Drs2p activity in vivo. In the case of the 
“NoC” form of Drs2p that lost its C-terminal tail during purification, this regulation was 
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lost and Drs2p was released from its auto-inhibition, at least in regard to ATPase activity. 
Therefore, it will be very interesting to test if the inactive Drs2p-TAPC preparation could 
be activated by Gea2p and PI4P in vitro. 
With the active TAPN-Drs2p preparation, the next step toward Drs2p reconstitution 
was to put it back into artificial membranes. Reconstitution of membrane proteins is 
usually achieved through detergent-mediated proteoliposome formation (Paternostre et 
al., 1988; Rigaud et al., 1988). The choice of detergent, method of detergent removal, 
and other reconstitution conditions such as protein to lipid ratio and temperature are all 
important factors that determine the outcome of reconstitution. 
Generally, the higher protein to lipid ratio, the more likely proteoliposomes will form 
successfully. The yield of TAPN-Drs2p after two-step purification was usually in the range 
of 1-10 μg per liter of culture, with which I could not obtain consistent incorporation of 
Drs2p in liposomes during initial trials (data not shown). To increase protein to lipid ratio, 
single-step purified TAPN-Drs2p was used directly for reconstitution followed by a 
glycerol gradient flotation to recover proteoliposomes from the top fractions. This method 
proved to work consistently and the proteoliposomes contained Drs2p with purity 
comparable to that from 2-step affinity purification. However, many more contaminating 
proteins, probably including some proteases, were present during reconstitution using 
single-step purified TAPN-Drs2p, and Drs2p is known to be very sensitive to proteases. 
Therefore, the most prominent drawback of this method was that Drs2p may be 
degraded during reconstitution. But retrospectively, exposure of Drs2p to proteases may 
be a key to the success in reconstituting the Drs2p flippase activity later, because this 
step may help generate the “NoC” form of Drs2p that may be responsible for the 
observed flippase activity (see discussion later). Because of the risk of Drs2p 
degradation, a relatively rapid approach to efficiently remove detergent was required. 
After many trials on different combinations of detergent and removal method (data not 
  
126 
shown), I succeeded in reconstituting Drs2p in proteoliposomes with the detergent 
polyoxyethylene 9-lauryl ether (C12E9) removed by Bio-Beads SM-2 adsorption, a 
process usually completed within 24 h at 4 C. 
Reconstituted Drs2p proteoliposomes were relatively small in size (~40 nm in mean 
diameter) as revealed by electron microscopy (EM) with negative staining and by cryo-
EM. Based on the protein to lipid ratio (Drs2p:lipid ~ 1:200, wt:wt) and the assumption of 
an equal distribution of Drs2p in the liposomes, it was estimated that one Drs2p 
molecule was present per 2-3 liposomes. In other words, a maximum of 40% of the 
liposomes contained Drs2p, and the rest were protein-free liposomes. Reconstituted 
Drs2p seemed to be preferentially incorporated in the liposomes with the cytosolic 
ATPase domain facing outward. This preferential orientation may result from the 
limitation of small intravesicular space of the liposomes for placement of the bulky 
cytosolic domain of Drs2p. Nevertheless, the orientation of Drs2p in the proteoliposomes 
was in favor of measuring its flippase activity. Any Drs2p molecules that were oriented in 
the other direction would not be activated upon external addition of Mg2+-ATP. 
The last but also the key step of flippase reconstitution is to measure flippase activity 
in reconstituted proteoliposomes. This measurement was achieved with the help of 
fluorescent NBD-labeled phospholipid analogues, which were also incorporated into the 
proteoliposomes during reconstitution and were present in both leaflets. Flippase activity 
was measured by monitoring the change of inter-leaflet distribution of NBD-phospholipid 
probes using a membrane-impermeant fluorescence quencher, dithionite, which reduces 
the fluorescent NBD group to the non-fluorescent ABD group (McIntyre and Sleight, 
1991). When Mg2+-ATP was added externally, a positive flippase activity would be 
measured as an increase in the fraction of NBD-phospholipid probes present in the outer 
leaflet of the liposomes available to dithionite quenching (NBDouter%). 
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Initial trials of flippase assay with TAPN-Drs2p proteoliposomes seemed to show some 
flippase activity toward NBD-PS (0-2% increase in NBDouter%), but the signals were too 
weak to draw a firm conclusion (data not shown). Because of the small size of the 
proteoliposomes, most of the NBD-phospholipid probes were initially present in the outer 
leaflet and did not contribute to flippase activity, but contributed to background 
fluorescence. Eliminating these probes from the system by prequenching the 
proteoliposomes with dithionite reduced background fluorescence and increased the 
sensitivity for detecting flippase activity. Although the prequenching conditions (a low 
concentration of dithionite at low temperature) I used did not result in a complete quench 
of the fluorescent probes in the outer leaflet (with 10-20% remaining), the improvement 
of the signal was adequate for detecting flippase activity. Further improvement may be 
achieved by optimizing the prequenching conditions. 
After optimizing the assay, flippase activity was detected in the TAPN-Drs2p 
proteoliposomes. The activity was specific for NBD-PS, because no activity was 
observed with the PC and SM analogues. The NBD-PS flippase activity was also 
protein-mediated, as protein-free liposomes did not show flippase activity toward NBD-
PS. Furthermore, control proteoliposomes reconstituted with the inactive, purified Drs2p-
TAPC showed no NBD-PS flippase activity and still contained a protein composition 
almost identical to that of the TAPN-Drs2p proteoliposome, strongly arguing that it is the 
active Drs2p that was responsible for the observed flippase activity, and other 
contaminating proteins were incapable of catalyzing this activity alone. However, since 
Cdc50p was also present in the TAPN-Drs2p proteoliposome, it remains possible that 
Cdc50p is required for Drs2p flippase activity (see discussion below). 
In reconstituted samples, a maximum of 40% of the liposomes were estimated to 
contain Drs2p (proteoliposomes), and so 40% would be the upper limit of detectable 
NBD-PS translocation. I observed a nearly saturated Mg2+-ATP-dependent flip of 4% 
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NBD-PS, indicating that only 10% of the maximum flippase activity was achieved. This 
observation either suggests that all proteoliposomes contained active flippase and only 
10% of their probes were flipped, or that only 10% of the proteoliposomes contained 
active flippase and all of their probes were flipped. If the former was true, all TAPN-Drs2p 
molecules would be active and catalyzing flippase activity in the proteoliposomes. 
Because the molar concentration of Cdc50p was estimated to be only 10-20% of the 
TAPN-Drs2p concentration in the proteoliposomes, most likely TAPN-Drs2p would not 
require Cdc50p for flippase activity. However, if the latter possibility was true, only 10% 
of the TAPN-Drs2p molecules would be active in regard to flippase activity. Because the 
TAPN-Drs2p/Cdc50p complex form may be close to 10% of the total Drs2p in the 
proteoliposomes, it is possible that only the complex form catalyzed flippase activity. 
Alternatively, Cdc50p may not be required, and it may be the “NoC” form of TAPN-
Drs2p, which was also estimated to be 10% of the total Drs2p, that conveyed flippase 
activity. My current data favor this possibility, because Drs2p molecules complexed with 
Cdc50p seem to be less active in detergent solutions in regard to ATPase activity. Other 
possible reasons accounting for the suboptimal flippase activity include the physical 
restraint of small liposome size, an unequal distribution of Drs2p in the proteoliposomes, 
and/or the absence of other potential regulators of Drs2p activity, such as Gea2p and 
PI4P (Natarajan et al., 2009).  
Further work will be required to determine the extent that Cdc50p contributed to 
flippase activity. For example, Drs2p preparations enriched either in the TAPN-Drs2p 
monomeric form or in the TAPN-Drs2p/Cdc50p-TAPC complex form may be reconstituted. 
If the complex form is essential for flippase activity, the proteoliposomes reconstituted 
with the TAPN-Drs2p/Cdc50p-TAPC complex form would be expected to show a higher 
flippase activity. Similarly, to test if it is the “NoC” form of Drs2p that catalyzed flippase 
activity, the TAPN-Drs2p-TAPC “NoC” form may be enriched by separating it from the 
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intact form, reconstituted and assayed. Meanwhile, if the cleavage site for the “NoC” 
form is identified, the TAPN-Drs2p-TAPC “NoC” form may be directly engineered, purified 
and reconstituted, and a higher flippase activity will be expected if the “NoC” form is the 
active form. Another experiment related to the “NoC” question is to test if the current 
proteoliposomes reconstituted with TAPN-Drs2p or Drs2p-TAPC can be stimulated by 
addition of Drs2p regulators, such as Gea2p and PI4P. 
Interestingly, reconstitution of flippase activity with another purified P4-ATPase, 
Atp8a2 from bovine rod outer segments, has been reported very recently by Coleman et 
al. (Coleman et al., 2009). With a different detergent (n-octyl-β-D-glucopyranoside) and a 
different removal method (dialysis), the authors reconstituted untagged Atp8a2 and 
successfully detected flippase activity toward NBD-PS. Furthermore, native PS was 
shown to compete against NBD-PS translocation in reconstituted Atp8a2 
proteoliposomes, suggesting that native PS was also flipped by Atp8a2. Although PE 
also weakly stimulates the ATPase activity of purified Atp8a2, flippase activity toward 
NBD-PE was not detected, possibly due to an insufficient sensitive of the flippase assay. 
A mammalian Cdc50p homolog, Cdc50a, was found in the rod outer segments by mass 
spectrometry, but was not readily detected in purified Atp8a2 by Coomassie staining, 
which is not a sensitive method for detecting proteins in low abundance. Therefore, 
whether Atp8a2 requires a Cdc50p homolog for flippase activity remains to be 
determined. Both purified Drs2p and Atp8a2 are sensitive to orthovanadate, and have a 
similar optimal pH and a relatively high Km for ATP. But differently, purified Atp8a2 has a 
very high PS-stimulated ATPase activity (~50 μmol Pi released/min/mg) in detergent 
solutions, ~100 fold greater than that of purified Drs2p. Whether this reflects a difference 
in the purification method or a difference in protein nature needs further test. Another 
apparent difference between purified Drs2p and Atp8a2 is that Atp8a2 seems to be fairly 
resistant to proteases such as trypsin. These data suggest that every flippase is unique 
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and so their reconstitution may be different. However, the common conclusions between 
Drs2p reconstitution and Atp8a2 reconstitution support strongly that P4-ATPases in 
general are flippases. 
Summarized from my data and discussions, I propose a model for Drs2p regulation 
(Figure 1-9). In vivo, Drs2p is synthesized and folded at the ER. Properly folded Drs2p 
that can be phosphorylated and reach the E2P state binds Cdc50p and leaves the ER 
for the TGN. At the TGN, Drs2p is activated by Gea2p, PI4P and possibly other 
regulators through binding to the C-terminal tail of Drs2p (Figure 1-9C). When purified in 
vitro, the intact form of Drs2p remains in an inactive conformation (perhaps the E2P 
state) and cannot complete the catalytic cycle due to the absence of its regulators 
(Figure 1-9B). A cleaved form of Drs2p (the “NoC” form), which may result from an 
unknown cleavage event within the C-terminal tail during purification, becomes active 
because of loss of the auto-inhibitory C-terminal tail of Drs2p (Figure 1-9D). This “NoC” 
form of Drs2p can catalyze ATP hydrolysis and PS translocation in vitro even in the 
absence of regulators such as Gea2p and PI4P. Cdc50p may also play a role in PS flip, 
and is possibly an essential component of the flippase unit. So far, my data are 
consistent with this overall model, but more work is needed to validate it. 
In addition to generating membrane asymmetry by pumping specific phospholipids to 
the cytosolic leaflet, some P4-ATPases, such as Drs2p, are also involved in vesicle-
mediated protein transport (Graham, 2004; Muthusamy et al., 2009a; Zhou et al., 2010). 
Hence, a big question remaining in the flippase field today is whether flippases (e.g. 
Drs2p) also help to bend membranes and form vesicles through phospholipid 
translocation. In this hypothesis, phospholipid translocation across a membrane bilayer 
by flippases will cause an imbalance in phospholipid number and surface area between 
the two leaflets. Because the two leaflets of a bilayer are physically tightly coupled 
(Sheetz and Singer, 1974), this imbalance will promote deformation of the membrane 
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and generate curvature, which is a critical step in vesicle formation. Drs2p deficiency 
was found to perturb formation of a subset of clathrin-coated vesicles (Chen et al., 1999; 
Gall et al., 2002), supporting the notion that flippases may play an important role in 
vesicle budding. Moreover, it has been shown that a membrane bilayer bends toward 
the side with increased leaflet area when phospholipid number of the two leaflets was 
manipulated (Daleke and Huestis, 1985; Daleke and Huestis, 1989; Farge and Devaux, 
1992; Papadopulos et al., 2007; Seigneuret and Devaux, 1984). However, there is no 
direct evidence demonstrating that a flippase such as Drs2p facilitates vesicle budding 
by flipping phospholipid and inducing membrane curvature. 
With the success of Drs2p reconstitution, it is possible now to assess the 
consequence of phospholipid translocation in regard to shape changes of the 
proteoliposomes. Predicted shape changes after moving PS from the inner leaflet to the 
outer leaflet include liposome elongation and tubulation, protrusion formation and 
crenation, or bud formation and vesicle shedding. However, the small size of the 
proteoliposomes (40 nm in diameter) imposes a physical restraint on shape changes as 
well as technical hurdles in visualization (Zhou and Graham, 2009). These problems can 
be overcome by converting the small proteoliposomes into giant unilamellar vesicles 
(GUVs, >5 μm in diameter) via an electroformation method (Girard et al., 2004; 
Papadopulos et al., 2007). The biggest advantage of GUVs is that they can be observed 
directly under an optical microscope in real-time. Currently, I have succeeded in 
generating GUVs as big as 50 μm in diameter from small, protein-free liposomes and 
have successfully observed some expected shape changes by inducing phospholipid 
movement and manipulating osmolarity of the GUV system. Further work is needed to 
determine the proper conditions to form GUVs containing active Drs2p, which can be 
aided by monitoring Drs2p ATPase activity in GUVs. With this system, we will be able to 
study not only the relationship between phospholipid translocation and vesicle budding, 
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but also the substrate specificity using native phospholipids, and the influence of 
regulators such as Gea2p and PI4P. 
By flipping phospholipid, Drs2p and other flippases help generate an asymmetrical 
membrane in liposomes, and probably in cells as well. In the flippase and its related 
fields, one problem is solved, but more questions are awaiting answers. 
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